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Abstract 
Introduction 
High flow nasal cannula (HFNC) oxygen therapy is a non-invasive form of respiratory 
support that is rapidly being taken up in paediatric intensive care units (PICU). For infants 
with bronchiolitis – who are the largest non-elective source of admissions to a PICU – 
there is some evidence that using HFNC therapy reduces the need for intubation and 
mechanical ventilation. The aim of this thesis is to explore, describe, critique and add to 
the evidence surrounding the use of HFNC therapy in the paediatric population for the 
management of respiratory distress.  
Methodology 
A case series analysis was undertaken to describe common pathophysiology 
presentations to a PICU that used HFNC therapy as a method of respiratory treatment. 
Consent was sought from individual patients who represented common presentations of 
patients requiring respiratory support in a PICU (asthma, bronchiolitis and 
cardiomyopathy).   
A Cochrane systematic review was undertaken to determine the evidence for the clinical 
application of HFNC in the paediatric population. However, there remains a paucity of 
literature on HFNC application in lower acuity settings.  
To address this, a pilot study was undertaken in the Paediatric Emergency Department 
(PED) of the Mater Children's Hospital (MCH), Brisbane, Australia, with infants with 
bronchiolitis who met the inclusion criteria and for whom parental consent was obtained. 
Once enrolled, HFNC therapy was commenced, and observations recorded at least hourly 
until treatment cessation. A comparison group was identified and included during the 
course of the study, consisting of all infants who were eligible but not enrolled during the 
study period. The study protocol detailed the clinical treatment of those infants in the trial 
group, and no other changes were made to the usual management of infants with 
bronchiolitis during the study period. The primary outcome of interest was PICU 
admission. Secondary outcomes included: physiological response to HFNC; adverse 
outcomes; intubation rates; and hospital and PICU length of stay. 
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Results 
The case series analysis conducted indicated that HFNC therapy was successful in 
managing three patients with differing underlying pathophysiologies that caused 
respiratory distress.  
The Cochrane systematic review did not identify any studies that matched its inclusion 
criteria.  
Sixty-one infants were enrolled in the pilot study and 33 who met the inclusion criteria were 
later identified and formed the comparison group. Infants managed with HFNC therapy 
were four times less likely to require admission to PICU compared to those infants 
managed with standard low flow nasal oxygen therapy (OR 4.086, p=0.043). No infant, in 
either group, required intubation or mechanical ventilation. However, not all infants 
responded to HFNC therapy. Heart rate, respiratory rate and HiFOD score (a composite of 
physiological scores) indicated response to treatment over time (Generalised Linear Model 
p<0.001). The HFNC group successfully managed on the ward (Responders) had a mean 
reduction in heart rate of 13 bpm within 60 minutes of HFNC commencing. Whereas the 
heart rate of the HFNC group who were admitted to PICU (Non-Responders) increased 
(p=0.02). Likewise HiFOD scores also significantly reduced in the HFNC Responders with 
Non-Responders maintaining or slightly decreasing their HiFOD score (p=0.006) at 60 
minutes. A similar trend was observed with respiratory rate; however this did not become 
significant until 180 minutes (p=0.001).  
Discussion 
Clinical uptake of HFNC in the intensive care setting is increasing Intensive care settings 
are increasingly using HFNC therapy with reported clinical effect. However, the literature 
contains a paucity of evidence about its appropriate use and effectiveness, with only one 
small paediatric RCT conducted to date. The case series analysis revealed that using 
HFNC therapy may be safe and effective in the clinical management of infants with 
respiratory impairment. Further, the results of the pilot study indicate that HFNC therapy in 
low acuity settings, implemented as per the developed protocol, may reduce PICU 
admissions for infants with bronchiolitis. Additionally, the clinical reduction in heart rate and 
HiFOD scores at 60 minutes suggests that individual infants who receive HFNC therapy in 
a low acuity environment, but who do not respond within this time, may need to have their 
treatment reviewed and intervention escalated. These findings have implications for the 
effective management of bronchiolitis globally. 
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Conclusion 
Bronchiolitis is the largest cause of PICU admissions. This thesis examines the evidence 
and builds on the extant literature by reporting a case series, a systematic review and a 
pilot study. Based on the results of this thesis, a trial of HFNC therapy in a low acuity 
setting may be considered, with anticipated clinical improvement evident in 60 minutes.  
This may indicate that the patient can be managed outside of an intensive care setting. 
Preventing PICU admissions will likely reduce both financial and social impact on hospitals 
and families.  
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Chapter 1: Introduction 
The most frequent reason that children less than two years of age are admitted to hospital 
is due to viral lower respiratory tract infections,1 the most common of which is bronchiolitis. 
Bronchiolitis is characterised by an acute inflammatory response in the small airways of 
the lower respiratory tract, with common symptoms including fever, cough, expiratory 
wheeze, bronchospasm, and rhinitis.1,2 The treatment has remained unchanged since the 
1950s and 60s and incorporates oxygen therapy and fluid management.3,4 Infants with 
bronchiolitis can, however, still develop symptoms of respiratory distress. It is estimated 
that 10–15% of infants admitted to hospital with bronchiolitis will go on to require intensive 
care for their worsening respiratory state.5 
Of those admitted to an Intensive Care Unit (ICU), 9% will require mechanical ventilation.6 
Mechanical ventilation can damage the lungs further, and this ventilator induced lung injury 
(VILI), may lead to chronic lung disease.7 Finding other conservative methods of 
supporting the respiratory system, without resorting to invasive means such as intubation 
and mechanical ventilation, is therefore important.   
Non-invasive ventilation in the form of continuous positive airway pressure (CPAP) has 
become an increasingly popular modality to prevent invasive mechanical ventilation and its 
associated risks.6 CPAP can be delivered via a face or nasal mask, via nasopharyngeal 
tube with a water column (such as nasal bubble CPAP), or with a dedicated driver.8,9 The 
benefit of CPAP is that it delivers measurable positive airway pressure that is relatively 
easily controlled.6 While clinical experience suggests CPAP delivered via a nasal/facial 
mask is often poorly tolerated by infants and children, there are no studies to date which 
have examined this behavioural response in a critical care environment.  However, 
compliance with CPAP in these populations indicates that their behavioural responses are 
likely to be similar to those observed in children with obstructive sleep apnoea.10,11    
Recently, a relatively new means of delivering non-invasive respiratory support has 
emerged, that of high flow nasal cannula (HFNC) or heated humidified high flow nasal 
cannula (HHHFNC) oxygen therapy. These terms are often used interchangeably within 
the literature, for the purpose of this thesis the acronym HFNC will be used. This new 
therapy allows the delivery of high inspired gas flows (with or without blended oxygen) that 
can be heated and humidified. 
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HFNC therapy is postulated to deliver a degree of CPAP, albeit uncontrolled and 
unpredictable, and may therefore help reverse some of the atelectasis that eventuates 
from respiratory illness.12–14 This has been the focus of many studies in neonatal and adult 
populations.  However it is important to note that there is no universally agreed rate of flow 
for high flow in different patient age ranges.  Factors which determine the rate of flow may 
be context dependent and this is somewhat determined by the devices used.  Furthermore 
the majority of the studies have examined HFNC delivered in intensive care settings. While 
HFNC therapy is commonly used within the intensive care setting, the potential exists for 
its application in wards and emergency departments. 
As a clinician, I have worked for the past 20 years in critical care environments, with the 
last 14 focused in paediatrics. I have had the opportunity to work in many different ICUs 
both nationally and internationally. In 2000, at the first paediatric ICU I worked in, most 
infants with bronchiolitis were intubated and mechanically ventilated. This changed 
dramatically with the introduction of HFNC therapy. In my current PICU, intubation and 
mechanical ventilation of infants with bronchiolitis decreased from 36% to 7% over a 5 
year period.15 This potential to improve the clinical outcomes for infants, as a specific 
paediatric population, and to reduce the need for invasive ventilation has fascinated me, 
and lead me to question whether such a simple, and seemingly effective, paediatric 
intensive care therapy could also be safely used outside the high technology environment. 
The opportunity to explore the practical application of HFNC outside of the ICU and to 
acquire research skills concurrently was one I wholeheartedly embraced. 
This research ultimately aimed to acquire, examine and disseminate knowledge that will 
assist the clinicians using HFNC therapy in managing infants with respiratory distress. The 
thesis that follows is the culmination of this research aim. 
1.1 Overview of thesis 
This thesis is presented in nine chapters.  Figure 1 provides a schematic representation of 
the thesis, minus Chapter 9: references. 
Chapter 2 provides an overview of bronchiolitis, its natural history, health service 
responses, and current and emergent treatment options.   
Chapter 3 relates the proposed mechanism of action of HFNC and describes its use in the 
neonatal, adult and paediatric settings.  It contains the case series publication.  
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Chapter 4 sets out a Cochrane review, with related publication incorporated.  
Chapter 5 details the pilot study methodology.  
Chapter 6 details the results of the pilot study with the related publication included.  
Chapter 7 explores the implications of the findings of the systematic review, case series 
and pilot study as well as exploring the limitations of the thesis. 
Chapter 8 details the conclusions of the thesis and provides recommendations for further 
research.  
Chapter 9 is the list of references used throughout the thesis. 
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Chapter 2: Bronchiolitis 
2.1 Introduction 
The previous chapter introduced the components and reason behind embarking on this 
thesis. This chapter provides an overview of bronchiolitis, its natural history, health service 
responses, and current and emergent treatment options. 
Bronchiolitis is the most common disease affecting infants less than two years of age,2,16 
and is the leading cause of hospitalisation during the first year of life.17 It is characterised 
by a prodrome of symptoms, such as fever, cough, expiratory wheeze and rhinitis.18 The 
underlying pathophysiology is an acute inflammation of the terminal bronchioles and 
alveolar inflammation, typically viral in nature.19 While most infants experience a self-
limiting illness and can be managed in the community, approximately 1−3% will require 
hospitalisation.1,20  
The treatment for bronchiolitis revolves around supportive care to maintain oxygenation,  
nutrition and fluid management.4 A wide variety of practices are employed among 
clinicians worldwide, using differing treatment options depending on the severity of the 
presenting illness. However, no one therapy has been proven to reduce the length of 
hospital stay or change the course of the disease process.21 
2.2 Natural history of bronchiolitis 
The diagnosis of bronchiolitis is a clinical one. Infants will typically present with a history of 
coryzal symptoms; fever; wheezy cough; mild, moderate or severe respiratory distress; 
and on examination, have inspiratory crackles and/or expiratory wheeze.20,22 The duration 
of symptoms varies. Severity often increases in the first 72 hours with a return to baseline 
in around 2 weeks.20,21,23 Yet wheezing can continue for up to a month in some patients,23 
and reactive airway disease can be seen into early adolescence.24 In addition, other 
conditions may present as bronchiolitis and differential diagnoses include: asthma, 
pneumonia or pneumonitis, congenital lung disease, cystic fibrosis, airway lesions, 
congenital heart disease and sepsis.20,22  
The most common virus associated with bronchiolitis is the respiratory syncytial virus 
(RSV).25,26 In the United States of America (US), RSV accounts more than 80% of all 
bronchiolitis cases.27 However other viruses such as influenza, parainfluenza and 
adenovirus may also have a causative role.28 Epidemics are usually seasonal in nature, 
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typically occurring in the winter months. In the southern hemisphere, incident peaks are 
observed in July29 and in the northern hemisphere incident peaks are observed in January 
and February.30 While the global burden of RSV disease is unknown, recent data suggest 
that it is not only the leading cause of acute lower respiratory infection (ALRI) for children 
less than 5 years of age, but also the main reason these children are hospitised.31 
Exposure to RSV does not grant immunity, and reinfections are common throughout life.1 
Prevalence studies from Europe suggest that 50% of infants are infected with RSV before 
their first birthday, with 100% infected by 2 years of age.32 In Australia, RSV is not a 
notifiable disease and therefore reliable data on the disease prevalence does not exist. 
However, it is reasonable to expect that prevalence would mirror the US and European 
evidence. 
The determinants of hospitalisation vary from clinician to clinician and country to country, 
yet revolve around need for oxygen therapy and hydration.20,33 In one US study, the mean 
length of hospitalisation for uncomplicated bronchiolitis was 3.6 days, with a range of 1–17 
days.33  
Infants with bronchiolitis can progress to develop symptoms of respiratory failure. It is 
estimated that 10–15% of infants admitted to hospital with bronchiolitis go on to require 
intensive care for worsening respiratory distress.5,34 The underlying pathology includes an 
increase in mucus production and sloughing of necrotised epithelial cells, leading to 
decreased airway clearance. Along with mucosal oedema and inflammation of the small 
airways, this can lead to hypoxemia and hypercapnea. Symptoms of respiratory distress 
include an increased respiratory rate; substernal, subcostal, intercostal recession; head 
bobbing; grunting; air trapping; nasal flaring; apnoea; and thoracic-abdominal 
asynchrony.18,35  
Those infants and children who are immunocompromised, have chronic lung or congenital 
heart disease, or are premature, are at an even greater risk, not only of developing severe 
bronchiolitis, but requiring admission to intensive care, at rates as high as 36%.5 Ethnic 
background also has an association between not only bronchiolitis but severity of disease, 
with increased hospital admission rates for infants from indigenous Australian, Maori and 
First Nation backgrounds.36–38 Within Australia and New Zealand, the mean length of stay 
in ICUs for infants with bronchiolitis is 3.37 days.39 
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2.3 Health service response 
In the US, bronchiolitis admissions are estimated to cost more than US$500 million 
annually,40 and when diagnoses of pneumonia are included, the cost almost doubles. The 
rates of hospitalisation for bronchiolitis have increased over time, doubling in the US from 
1988 to 1996, with no change in mortality rates.41 Multiple factors may have influenced the 
increased rate of hospitalisation, including, greater detection of hypoxia via pulse 
oximetry33 lowered cut-off points for hypoxia and the administering of oxygen, increased 
survival of premature infants, prevalence of  infants with chronic disease, and increased 
day-care attendance by children at younger ages.17,20,26,34  
In Australia, bronchiolitis results in approximately 16,000 admissions to hospital a year.42 It 
is also the most common reason for non-elective admission to Australian Paediatric 
Intensive Care Units (PICUs) and general ICUs, with over 850 admissions annually.39 
Although it may be assumed that this places a substantial burden on our health care 
services, this claim is difficult to support – to date no estimate of quantified cost to the 
Australian health care system is available. While costs could be extrapolated from the US 
study, this would be misleading as health care systems significantly differ.  
A recent report by The Australian Lung Foundation (2007)43 has, however, identified that 
respiratory infectious disease amongst all ages in Australia does place a significant burden 
on our health system, and is a major health priority. The report extrapolated costs based 
on US admission rates in 1991, and with these rates converted to the Australian 
environment, the cost would be A$20 million.43 Yet epidemiological studies on RSV and 
bronchiolitis remain limited in Australia.44 This would be a worthwhile area of investigation, 
along with the fiscal implications to the Australian health care system for both these 
conditions.  
2.4 Sequelae 
Encompassing bronchiolitis and pneumonia, ARLI are the leading worldwide cause of 
mortality and morbidity in young children (aged less than 5 years), with an incidence rate 
of 17%.45 While hospitalised infants have a mortality of <1%, it may be as high as 3.5% in 
high-risk patients (those with chronic lung or heart disease, and prematurity).5 Within the 
UK, 2.9 deaths per 100,000 population are estimated per year in infants (less than 
12 months) with a respiratory cause and RSV infection.46 In the US, mortality is estimated 
at 5.3 per 100,000 population.47 The Australian Bureau of Statistics (2002) reports 
postnatal mortality for 28 days to 1 year of age at 1.7 per 1,000 live births.48 Diseases of 
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the respiratory system account for 6.5% (of these total deaths) however neither 
bronchiolitis nor RSV is distinguished in these statistics, making it difficult to compare to 
other countries.  
Post-discharge readmission is another objective sequelae. In a study by Norwood et al,49 
the predictors of a possible readmission after first presentation to the emergency 
department were: age less than two months, prematurity of less than 35 weeks gestation, 
and a history of hospitalisation. Finally, a small number of infants are at risk of recurrent 
wheezing illnesses throughout their childhood due to early RSV infection.20 
2.5 Current treatment options 
First-line treatment of bronchiolitis can be broadly classified into two distinct groups: 
pharmacologic and non-invasive respiratory support.  
2.5.1 Pharmacological treatment options 
Several pharmacological therapeutic options are used in the treatment of bronchiolitis. 
While they may offer short term relief of the symptoms, none have shown a clear benefit in 
altering the course of the disease, or modifying length of hospital stay.21 Most 
pharmacologic respiratory support aims to reduce either the inflammatory response, or to 
promote smooth muscle relaxation of the small airways. The eight major pharmacological 
treatment options are detailed in the following sections. 
2.5.1.1 Bronchodilators 
Bronchodilators administered as aerosols are used to relax the bronchial smooth muscle, 
reducing bronchospasm and bronchial hyper-reactivity, subsequently increasing the 
diameter of the airways.50 This modality is effective in children and adults with asthma. 
However, bronchiolitis is different as the airways are typically obstructed and oedematous, 
rather than constricted. Therefore infants and children with bronchiolitis are unlikely to 
respond to bronchodilators.50  
A Cochrane Collaboration systematic review of the use of bronchodilators (specifically 
albuterol, ipratropium bromide and adrenergic agents) found that while use in managing 
bronchiolitis was common, and short term improvements in clinical scores may occur, 
“bronchodilators cannot be recommended for routine management of first time wheezers 
who present with the clinical findings of bronchiolitis, either in the inpatient or outpatient 
settings”.50, Part of this is due to increasing reports of adverse effects, such as tachycardia 
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and tremors, reported in children and infants treated with bronchodilators.50 Uncertainty of 
their effectiveness also exists, especially with those presenting with a clinical picture of 
bronchiolitis and first-time wheezing.50 This is in addition to the high cost involved in using 
bronchodilators. To conclusively determine the efficacy of bronchodilators in the treatment 
of bronchiolitic infants, large multicentre controlled trials would be needed, in which infants 
and children with recurrent wheezing which may indicate asthma (and have a positive 
effect from bronchodilators) and infants with bronchopulmonary dysplasia would be 
excluded.50 
2.5.1.2 Adrenaline (epinephrine) 
Adrenaline is a drug with both alpha and beta adrenergic properties. The rationale for 
using adrenaline to treat bronchiolitis is that the alpha adrenergic effects cause 
vasoconstriction, thereby reducing the oedema of the small airways.51 This mechanism 
could help reduce the symptoms of bronchiolitis.  
 A recent review assessed the evidence supporting the use of adrenaline and other 
bronchodilators (salbutamol),compared with a placebo, for treating infants less than 2 
years of age with bronchiolitis. Bronchodilators have been proven to benefit children with 
asthma, and as both conditions produce symptoms of wheezing, it could be thought that 
these same drugs would work in a similar way in both conditions. However bronchiolitis 
and asthma are distinctly different and the effects of adrenaline on infants with bronchiolitis 
is less dramatic.52  
2.5.1.3 Glucocorticoids 
Glucocorticoids are a class of steroid hormone. As bronchiolitis is associated with first-time 
wheezing, similar to asthma, the use of steroids was thought to potentially have similar 
benefits to those with acute asthma.16 However, it is now understood that bronchiolitis is a 
heterogeneous disease and distinctly different to asthma.  
In a Cochrane Collaboration systematic review of children with bronchiolitis administered 
systemic or inhaled corticosteroids, no difference was found in hospitalisation rates, length 
of stay, readmission rates and clinical scores when compared with a placebo.53 However, 
a study where dexamethasone-epinephrine were administered in combination resulted in a 
reduction in hospitalisation within the 7 days following treatment.54 While a synergistic 
effect is postulated, subgroup analysis was inconclusive.53 Further research needs to be 
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carried out to clarify the efficacy, potential harm and applicability of combining these two 
therapies.53 
2.5.1.4 Heliox 
In bronchiolitis, a critical narrowing of small airways results in turbulent flow, increased 
airway resistance, and ventilation/perfusion mismatch.55 Helium has a lower density 
compared to air and may improve gas flow through high resistance airways by making the 
flow more laminar.56 While it has no anti-inflammatory or bronchodilatory properties, 
helium can aid in increasing oxygen flow to the alveoli, and decrease the work of 
breathing.57 Also, carbon dioxide (CO2) diffuses through helium four times faster than air, 
aiding in CO2 removal and consequently ventilation.55 However, a review of the current 
literature reveals that when heliox (helium-oxygen mixture) is administered, there is no 
reduction in the need of mechanical ventilation, intubation or PICU length of stay.55 
2.5.1.5 Antibiotics 
Antibiotics are not recommended for treating bronchiolitis unless an indication of 
secondary bacterial infection is present.22 Therefore, antibiotics being prescribed in 
34−99% of uncomplicated bronchiolitis cases is surprising.58 A systematic review by 
Spurling et al58 concludes that antibiotics may be justified in children with bronchiolitis who 
worsen and develop respiratory failure, however further research is warranted to 
determine the subgroup of patients who may benefit. 
2.5.1.6 Nebulised 3% saline (hypertonic saline) 
Hypertonic saline works by decreasing the viscosity of the mucous in the airways. It has 
been shown to be effective in patients with cystic fibrosis, asthma, bronchiectasis and 
sino-nasal disease.59 Benefits seen in these patients may also be expected in infants with 
bronchiolitis – hypertonic saline may help reverse some of the pathophysiological 
abnormalities by rehydrating the airway surface thereby improving mucous clearance; 
lowering the viscosity and elasticity of the mucous; reducing airway oedema; and inducing 
coughing to help clear secretions and relieve obstruction of the upper airways.60 
A meta-analysis showed a significantly shorter length of hospital stay and lower clinical  
severity scores in those infants already hospitalised with non-severe acute bronchiolitis, 
and treated with hypertonic saline.59 Treatment regimes in terms of optimal delivery times, 
duration of treatment, and saline concentration remain to be evaluated. Large multicentre 
trials are required to further evaluate the effectiveness of this therapy.59 
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2.5.1.7 Ribavirin 
Ribavirin is an antiviral agent that can be administered by aerosol. In in vitro studies,61 it 
seems to produce good activity against the viruses causing bronchiolitis, however more 
recent studies have shown no clear benefit,62 and the American Academy of Pediatrics 
(2006)1 has recently recommended against its routine use. As an aerosol, Ribavirin can be 
cumbersome to use, is high in cost, may have teratogenic effects for caregivers, and 
haemolytic side effects for patients.21 However, it may be considered for high-risk patients 
(immunocompromised, and those with significant cardiopulmonary disease).1 
2.5.1.8 Surfactant 
The use of surfactant in pre-term infants with primary surfactant deficiency is known to 
reduce mortality and the incidence of air leak syndrome.63 Due to the pathophysiological 
changes in the airways of infants and children with severe bronchiolitis, and the changes 
that occur with mechanical ventilation, there is the possibility of secondary surfactant 
deficiency, which could prolong recovery time, and increase the length of stay in the ICU 
and within the hospital.62 Administering surfactant in pre-term infants has proven 
successful, and it is plausible that the same would be true in viral bronchiolitis. However, a 
Cochrane Collaboration systematic review found that while the administration of surfactant 
may be reasonably safe, the limited data and heterogeneity of the trials makes it difficult to 
draw strong conclusions, and further studies are required.64 
2.5.2 Summary of pharmacological treatment options 
Pharmacological treatments for bronchiolitis employ agents that attempt to address either 
the issue of airway inflammation, or to relax the smooth muscles of the airways. 
Internationally there is variation in the use of the clinical markers (crackles, wheeze and 
age) to distinguish between bronchiolitis,  early asthma and reactive airway disease 
presentations.20 This can explain some of the commonality in treatment modalities 
between the different diagnoses. While no one treatment is entirely effective in shortening 
the course of the disease or length of hospital admission, there may be potential benefits 
with the combination of dexamethasone and epinephrine. However, all studies and 
systematic reviews of studies acknowledge that further investigation into the use of these 
treatments is warranted to provide clinicians with more comprehensive evidence to support 
their practice.  
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2.5.3 Non-invasive respiratory support 
Options to reduce work of breathing include non-invasive methods of respiratory support. 
Traditionally these range from steam inhalation, to CPAP administered with a facial/nasal 
mask interface, connected to a ventilator or to a specific driver. Evidence relating to five 
means of non-invasive respiratory support is detailed in the following sections. 
2.5.3.1 Steam inhalation 
The rationale for using steam inhalation (or cool mist therapy) is that steam acts as a 
secretolytic agent, making secretions easier to expel from the respiratory tract and 
relieving respiratory distress.28 While this sounds plausible, a Cochrane Collaboration 
systematic review found only one study for inclusion, although they noted a number of 
methodological weaknesses. The included study found no difference in respiratory distress 
symptoms in those patients treated in a mist tent compared with a placebo (nebulised 
saline).65 The review concluded there was insufficient evidence to inform practice and 
further trials should be considered.66  
2.5.3.2 Chest physiotherapy 
The aim of chest physiotherapy in bronchiolitis is to clear the airways of obstruction, and 
by doing so enhance gas exchange and reduce the work of breathing.67 Techniques used 
in paediatric patients include chest percussion, vibration, postural drainage, directed 
coughing, and passive forced expiration.68,69 The techniques and use of this therapy vary 
between countries and regions, so there is no standard use in bronchiolitis. A Cochrane 
Collaboration systematic review of chest physiotherapy in bronchiolitis draws the 
conclusion that the evidence is weak both for and against its use.67 The specific 
techniques of vibration and percussion were not shown to decrease length of hospital stay 
or improve the clinical severity score.67 However, in a subsequent study using a different 
physiotherapy method that included nebulised hypertonic saline, improvement was 
observed in the infants' clinical severity scores.70 The recommendation from this trial is for 
further multicentre studies to confirm the preliminary results.  
2.5.3.3 Continuous positive airway pressure (CPAP) 
Infants with severe bronchiolitis have the potential to develop severe respiratory distress, 
apnoea and hypoxia, and regional atelectasis of the lung is a common feature in infants 
breathing near their closing volume.71 CPAP can reduce the work of breathing and 
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improve functional residual capacity, potentially avoiding intubation.72 This level of 
respiratory support is usually administered in a dedicated ICU setting. 
A retrospective study reported the use of non-invasive ventilation for treating severe 
bronchiolitis over two winter seasons. In the second season where non-invasive ventilation 
was primarily used, there was a shorter duration of oxygen therapy required and  fewer 
cases of ventilator associated pneumonia.73 However, the retrospective design and small 
sample size (winter 1, n= 53 and winter 2, n=27) necessitates cautious consideration of 
the findings.  
The underpowering of studies was highlighted in a recent systematic review evaluating 
CPAP. Five studies were included for assessing CPAP, with only one being a randomised 
controlled trial. While individual studies reported potential benefits of CPAP in preventing 
endotracheal intubation for severe bronchiolitis,74–77 this outcome could not be 
substantiated in the review. Therefore, the role of this supportive therapy is still 
undetermined.6 This result is further supported by similar conclusions in a Cochrane 
Collaboration systematic review into CPAP for acute hypoxemic respiratory failure in 
children.78 Overall, there remains a lack of large, well designed, controlled trials to 
evaluate the role, risks and benefits of non-invasive modes of respiratory support.  
2.5.3.4 CPAP and heliox 
The use of heliox in combination with CPAP may decrease the work of breathing.79 Heliox 
can overcome airway resistance, a feature of bronchiolitis, due to the increased laminar 
flow of gas. This treatment may improve oxygenation and the removal of carbon dioxide, 
with CPAP helping to keep these airways open.79 Again, from a systematic review of the 
literature, the benefits of heliox and CPAP cannot be evaluated due to underpowered 
studies.6 
2.5.4 Summary of non-invasive respiratory support 
Non-invasive forms of respiratory support for bronchiolitis employ techniques, including 
CPAP, to overcome airway resistance and support the work of breathing. However no one 
study can draw definitive conclusions about the benefits and risks of each therapy 
described. All therapies need further study to provide the power necessary to inform 
clinical practice. 
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2.5.5 Emergent treatment – high flow nasal cannula  
One of the drawbacks with CPAP delivered via a nasal/facial mask is that is it often poorly 
tolerated by infants and children.80 A relatively new system in delivering non-invasive 
respiratory support has emerged, that of high flow nasal cannula (HFNC) therapy. This 
treatment option is the focus of this thesis and is considered in more depth in the next 
chapter. 
2.6 Conclusion 
This chapter has summarised bronchiolitis and identified it as the most common ALRI in 
infants aged less than two years. Admission rates to hospitals in high income countries are 
increasing, which places a substantial burden on any health care budget. Management 
approaches, which vary throughout the world, with no clear evidence for any single 
treatment approach, have been described.34 While systematic reviews have assessed a 
wide variety of therapies – and found potential benefit with nebulised hypertonic saline, 
surfactant, and epinephrine/dexamethasone combinations – there remains no one 
standout treatment for infants with bronchiolitis. Further investigation with larger, well-
conducted, multicentre controlled trials is still required to evaluate many of these therapies. 
The mainstay of treatment remains supportive care in the form of supplemental oxygen 
and hydration, with no singular routine treatment recommended.1 
HFNC oxygen delivery may offer an alternative mode of treatment for bronchiolitis. This is 
an area that deserves further investigation to provide good quality evidence to further 
inform clinician practice and treatment options for this disease. The next chapter will 
present what is currently known about HFNC therapy across the age spectrum. 
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Chapter 3: High flow nasal cannula therapy 
3.1 Introduction 
The preceding chapter detailed the cohort of paediatric patients most likely to require an 
admission to hospital, those with bronchiolitis, and examined the available treatment 
options. This chapter details the mechanism of action for HFNC therapy, and the studies 
that have been undertaken across patient age groups, from pre-term neonates to adults. 
Simple nasal cannula is one of the most frequently used methods to deliver supplemental 
oxygen to patients with hypoxemia. This common interface has been in use since the 
1940s, however, lack of humidification restricts the flow rates that can be delivered.12,81 
This can result in an inability to match a patient's spontaneous inspiratory flow rate, 
leading to worsening respiratory distress. In contrast, some systems – termed HFNC – can 
deliver higher flows of heated and humidified oxygen-gas mixtures. These have the 
potential to meet or exceed a patient's spontaneous inspiratory flow, thereby reducing their 
respiratory distress.82  
While 'high flow' rates have been studied as far back as 1994,83 neonatal ICUs have 
advanced clinical usage over the past 10 years as an alternative respiratory support mode 
to nasal CPAP.84 Therefore, high flow delivery systems have been increasingly used 
across a wide range of age groups of patients with respiratory distress.  
3.2 Mechanism of action 
While the clinical use of HFNC therapy is rapidly growing, the exact mechanism through 
which it works remains unclear.  There is increasing physiological evidence that supports 
the postulation by Dysart et al12 that there are a number of factors that influence the 
mechanism of action of HFNC therapy. 
3.2.1 Washout of nasopharyngeal dead space 
The first postulated mechanism of action is that HFNC therapy washes out anatomical 
nasopharyngeal dead space. This would reduce dead space overall and provide a 
physiological explanation for improved alveolar ventilation and respiratory effort.12,85 
Tracheal gas insufflation (TGI) has been used as a comparison for this mechanism of 
dead space washout.  TGI uses a catheter inserted into an artificial airway or specially 
designed endotracheal tube to use fresh gas to flush the mechanical dead space.86  The 
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additional flow during mechanical ventilation reduces volume and pressure requirements 
and facilitates pulmonary gas exchange, namely CO2 elimination. 87–90   
HFNC therapy is purported to have an effect on dead space due to improved ventilation 
rates.  The study by Dewan and Bell83 compared high and low flows through regular nasal 
cannula  and transtracheal catheters (TTC) in patients with chronic obstructive airways 
disease (COPD).  The use of high flows (3-8 L/min) provided greater exercise tolerance, 
but of interest is that delivery via nasal cannula (at higher flows) was just as effective for 
dead space washout as via TTC.83 
A recent neonatal animal study supports this view.  After inducing a lung injury on piglets, 
they were supported on HFNC therapy with increasing flows from 2 L/min up to 8 L/min. 
Results indicated that gas exchange was improved in a flow dependent manner.  
Increased carbon dioxide clearance and improved oxygenation enhanced overall 
ventilation.  It was also noted that at 8 L/min, tracheal pressures did not exceed 6±1 cm 
H2O, making it comparable to conventional CPAP.85  
3.2.2 Reduction in work of breathing 
A second postulated mechanism is that HFNC therapy reduces the overall work of 
breathing (WOB). This may be through either stenting of the airways or  through higher 
flow rates that either match, or exceed, a patient's peak inspiratory flow, and hence 
minimise the inspiratory resistance associated with the nasopharynx.12,86  
In a study by Miller et al91 it was demonstrated that CPAP reduced supraglottic resistance 
in the premature infant by 29 cmH20/L.  The reduction in resistance was postulated as 
being due to positive pressure effectively stenting the airways open. 
Saslow el al65 demonstrated that premature neonates supported with flow rates of 3-5 
L/min had similar WOB compared to nasal CPAP at 6cmH2O.    More recent clinical 
studies of neonates and children, using objective measuring techniques such as 
oesophageal or nasopharyngeal pressures, have demonstrated that increasing flow rates 
(1–8 L/min flow range) are associated with improved breathing patterns in these 
patients.92–94   
3.2.3 Delivery of warmed and humidified gas 
Another important mechanism is HFNC's effect on respiratory mechanics from the delivery 
of warmed and humidified gas. A study focusing on epithelial cells demonstrated that low 
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humidity or dry gas was detrimental to cells, resulting in increased inflammation and 
reduced cell function.95 In addition, dry, cold gas has been shown to elicit a 
bronchoconstrictive response in asthmatics and normal subjects.96,97 Humidification from 
HFNC therapy ameliorates this effect, demonstrating that adequate conditioning (warming 
and humidifying) of the airways does have a beneficial physiological effect.12,82 
3.2.4 Positive distending pressure 
Finally, HFNC therapy is postulated to provide positive airway pressure (PAP). 13,14,98–100  
The benefit of PAP is that it can help recruit alveoli and maintain alveolar patency, 
subsequently reducing ventilation-perfusion mismatch.  PAP has been inferred in these 
studies by using objective measures taken from a variety of sites including the oral cavity, 
nasopharyngeal, tracheal and oesophageal areas. As a partial consequence, the 
generated pressure reported varies, ranging from 2–8 cmH2O.  
The amount and effect of any positive pressure generated with HFNC can be influenced 
by a variety of factors.  Kubicka et al101 demonstrated in infants (weight 835-3735gm) that 
pressure was only generated with a closed mouth.  It was also determined that there was 
a linear relationship between the pressures generated, flow and weight of the infant.  
Urbano et al102 showed similar findings in a paediatric airway model.  A linear relationship 
was shown in the pressure measured in the pharynx and airway with increasing flow rates 
(5-20 L/min with maximal pressure 4cmH2O) with the mouth closed.  This was lost with an 
open mouth, regardless of the flow rate.  In a study on infants with bronchiolitis, Arora et 
al103 also showed that there were significant differences in nasopharyngeal pressures 
generated between open and closed mouth states, yet they determined that a linear 
relationship was only apparent between flow and pressure generated, not weight of the 
infant. 
The linear relationship between flow rate and pressure generated has been demonstrated 
in adult studies.  Groves and Tobin104 measured flow rates (up to 60 L/min) on health adult 
volunteers.  With increasing flow rates, increased pressure was generated, but the 
pressure generated was higher in a closed mouth state.  The study by Parke et al98 
showed similar findings, with pressure increasing with increasing flow, and greater 
pressure generated with the mouth closed.  A physical (test lung model) study by Hasan 
and Habib14 further showed that pressure delivered is also affected by the nares-prong 
interface.  Moderate leak around the nares resulted in lower upper airway pressures. 
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While many studies have demonstrated that HFNC therapy delivers positive pressure, it is 
unlikely to be above 8cmH2O105 and is compromised with the mouth being open and 
leakage around the nares.   
3.2.5 Summary of mechanism of action 
There continues to be a lack of universal agreement on the exact mechanism of action of 
HFNC therapy.  It has an ability to match inspiratory demands; wash out nasopharyngeal 
dead space; and generate, albeit unpredictably and uncontrollably, positive airway 
pressure (in the absence of leak around nares and mouth). Yet its use in clinical settings is 
increasing possibly due to its ease of use and application, patient tolerance and the 
perceived theoretical clinical benefits. 
3.3 HFNC therapy in pre-term to term neonates 
Several systematic reviews have assessed the evidence for using HFNC therapy as 
respiratory support in pre-term infants.86,106–108 Here, however, a dilemma arises in 
assessing the studies due to the heterogeneity in study design, participants, intervention, 
comparators, and primary and secondary outcome measures. While HFNC therapy has 
predominantly been compared to nasal CPAP in pre-term infants,109 other studies 
compared HFNC therapy to low flow nasal oxygen therapy,110,111 or another form of HFNC 
therapy.112 In those trials comparing HFNC therapy to nasal CPAP, the clinical context for 
its use varies: as an alternative to CPAP post-extubation,106 as support for respiratory 
distress instead of CPAP,113 and in weaning off CPAP.114 Yet, some studies only report the 
physiological effects of HFNC13,82,99 and fail to include important clinical measures such as 
the need for intubation/re-intubation. Designs ranged from randomised controlled trials 
(RCTs),106,110,112–114 to observational13,82,84,99,101,115 and retrospective116,117 studies (Table 
3.1).  Of the 16 studies the high flow interventions varied considerably, with flow rates 
ranging from 0.5 L/min to a maximum of 8 L/min 
The Cochrane Review by Wilkinson et al107, defined 'high flow' as rates >1 L/min, and 
identified four small RCTs that compared HFNC with other modes of respiratory support. 
Due to the heterogeneity of outcome measures and interventions, a meta-analysis was 
inappropriate. The overall conclusion was that there was insufficient evidence to determine 
the safety and efficacy of HFNC therapy compared to other forms of respiratory support for 
premature infants. 
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A subsequent systematic review in 2012, which included study designs beyond RCTs, 
found 19 studies to assess, of which 16 were clinical.106  While it found that distending 
pressures generated by HFNC therapy increased with increasing flow rates, there was still 
a lack of clarity in determining the safety and efficacy of this treatment option for premature 
infants. 
Another review in 2013, assessing HFNC studies from neonates to adults, appraised eight 
neonate-specific studies86.  In respect to the neonatal studies reviewed, the authors 
determined that there was no definitive data supporting the use of HFNC therapy over 
CPAP in neonatal respiratory distress. 
Despite all these reviews demonstrating an increasing use of HFNC therapy in nurseries 
globally, there remains inadequate evidence to fully endorse the safety or efficacy of this 
treatment. Large RCTs are needed, with consistency in design, methods, interventions, 
outcomes measured, and the type of HFNC device used. While earlier studies may have 
used unheated HFNC84,118–120, more recent studies demonstrate that heated and 
humidified HFNC systems are the norm65,99,110,115,116,121–126, and as such should be 
considered in any future study design.  
3.4 HFNC therapy in adults 
While the first published study on HFNC therapy was described in an adult population in 
1994,83 a paucity of clinical studies have been undertaken since.86 Three systematic 
reviews have assessed the available evidence,81,86,127 showing that to date, there are only 
two RCTs,98,128 six retrospective/prospective observational studies,129–134 three case 
studies,135–137 and two physiological studies on healthy adult volunteers100,138 (Table 3.2). 
Of note is that while neonatal studies used NCPAP as the comparative therapy for HFNC, 
adult studies used low flow nasal cannula or face mask oxygen therapy. Of the 16 studies 
the high flow interventions varied considerably, with flow rates ranging from 15 L/min to 60 
L/min. The common findings amongst the adult studies are that HFNC therapy may 
optimise oxygenation for patients with moderate hypoxaemic respiratory failure,81 HFNC is 
comfortable,132 and the need for escalation to other forms of support can be detected 
within 60–90 minutes of application.86,130 
Again, however, limited evidence exists to support the claim that ventilation is improved, 
and further research is required to both evaluate HFNC therapy effectiveness in the adult 
population, and provide evidence-based guidance for clinical application. 
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Table 3.1 – Neonatal (Pre-term to term) studies with HFNC therapy 
Author Year Study Design Participants (n= ) Comparator/Intervention Outcome Comments 
Locke118 1993 Observational 
n=13 neonates, 
mean GA 30 
weeks, mean BW 
1377g 
Unheated non-humidified 
HFNC at flow rates 0.5–
2 L/min. Two prongs at 
0.2 cm & 0.3 cm 
Oesophageal pressure 
monitored. No pressure 
generated at any flow 
with small prongs. 
Larger ones delivered 
increasing pressure 
with increasing flow. 
Mean pressure of 
9.8 cmH2O at 
2 L/min. 
Sreenan84 2001 Observational 
n=40 neonates, 
mean PCA 30.3 
weeks, mean 
weight 1260 g 
Unheated, humidified 
HFNC vs NCPAP. Flow 
rates 1–2.5 L/min 
Oesophageal pressure 
monitored. No 
difference in frequency 
or duration of apnoeas.  
Formula to predict 
flow required for 
pressure of 
6 cmH2O = 0.92 + 
(0.68 x infant 
weight). 
 
Campbell113 2006 Prospective RCT 
n=40 neonates, 
mean GA 27 
weeks, ≤1250 g, 
previously 
intubated 
Unheated, humidified 
HFNC (1.4–1.7 L/min) vs 
NCPAP (5–6 cmH2O)  
Significantly higher rate 
of re-intubation with 
HFNC vs NCPAP 
within 7 days. HFNC 
group had higher rate 
of apnoeas and 
bradycardias, and 
increased oxygen use. 
No difference in 
trauma to nares. 
Woodhead112 2006 
Prospective 
randomised 
crossover trial 
n=30 neonates, 
mean GA 32 
weeks, previously 
intubated 
24 hours of HHHFNC or 
unheated non-humidified 
HFNC (standard). Mean 
flow 3.1 L/min 
Higher re-intubation 
rate in standard HFNC. 
No difference in RR at 
24 hours. Lower 
incidence of nasal 
trauma and respiratory 
effort in HHHFNC. 
Comparator not 
relevant now as 
HFNC systems are 
heated and 
humidified. 
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Saslow82 2006 
Observational, 
crossover 
study 
n=18 neonates, 
GA 28 weeks, 
<2 kg with mild 
RDS 
HHHFNC (3–5 L/min) vs 
NCPAP (6 cmH2O) 
No difference in work of 
breathing and RR at 
any flow rate; pressure 
did not vary until 
5 L/min. 
Physiologic study, 
no clinical 
outcomes 
measured. 
Shoemaker117 2007 Retrospective, descriptive 
n=101 neonates, 
mean GA 28.1 
weeks (era 1), GA 
27.6 weeks (era 
2) 
HHHFNC (n=65) vs 
NCPAP (n=36). Flow rate 
5.2–8 L/min 
Lower re-intubation 
rates and days 
ventilated in HHHFNC 
group. HHHFNC well 
tolerated. 
No difference in 
adverse outcomes 
following 
introduction of 
HHHFNC. 
Spence99 2007 Observational 
n=14 (6 studied 
on both HFNC & 
CPAP, 2 studied 
on CPAP only, 6 
studied on HFNC 
only) neonates, 
median GA 30 
weeks, median 
weight 1589 g 
HFNC 1–5 L/min (n=12) vs 
NCPAP 2–6 cmH2O (n=8)  
Intrapharyngeal 
pressures measured. 
HHHFNC pressure 
increased with 
increasing flow. 
No comparison 
between pressures 
generated on 
HFNC and NCPAP. 
 
Holleman-
Duray116 2007 Retrospective 
n=114 neonates, 
mean GA 27 
weeks, mean 
weight 1000 g, 
with RDS and 
extubated 
HHHFNC 4–6 L/min 
(n=65) vs NCPAP (n=49) 
No major differences in 
outcomes or oxygen 
use. Infants extubated 
to HHHFNC spent less 
days on ventilator and 
had lower ventilator 
rate. 
Early extubation 
protocol in place 
during HHHFNC 
period. 
Jasin139 2008 Case study 
n=1 neonate, GA 
26 weeks, BW 
901 g 
 
Extubated to 4 L/min 
HHHFNC at 20 days, 
weaned to 2 L/min 
HHHFNC at 36 days. 
Scalp emphysema, 
pneumo-orbitis and 
pneumocephalus 
noted and 
HHHFNC ceased 
on day 36 of life. 
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Wilkinson115 2008 Observational 
n=18 neonates, 
median PCA 33.6, 
median weight 
1619 g 
HHHFNC 2–8 L/min 
Pharyngeal pressure 
monitored. Pressure 
increased with 
increased flow; inverse 
relationship between 
weight and pressure; 
mouth position 
irrelevant. 
Formula to predict 
pressure made: 
P(cmH2O) = 
2.6+(0.8 x flow rate) 
– (1.4 x infant 
weight). 
Kubicka101 2008 Observational 
n=27 neonates, 
PCA range 29.1–
44.7 weeks, 
weights 835–
3735 g 
HHHFNC, Vapotherm 
(n=16) and F&P (n=11) 
Oral pressure 
monitored. No pressure 
generated with mouth 
open; pressure 
increased with flow 
(infants <1500 g) with 
mouth closed. 
 
Lampland13 2009 Observational 
n=15 neonates, 
mean GA 29.5 
weeks, mean 
weight 1324 g 
HHHFNC 1– 6 L/min vs 
NCPAP 6 cmH2O 
Oesophageal pressure 
monitored. RR rate 
increased as flow rate 
decreased. Pressure 
increased with 
increasing flow. 
Other physiological 
parameters did not 
differ. 
Miller110 2010 Prospective RCT 
n=40 neonates, 
mean GA 28 
weeks, previously 
intubated 
Vapotherm vs Fisher & 
Paykel HHHFNC. Flow 
rate 6 L/min 
 
No statistical difference 
in rate of failure; 
Vapotherm group 9%, 
F&P group 18%, at 72 
hours. 
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Abdel-
Hardy114 2011 
Prospective 
RCT 
n=60 neonates, 
mean GA 31 
weeks, mean 
weight 1600 g 
Weaning from NCPAP 
with/without weaning to 
HHHFNC. Flow rate 0.5–
2 L/min 
No difference in 
success of weaning 
from NCPAP. 
Sustained NCPAP had 
fewer days on 
supplemental O2 and 
shorter duration of 
respiratory support. 
63% of infants on 
HHHFNC did not 
require FiO2 >0.21. 
Manley140 2012 
RCT, 
multicentre, 
non-inferiority 
n=303 neonates, 
mean GA 27 
weeks, mean 
weight 1041 g 
HFNC (5–6 L/min) vs 
NCPAP (7 cmH2O) after 
extubation 
HFNC was non-inferior 
to NCPAP, with 
treatment failure 
occurring in 34.2% of 
HFNC group and 
25.8% in NCPAP. 
17.8% infants’ 
re-intubated in HFNC 
compared to 25.2% in 
NCPAP group. 
Almost half the 
infants failing HFNC 
were successfully 
treated with 
NCPAP. Nasal 
trauma significantly 
reduced in HFNC 
group, no 
differences in 
adverse events or 
other complications 
between groups. 
de Jongh94 2014 
Observational, 
crossover 
study 
n=20 neonates, 
mean PCA 32 
weeks, mean 
weight 1516 g 
HHHFNC (3–5 L/min) and 
NCPAP (5–6 cmH2O) 
RIP used to measure 
WOB. HHHFNC is 
comparable to NCPAP 
as a viable non-
invasive mode of 
respiratory support. 
 
CPAP = continuous positive airway pressure; NCPAP = nasal CPAP; HFNC = high flow nasal cannula; HHHFNC = heated and humidified, high flow nasal cannula; 
GA = gestational age; PCA = post conceptual age; BW = birth weight; F&P = Fisher & Paykel Healthcare; RIP = respiratory inductive plethysmography; WOB = work 
of breathing; RDS = respiratory distress syndrome; RCT = randomised controlled trial 
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Table 3.2 – Adult studies with HFNC therapy 
Author Year Study Design Participants (n=) Comparator/Intervention Outcome Comments 
Dewan83 1994 Prospective observational 
n=10 patients with 
COPD, in clinic 
High flow trans-tracheal 
oxygen (mean 5.1 L/min) 
vs low flow trans-tracheal 
oxygen (mean 
1.05 L/min); and HFNC 
(mean 5.9 L/min) vs 
LFNC (mean 1.62 L/min)  
Exercise distance with 
HFNC was 2.38 times 
greater than LFNC; no 
difference in dyspnoea 
scores with HFTTO and 
HFNC. 
 
Chatila141 2004 
Non-
randomised 
crossover 
n=10 stable COPD, 
in outpatient clinic 
HFNC (Vapotherm) at 
20 L/min vs low flow, non-
humidified O2 at 2.5–
6 L/min 
Significant improvement 
in PaO2 and SpO2 
during exercise with 
HFNC. No significant 
improvement at rest with 
low flow. 
Only half of patients 
were able to 
complete both 
exercise periods (12 
minutes). 
Groves100 2007 Observational n=10 healthy individuals 
HFNC (F&P) with flows 0–
60 L/min 
Pharyngeal pressure 
monitored. Significant 
positive pressure 
generated, linear 
relationship with flow, 
and dependent on mouth 
open/closed. 
 
Calvano136 2008 Case study 
n=1 elderly 
dementia patient 
with severe 
hypoxaemia, in ICU 
HFNC (Vapotherm) 
HFNC improved gas 
exchange, dyspnoea and 
was well tolerated; 
marked improvement in 
quality of life. 
Unable to tolerate 
face mask. Patient 
was for palliative 
care. 
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Price142 2008 Prospective audit 
n=72 patients, 
majority with 
hypoxaemic 
respiratory failure, 
in HDU 
HFNC (Vapotherm) 
No significant 
improvements in 
baseline PaO2, arterial 
O2 saturation or RR. 
 
Roca132 2010 
Prospective 
sequential 
intervention 
n=20 patients with 
ARF in ICU 
HFNC (30 L/min) vs face 
mask oxygen (15 L/min) 
Less dyspnoea and 
mouth dryness, more 
comfortable on HFNC. 
Higher PaO2 and lower 
RR on HFNC. 
Self-evaluation of 
patient comfort after 
30 min of each 
therapy. 
Tiruvoipati128 2010 
Prospective 
randomised 
crossover 
n=50 patients post-
extubation in ICU 
HFNC (F&P) 30 L/min vs 
face mask 30 L/min 
No significant difference 
in SpO2, ABG and 
patient comfort. 
Tolerance 
significantly better 
with HFNC. 
Parke98 2011 Prospective RCT 
n=60 patients with 
mild–moderate 
hypoxaemia in ICU 
HFNC vs face mask 
Fewer treatment failure 
and desaturations in 
HFNC group. 
Flows from face 
mask not reported. 
Sztrymf130 2011 Prospective pilot study 
n=38 patients with 
hypoxaemic 
respiratory failure 
non-responsive to 
NRB mask, in ICU 
HFNC (mean 49 L/min)  
Improved PaO2 and 
PaO2/FiO2 at 1 and 
24 hr, decreased RR, HR 
and WOB up to 48 hr 
with HFNC. 
9 HFNC were 
intubated; did not 
decrease clinical 
signs at 1 hr. Well 
tolerated. 
Corley134 2011 Observational 
n=20 post-cardiac 
surgical patients 
with respiratory 
distress, in ICU 
HFNC (35–50 L/min) vs 
nasal cannula/face mask 
(variable flow) 
Oropharyngeal pressure 
and EELI measured. 
HFNC generated 
3±1.2 cmH2O. RR, 
dyspnoea score and 
PaO2/FiO2 ratio 
improved. 
 
Boyer135 2011 Case study 
n=1 with pulmonary 
fibrosis and ARF, in 
ICU 
HFNC at 40 L/min Improved PaO2, well tolerated. 
Was able to 
discharge home and 
palliated. 
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Carratala137 2011 Case study 
n=5 elderly patients 
with acute heart 
failure and 
pulmonary 
oedema, in ICU 
HFNC (F&P) up to 
60 L/min 
Analysis at 24 hours 
post-HFNC. Significant 
reduction in RR and 
increase in PaO2 post-
HFNC. 
All treated in ED 
with non-invasive 
ventilation prior to 
HFNC. High degree 
of patient comfort. 
Sztrymf131 2012 Prospective observational 
n=20, patients with 
ARF in ICU 
HFNC (32–50 L/min) vs 
non re-breathing mask 
(9–15 L/min) 
Improved RR, SpO2 and 
PaO2 immediately after 
HFNC, sustained up to 
12 hours. 
6 patients from 
HFNC intubated 
Lenglet129 2012 Prospective observational 
n=17 patients with 
hypoxaemic 
respiratory failure 
non-responsive to 
NRB mask, in ED 
HFNC (F&P) used 
following failure of non-
rebreather reservoir mask 
therapy 
Decreased RR, improved 
dyspnoea score, and 
increased SpO2 with 
HFNC use. 
Noise from HFNC 
similar to non-
rebreather mask 
and ambient 
department. 
Peters133 2012 Retrospective 
n=50 patients with 
do-not-resuscitate, 
in ICU 
HFNC (F&P) used for 
hypoxic respiratory 
distress 
Improvement in SpO2 
and RR, 18% escalated 
to NIV. 
 
Mundel138 2013 
Randomised, 
controlled, 
crossover 
study 
n=10 healthy 
individuals 
HFNC (F&P) at flows 15, 
30 and 45 L/min 
RIP measured. Increase 
in tidal volume and 
decreased  RR during 
wakefulness. During 
sleep, 20% fall in minute 
ventilation (Vt decrease 
not RR). 
4 x 60 minute visits, 
one week apart, 
during wakefulness 
and sleep. Nasal 
cavity model used to 
compare with CPAP 
during simulated 
breathing. 
Mechanism of action 
different between 
the two. 
HFNC = high flow nasal cannula; LFNC = low flow nasal cannula; HFTTO = high flow trans-tracheal oxygen; EELI = end expiratory lung impedance; ARF = acute 
respiratory failure; F&P = Fisher and Paykel Health Care-Optiflow system; NRB = non-rebreather; ED = emergency department; ICU = intensive care unit; HDU = 
high dependency unit; RIP = respiratory inductive plethysmography; Vt = tidal volume 
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3.5 HFNC therapy in infants and children 
Within the paediatric population (ages one month to 16 years), evidence from RCTs is 
even more limited than for adults and neonates, with only one published RCT.143 The 
remaining studies comprise retrospective cohort reviews, or prospective observational 
studies (Table 3.3). Of the 17 studies the high flow interventions varied considerably, with 
flow rates ranging from 1L/min to 8 L/min. However, one systematic review, limited to 
infants with bronchiolitis, identified six ongoing RCTs. In future these  may add to the 
evidence base.144 
Importantly, four studies distinguish 'responders' to HFNC therapy from 'non-
responders',15,145–147 suggesting that specific clinical indicators may be useful in predicting 
success of the therapy, and in a timely manner. Key clinical indicators identified are 
respiratory rate and heart rate, and those who 'respond' to HFNC therapy do so with a 
significant decrease (20%) from initial baseline in these parameters within 60–90 minutes 
of starting therapy. This may be clinically important in reducing the risk of delay in 
escalating respiratory support, and mitigating potential sequelae as a result of the delay.  
Other studies of children revolve around physiological measurements of pressure while on 
HFNC therapy. Two studies measured nasopharyngeal pressure,80,148 one oesophageal 
pressure (as a proxy for pleural pressure),92 and the other measured both pharyngeal and 
oesophageal pressures.93 All studies determined that increasing flow resulted in increased 
pressure, and that this likely improved the effort of breathing.80,92,93,148 Milesi et al93 
concluded that flows ≥2 L/kg/min were associated with a mean pharyngeal pressure of 
≥4 cmH2O. Arora et al148 determined that there was a linear relationship between 
increasing flow (1–6 L/min) and nasopharyngeal pressure (NP) in both open and closed 
mouth states. A mean NP of 3.4 cmH2O showed clinical improvement, with a pressure 
maximum of 5 cmH2O. Rubin et al92 measured oesophageal pressure as a reflection of 
pleural pressure and hence an objective measurement of breathing effort (as opposed to 
subjective scoring systems). In this study, effort of breathing decreased 25% when the flow 
rate was increased from 2 to 8 L/min.  
The majority of paediatric studies focus on a specific population group: infants with 
bronchiolitis. This is likely due to the fact that bronchiolitis is the leading cause of non-
elective hospitalisation worldwide20, and that this population is a homogenous group. Most 
studies took place in an ICU. This may be because this level of respiratory support has 
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normally been administered in a dedicated ICU setting, whether paediatric or mixed 
population ICUs. However it may be possible to deliver this level of support outside the 
PICU, in lower (ward) environments.  
Three studies examined HFNC therapy in the ward environment.143,149,150 Another study 
commenced support in the emergency department, and then transferred patients to the 
PICU,151 and another assessed HFNC therapy used in the retrieval of paediatric 
patients.152 In two of the three ward studies, no escalation to further respiratory support 
occurred.143,149 Only one study reported transfer of patients to the PICU, where out of 5 
patients transferred (25 patients in study), 1 was intubated and the remaining 4 required 
NIV.150 This study also showed an economic benefit to managing patients on the ward, 
when compared to historical data for infants with bronchiolitis admitted to the PICU. The 
percentage of costs derived from these patients being cared for in the PICU (over the 
previous 5 seasons) was 12.6%, and decreased to 4.8% with the implementation of HFNC 
therapy in this hospital's ward environment.150 However, the study acknowledged that 
further studies are required to completely determine the cost saving for this institution. 
Two case series studies of HFNC therapy use in paediatrics have been reported. One 
details HFNC therapy used in a child with inhalation burns and a post-extubation stridor. In 
this scenario, HFNC therapy successfully prevented urgent intubation, with the patient 
maintained comfortably over a number of days.153 The second case series reported three 
cases of air leak syndrome (pneumothorax and pneumomediastinum) which occurred 
during the use of HFNC therapy in children with bronchiolitis, pneumonia and post-
extubation (for subdural haematoma)154. However, the authors concluded that there was 
no way to determine cause and effect in these three cases. Certainly, infants with 
bronchiolitis developing spontaneous pneumothorax has been documented, and in one 
case series this was successfully treated with HFNC therapy.155 So while it remains a 
potential adverse event, no other reports exist to date of spontaneous air leak syndrome 
occurring in any studies presented here, or assessed in various systematic reviews. 
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Table 3.3 – Studies of HFNC in infants and children 
 
Author
  
Year Study Design Participants (n=) Comparator/Intervention Outcome Comments 
Byerley153 2006 Case study 
n=1, 12 month old 
burn patient with 
inhalation injury 
and post-extubation 
stridor, in PICU 
HFNC 
Prevented urgent 
intubation, comfort 
increased as respiratory 
distress decreased. 
 
McGinley156 2009 
Prospective 
observational 
study 
n=12 children (10±1 
years) with 
obstructive sleep 
apnoea. In Sleep 
Clinic 
Nasal insufflation at flow 
20 L/min 
Improved oxygenation and 
decreased arousal led to 
decreased occurrence of 
obstructive apnoea. 
Comparable 
therapy to CPAP. 
Spentzas80 2009 
Prospective 
observational 
study 
n=46, newborn to 
12 years, median 
age 2.8 years, in 
PICU 
Received NC or mask 
before switch to HFNC. Flow 
rates 8–12 L/min for infants 
and 20–30 L/min for 
children. Np measured. 
Clinical indicators including 
RDS, COMFORT scale, 
and SpO2 improved on 
HFNC within 60–90 mins. 
Average positive airway 
pressure 4±1.99 cmH2O. 
 
Pressure increased 
with flow, and an 
association with 
weight. 
 
Heterogeneous 
population. 
No adverse events. 
McKiernan145 2010 
Retrospective 
observational 
study 
n=115 infants 
<2 years with 
bronchiolitis (median 
age 2 and 3 months 
respectively), in 
PICU 
Pre-HFNC n=57, post-
HFNC n=58, flow rate 7 and 
8 L/min. 
Reduced intubation after 
HFNC implemented (14% 
absolute risk reduction). 
No significant decrease of 
RR to HFNC within 1 hour 
predicted failure. 
No adverse events 
in HFNC group.  
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Schibler15 2011 
Retrospective 
observational 
study 
n=298 infants 
<2 years, in PICU  
HFNC to max flow of 
8 L/min 
19% required NIV and 
12% required intubation 
overall. In bronchiolitis 
patients only 4% required 
escalation of therapy. 
Bronchiolitis responders 
identified by 20% reduction 
in HR and RR within 
90 mins of therapy 
commencing. 
No adverse events. 
Overall there was a 
decrease in 
intubation from 
37% to 7% over 
study period.  
Abboud147 2012 
Retrospective 
observational 
study 
n=113, age ≤12 
months with 
bronchiolitis, in PICU 
HFNC (flow 3–8 L/min) 
n=92 responders, n=21 
non-responders. Non-
responders did not 
change their RR and 
had higher PRISM 
scores. 
Persistence of 
desaturations was 
strongly associated 
with HFNC failure. 
RR was predictive, 
responders 
decreased their RR 
significantly (non-
responders did not 
change their RR 
and had lower RR 
to begin with and 
higher PCO2, 
possibly due to 
inability to 
compensate.  
Arora148 2012 
Prospective 
observational 
study 
n=25, mean age 
78.1 days, infants 
with bronchiolitis in 
PED 
HFNC commenced 1 L/min 
to max of 8 L/min. 
Np measured 
Linear increase in 
pressure as flow 
increased. Average 
0.45 cmH2O pressure 
increase with each 1 L/min 
flow increase. 
Weight and gender 
not associated with 
pressure 
generated. Patients 
transferred to ward 
and PICU. 
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Hilliard143 2012 
Prospective, 
randomised, 
open pilot study 
n=19 infants (median 
age 3.0 months) with 
bronchiolitis, in a 
ward 
HFNC (n=11) vs head box 
(n=8) 
Median SpO2 higher in 
HFNC group at 8 and 12 
hours. 
No adverse events, 
no admission to 
PICU or escalation 
of respiratory 
support. 
Wing151 2012 
Retrospective 
observational 
study 
n=848. Three 
cohorts, pre-HFNC 
(mean age 
4.6 years), pre-
guidelines (mean age 
4.1 years) and post-
guidelines (mean age 
4.8 years). In PED 
then admitted to 
PICU 
HFNC 
Post guideline 
implementation there was 
a 50% relative risk 
reduction in intubations, 
mostly accounted for in the 
PED. 
Heterogeneous 
population with 
acute respiratory 
insufficiency. 
Bressan149 2013 
Prospective 
observational 
pilot study 
n=27 infants (median 
age 1.3 months) with 
mod–severe 
bronchiolitis, in ward 
HFNC at flow rate = weight 
+ 1 (L/min) 
RR decreased by 13–20 
breaths per minute in the 
first 3 hours of HFNC. 
No adverse events, 
no escalation of 
therapy. 
Brink146 2013 
Prospective 
observational 
study 
n=109, children 
(median age 6 and 5 
months respectively) 
requiring respiratory 
support, in PICU 
HFNC at 2 L/kg/min (n=72) 
vs NP-CPAP (n=37) 
Escalation of therapy could 
be predicted by failure of 
HR and RR response, and 
FiO2 ≥0.5 within 2 hours. 
26% of HFNC 
required escalation 
of therapy 
compared to 18% 
on NP-CPAP. 
HFNC had a 
shorter therapy 
time compared to 
NP-CPAP. No 
pneumothorax in 
the HFNC group, 2 
in the NP-CPAP. 
Reduced sedation 
use in HFNC 
group. 
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Kelly157 2013 
Retrospective 
observational 
study 
n=498 infants 
<2 years presenting 
with respiratory 
distress, in two PEDs 
HFNC 
8% required intubation. 
Initial RR >90th percentile 
for age, venous 
PCO2  >50mmHg and pH 
<7.3 increased risk of 
HFNC failure. 
Prematurity was 
not predictive of 
failure. 
Milesi93 2013 
Prospective 
observational 
study 
n=21, <6 months with 
RSV bronchiolitis, in 
PICU 
HFNC at flow 1, 4, 6, 
7 L/min, 
Pp and Op measured 
simultaneously 
Flow ≥2 L/kg/min 
associated with mean PP 
≥4 cmH2O. 
Homogenous 
population. No 
adverse events. 
Gonzales-
Martinez150 2013 
Prospective 
observational 
study 
n=25, infants 
<18 months (median 
age 2.0 months) with 
bronchiolitis, in ward 
HFNC 
Significant reduction in 
HR, RR and scale of 
severity after initiation of 
HFNC. 
No adverse events. 
5 admitted to PICU 
(80% reduction on 
historical data, and 
substantial 
economic saving), 
1 intubated, 4 NIV. 
Hedge154 2013 Case study 
n=3, 2 month old with 
bronchiolitis and flow 
6 L/min (PICU), 
16 year old with 
cerebral palsy with 
flows at 4, 8, 15, 
20 L/min (HDU to 
PICU), 22 month old 
with subdural 
haematoma with 
6 L/min flow post-
extubation (PICU) 
HFNC and insufflation used All developed air leak syndrome. 
Exact cause and 
effect could not be 
established. 
Rubin92 2014 
Prospective 
observational 
study 
N=25, children 
<18 years, median 
age 6.5 months. In 
PICU and 
cardiothoracic ICU 
HFNC at 2–8 L/min and 
compared to CPAP 4–
5 cmH2O (while intubated) 
and NC. Op measured 
Increased flow increased 
pressure. Decreased RR 
with increased flow. 
Not powered for 
CPAP comparison. 
Heterogeneous 
population. No 
adverse events. 
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Schlapbach152 2014 
Retrospective 
observational 
study 
n=793 infants 
<2 years, transported 
by specialised 
paediatric retrieval 
team (2005–2012) 
Pre- and post-HFNC 
introduction to retrieval 
Significant reduction in 
intubation by retrieval 
team. 
No patient retrieved 
on HFNC needed 
intubating during 
transport or 
developed 
pneumothorax or 
cardiac arrest. 
HFNC = high flow nasal cannula; NC = nasal cannula; CPAP = continuous positive airway pressure; NP-CPAP = nasopharyngeal CPAP; NIV = non-invasive 
ventilation; RR = respiratory rate; HR = heart rate; RDS = respiratory distress syndrome; Np = nasopharyngeal pressure; Op = oesophageal pressure; 
Pp = pharyngeal pressure; PICU = paediatric intensive care unit; PED = paediatric emergency department 
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3.6 Adverse events 
Reports of adverse events appear to be limited in the studies published to date. Within the 
pre-term/neonatal population, nasal mucosal trauma has been associated with HFNC that 
is unheated and not humidified.112 One case report exists of an incidence of scalp 
emphysema and pneumocephalus in a neonate.139 In infants and children, most studies 
report no adverse events. However in a recent prospective study, two patients had 
abdominal distension and one a mucosal injury during HFNC therapy.146 These cases are 
relatively infrequent, and causation is unclear. In adult studies there have been no reports 
of adverse events such as pneumothorax/air leak syndrome, abdominal distension or 
nasal trauma. However, ongoing concern remains over the potential for adverse events 
from HFNC therapy, thus further research is required, as is monitoring of outcomes where 
HFNC therapy has become part of practice. This may be addressed with large RCTs. 
3.7 Feeding method during HFNC therapy 
During HFNC therapy delivery, the mode of feeding used may also be of interest. 
Generally, when there is severe respiratory distress, patients are hydrated either via 
intravenous fluid infusion or entrally via nasogastric tubes.2 However, as a patient's 
respiratory status improves, the potential exists to transition to oral feeding. This is 
valuable, especially in the pre-term, neonatal and infant populations due to comfort derived 
from breast/oral feeding, and the associated establishment of suck/swallow reflex 
especially with pre-term neonates. However, within the current literature, feeding mode 
while receiving HFNC is seldom reported. In a recent survey (2013) of neonatal ICUs in 
the United Kingdom, 46% of respondents found it easier to bottle/cup feed infants on 
HFNC, compared to nasal CPAP.158 Three paediatric studies report the use of oral feeding 
while on HFNC, all with no apparent adverse events such as aspiration.145,146,150 For 
clinicians, it is likely that the argument surrounding whether to orally feed stems from the 
amount of flow  delivered and the perceived inability of the neonate/infant to coordinate a 
suck-swallow reflex with higher flows. However, an equally likely explanation may be that a 
neonate/infant's work of breathing may reduce their ability to suck/swallow effectively in 
these situations, and as their respiratory function improves, they are at no greater risk of 
aspiration from orally feeding on high flows than at any other time.  
The importance of resolving this dilemma lies in the comfort that breast/bottle feeding can 
deliver, as well as the impact on hospital length of stay. Close clinical observation would 
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be needed to ensure the neonate/infant is not compromised while feeding, and 
determinations made in the first instance as to the neonate/infant's ability to manage oral 
feeds and work of breathing. Usual practice is to ensure infants are established on oral 
feeds prior to hospital discharge, so commencing oral feeds while still on HFNC therapy 
may assist with decreasing hospital length of stay. However, although it lies beyond the 
scope of this thesis, further robust research is needed to determine if there is higher risk of 
aspiration during oral feeding, and what the benefits are, compared to other modes such 
as enteral or intravenous feeding.  
3.8 Practice creep 
Scope creep is a term often used in project management and refers to uncontrolled 
changes or continuous growth in a project's scope.159 Within medicine and nursing, a 
situation that moves beyond traditional boundaries can be labelled similarly as 'practice 
creep'.160,161 This concept can be applied to the rapid uptake of HFNC therapy within 
clinical practice, not only in ICUs but also other acute care environments.  
The conundrum with practice creep in this context is that it is based on collections of 
studies that still have limited power to determine the effectiveness, efficacy and safety of 
HFNC across the whole patient age range. Yet, as it has been perceived in clinical 
practice to be a useful modality of respiratory support, it is becoming more widely used 
without the rigour of a well-constructed RCT underpinning its process and limits. 
3.9 Conclusion 
This chapter described the mechanism of action of HFNC and presented the studies that 
have been undertaken across the spectrum of patient ages. The consistent message is 
that large RCTs are needed to underpin the initial findings that all these studies have 
reported. Those findings are that HFNC therapy may offer an alternative mode of 
treatment for a range of patients with respiratory compromise; potentially offer a degree of 
PAP, which may help to keep obstructed airways open and provide respiratory support; 
improve work of breathing, be more comfortable and better tolerated than face masks; and 
may prove to be a cost-effective treatment, reducing hospital length of stay, PICU 
admission rates and the need for intubation. With the growing evidence of practice creep 
in the ward environments, it may also have a safe application outside of the ICU, where 
responders to therapy can be identified early, by predefined markers denoting escalation 
of therapy.  
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3.10 Publication 
The following publication presents the PICU experience at the Mater Children's Hospital, 
Brisbane, and the clinical use of HFNC therapy in managing patients with respiratory 
compromise. HFNC therapy has been in use since 2005, and in-unit data illustrates 
dramatically reduced intubation rates for infants presenting with bronchiolitis.15 Within this 
unit, HFNC therapy has become the first line of support for any patient with respiratory 
difficulties. In consultation with clinical experts in PICU and the advisory team, three 
patients were chosen with moderate to severe work of breathing with differing and distinct 
underlying pathophysiologies.   Cases were examined from each three categories over a 2 
year period.  Presented as a case series, three patients are profiled and their course of 
treatment and management during their PICU stay presented. The range of patients 
encompasses physiological conditions affecting small airways (bronchiolitis), large airways 
(asthma), and cardiopulmonary interplay (cardiomyopathy). 
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Introduction: High flow nasal cannula is an emerging treatment option in Paediatric Intensive Care Units
for paediatric patients in acute respiratory distress. Yet there is a paucity of literature describing its
clinical application in various presenting pathophysiologies.
Aim: To describe three cases with differing underlying pathophysiologies and their response to high flow
nasal cannula oxygen therapy.
Method: Patients admitted to the Paediatric Intensive Care Unit with bronchiolitis, asthma and cardiomy-
opathy, and treated with high flow nasal cannula therapy were searched in the Paediatric Intensive Care
database. The most representative cases were chosen to review.
Results: One infant and two children were reviewed. All were commenced on high flow nasal cannula
therapy in the Paediatric Intensive Care Unit and all demonstrated an improvement in their work of
breathing. There was also a substantial improvement in their haemodynamic status. No patient required
escalation to other forms of respiratory therapy.
Conclusion:High flownasal cannula therapy is a viable treatment option for a range of patients presenting
to the Paediatric Intensive CareUnitwith acute respiratory distress.More invasivemethods of respiratory
support may be avoided by the use of high flow nasal cannula therapy.
© 2013 Australian College of Critical Care Nurses Ltd. Published by Elsevier Australia (a division of
Reed International Books Australia Pty Ltd). All rights reserved.
Introduction
Respiratory illness is the leading cause of admission of infants,
children and adolescents to Australian hospitals each year.1
Bronchiolitis, asthma and pneumonia comprise the majority of
non-elective admissions due to acute respiratory insufficiency
(ARI) or acute respiratory failure (ARF) to Paediatric Intensive Care
Units (PICUs) across Australian and New Zealand hospitals (25% of
all admissions in 2011).2 Patients experiencing ARI due to cardiac
failure represent a smaller but no less important group.
For many of these patients, management with mechanical ven-
tilation through an endotracheal tube (ETT) is well established and
often lifesaving. More recently many have been managed non-
invasively (NIV) using continuous positive airway pressure (CPAP)
withnasal or facialmasks/prongs toavoid intubation.3,4 Bothmeth-
ods have clinical limitations. Intubation andmechanical ventilation
∗ Corresponding author at: Mater Children’s Hospital, Raymond Terrace, South
Brisbane 4101, Queensland, Australia. Tel.: +61 3163 5698; fax: +61 3163 1642.
E-mail addresses: Sara.Mayfield@mater.org.au,
saramayfield@hotmail.com (S. Mayfield).
can include complications such as ventilator associated pneumo-
nia (VAP), ventilator induced lung injury (VILI), airway injury due
to ETT placement and complications arising from sedation. For the
cardiac patient, intubation and mechanical ventilation can further
compromise left ventricular function especially in the presence of
cardiac failure.5 The limitations of NIV includemaintaining an ade-
quate seal to the face/nasal area, difficulty in keeping the apparatus
on and potential for septal erosion with nasal prongs.4,6
Heated and humidified high flow nasal cannula (HFNC) oxygen
therapy is an emerging treatment option for respiratory sup-
port in patients of all ages. HFNC therapy allows delivery of high
inspired gas flows of 2–70L per min, with or without blended
air/oxygen mix, is heated and humidified and is delivered via
nasal cannula. The humidity and warmth achieved with HFNC
improves mucociliary clearance and this facilitates the removal of
secretions.7 Additionally the bronchoconstriction reflex triggered
by cold, dry air is diminished.7 HFNC has been used successfully
as an alternative to nasal CPAP in the preterm infant population to
manage apnoea of prematurity and ARF.8–11 It has been reported
in preterm infants that HFNC provides end-expiratory pressures
of up to 6 cm H2O using flow rates of up to 8 L/min.
8,12 A recent
study by Spentzas and colleagues,13 demonstrated that in older
1036-7314/$ – see front matter © 2013 Australian College of Critical Care Nurses Ltd. Published by Elsevier Australia (a division of Reed International Books Australia Pty Ltd). All rights reserved.
http://dx.doi.org/10.1016/j.aucc.2013.05.004
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children HFNC provides an average positive expiratory pressure of
4.0±1.99 cm H2O. A physiologic study by Milesi and colleagues
14
has shown that a flow rate of ≥2L/kg/min improves the breath-
ing pattern and WOB of infants with bronchiolitis. While the CPAP
effect is yet to be fully understood it is hypothesised that the high
flow rates flush the anatomical dead space of the nasopharyngeal
cavity, resulting in improved alveolar ventilation as well as wash-
ing out carbon dioxide which has an effect on reducing apnoeas
secondary to hypercarbia.7
There is increasingevidence inpaediatric populations thatHFNC
is an effective treatment for ARI and ARF and is associated with
a decreased need for intubation and ventilation.13,15–17 Another
benefit of HFNC over NIV systems is an overall increase in patient
comfort levels and tolerance of the device.13,18 This may trans-
late into a reduced need for sedation agents. Furthermore there
is an overall decrease in both respiratory rate and WOB with this
apparatus as well as a reduced incidence of nasal trauma.12,14,19
While there is increasing uptake of the use of HFNC in the clin-
ical environment, some reviewers have urged caution in relation
to widespread use.20,21 Yet in the absence of higher levels of evi-
dence to guide clinical decision-making it becomes important to
report on the use of HFNC in the clinical setting to facilitate under-
standing of this therapy as an aspect of care. Case studies can be a
valuable research and educational resource and when reported as
such around a particular aspect of care, can provide new insights
and stimulate research in response to knowledge gaps.22 Following
an extensive literature search the use of HFNC as a treatment for
respiratory compromise arising from varied pathophysiologies in
paediatric patients has not been previously reported.
This paper aims to report the use of HFNC therapy within a
PICU on three patients with moderate to severe WOB and differ-
ing underlying pathophysiologies. We provide tertiary care in a
metropolitan paediatric hospital. In 2011, 17,618 patients were
admitted to our children’s hospital with over 1200 patients to our
PICU. Of the PICU admissions, 53%were non-elective admissions of
which28%werecomprisedof respiratoryor cardiac failurepatients.
HFNC therapy was used in 30% of all our patients to manage their
respiratory function at some point during the PICU admission,
either as primary support or following extubation. This was across
a range of patient diagnostic categories from respiratory to cardiac
topost-surgical cases andages (neonates, infants, childrenandado-
lescents). The three cases reported here were identified following
a review of the PICU electronic database.
This case series report was approved by the Mater Human
Research and Ethics Committee. The three cases were chosen as
representative of the use and management of patients on HFNC in
our unit. Parental consent was obtained to report the three cases
with the understanding that the cases would be non-identifiable.
Case histories
Case one
A 3-month-old (age adjusted) girl, born at 26 weeks gesta-
tion and weighing 3kg was admitted to PICU via the emergency
department (ED) with Respiratory Syncytial Virus (RSV) positive
bronchiolitis. On presentation she had severe to moderate WOB
with an increased respiratory rate (RR) and heart rate (HR). This
was day 4 of her illness.
She had previously required intubation at birth for increased
WOB andwas extubated to CPAP at 10h of age. CPAP continued for
six weeks prior to discharge home.
In PICU she was commenced on HFNC therapy at 6 L/min
(2 L/kg/min) and FiO2 adjusted to maintain oxygen saturations
>94%. The flow was dialled up slowly over a couple of minutes.
Fig. 1. Mean heart rate (HR) and respiratory rate (RR) from HFNC commencement
(time 0).
Within the first hour she responded to treatment as evidenced
by a significant decrease in her HR and RR from 170bpm and
70bpm to 149bpm and 51bpm respectively (Fig. 1). While she had
paracetamol prescribed as needed, she did not require any phar-
macological sedation (e.g. chloral hydrate) to assist tolerance of the
HFNC device. Feeding was managed via a nasogastric tube at a rate
specified by the dietician to meet her caloric needs. Within 24h
her WOB had improved to mild, and HFNC therapy was ceased by
turning the flowoff completely. During her admission therewas no
need to progress to other forms of ventilation such as mask/nasal
NIV or invasive ventilation. She was discharged from PICU after
37h to the ward on low flow nasal cannula oxygen of 0.5 L/min.
Four days later she was discharged home.
Case two
A 3-year-old girl weighing 17.5 kg was admitted to the PICU via
ED with viral (human metapneumovirus) induced exacerbation of
asthma. She had an increasedWOB thatwas unresponsive to salbu-
tamol metered doses (200mg/dose as bursts of 6 via spacer) in
the ED. She had been given a magnesium load of 1.8mmol intra-
venously (IV) in the ED and commenced on Cefotaxime 900mg,
eighth hourly (q8), IV. Steroids (hydrocortisone) were also com-
menced in the ED to address the inflammatory process, in addition
to the Cefotaxime to cover a suspected pneumonia.
On arrival to PICU she was speaking in short sentences with
little air movement on auscultation and she had severe intercostal
recession and a tracheal tug. Salbutamolwas continued in the PICU,
initially as a metered aerosol 200mg/dose (4 episodes over 1.5h
via a spacer) then as 5mg hourly via nebuliser. HFNC therapy was
commenced at 2 L/kg/min equating to 35 L/min on arrival to PICU.
Within the first hour of application of HFNC her HR and RR
dropped considerably from 157bpm and 56bpm to 146bpm and
48bpm respectively and continued to improve (Fig. 2). As herWOB
improved she was able to speak in longer sentences. After 38h of
HFNC therapy shewas able to beweaned to low flow nasal cannula
oxygen therapy.Weaning was achieved by reducing the FiO2 to .30
(maintaining saturations >92%) and turning the flow off.
She was transferred to the ward with a faint bibasal wheeze,
continuing salbutamol nebulisers (as required) and low flow nasal
cannula oxygen requirement tomaintain SaO2 >92%. Her PICU stay
was 1.75 days and she was discharged to home three days later.
Case three
A 2-year-old boy weighing 12kg was admitted to the PICU via
EDwith ahistory of cough, lethargy anddecreased oral intake. After
examination itwas determined that hewas in cardiac failure due to
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Fig. 2. Mean heart rate (HR) and respiratory rate (RR) over the first 5h of HFNC
commencement (time 0).
Fig. 3. Mean heart rate (HR) and respiratory rate (RR) during admission. HFNC
commenced at time 39, and ceased at time 135.
dilated cardiomyopathy. An echocardiogram revealed an ejection
fraction of 19% with severe mitral regurgitation and mild aortic
incompetence.
Initial treatment involved restricting fluid intake and admin-
istering oral Frusemide 10mg twice daily and a continuous
intravenous infusion of Milrinone at 0.5mg/kg/h. An oral
angiotensin-converting enzyme (ACE) inhibitor, captopril, was also
commenced at 0.6mg daily but ceased on day 2 and levosimen-
dan infusion commenced in its place (as a loading dose then as an
infusion at 0.05mg/kg/min) due to clinical deterioration.
On admission he was self-ventilating in room air with oxygen
saturations >96% and no increase in his work of breathing over the
first day of admission.
However over the following hours of day 2 his clinical condition
began todeterioratewith an increase inhis RR to93bpm,WOB (tra-
cheal tug, intercostal recession and ancillarymuscle use) and HR to
157bpm.HFNC therapywas commenced at 10 L/min andgradedup
to 24 L/min (2 L/kg/min) over 8h. Therewas improvement in his RR
(40bpm),WOB (only a tracheal tug) andHR (137bpm)within a few
hours of HFNC commencing and this continued to improve as the
flow gradually increased (Fig. 3).
HFNC therapy was continued for four days and then discon-
tinued as his WOB and respiratory status improved. He was then
transferred to another institution after 6 days for ongoing cardiac
management and work up to heart transplantation.
Discussion
The aim of this case series was to describe three cases with dif-
fering presentations and the effect of HFNC treatment on RR, HR
and WOB. Our previous practice typically used NIV for respiratory
support in the presence of ARI or ARF due to bronchiolitis, asthma
and for left ventricular afterload reduction in cardiac failure. Since
HFNC is delivering a similar type of respiratory support to NIV,19
we describe cases where this type of support has had an apparent
impact on the improvement of the patient.
Case one represents a typical infant presenting with bronchi-
olitis often seen as a seasonal presentation in the winter months.
In this case there was a positive response to the HFNC therapy
within the first hour as evidenced by a decrease in HR and RR and
no subsequent need to progress to any other form of respiratory
support. This is supported by findings from a previous study which
showed that thosewho responded to HFNC therapywithin the first
90min by a decrease in HR and RRwere unlikely to progress to any
other form of respiratory support. 16 Since commencing use of the
HFNC systemwithin our unit to treat infants with bronchiolitis we
have decreased our PICU length of stay for these patients by 24h
as compared to other centres in Australasia.2 When reviewing our
unit data for intubation rates in bronchiolitic infants, we observed
a decrease from 8% in 2011 to 3% in 2012, with both rates being
much lower than any other PICU in Australia and New Zealand. By
avoiding intubation in thesepatients the risks associatedwith inva-
sive ventilation, such as VAP, VILI and issues surrounding the use
of sedation (such as neuromuscular wasting and withdrawal) are
also avoided.
In Case two there was a drop in the HR and RR within the first
2h after HFNC treatment commenced. The response is unlikely to
be due to the effect of steroids as only one dose had been give prior
to HFNC commencing. Likewise, Salbutamol had been given via
a spacer/metered aerosol combination in ED and PICU with little
effect on decreasing HR, RR or WOB. Given the dose response time
for Cefotaxime is a number of hours this would not have had an
effect at this stage either. We suggest that the improvement in HR
and RR coincides with the commencement of HFNC therapy. This
effect is also in concordance with an earlier paediatric study.16 In
an adult case report by Boyer and colleagues,23 they also described
a similar treatment effect of improvement in HR and RR with the
application of HFNC therapy for an adult patient in respiratory dis-
tress with underlying pulmonary fibrosis.
Case three represents a challenge in balancing cardiac function
and support with respiratory function. In a healthy heart, the influ-
ence of spontaneous respiration on left ventricular (LV) function
is relatively unimportant. However in patients with diminished
myocardial function, such as dilated cardiomyopathy, a change
in intrathoracic pressure due to positive pressure ventilation (via
endotracheal tube), can cause an acute decrease in right ventricu-
lar (RV) preload and further decrease cardiac output, especially in
an under filled heart.5 The application though of short term CPAP
via NIV in these patients can reduce both RV and LV preload, but
without the adverse effects of invasive ventilation.24 This can give
the benefits of improved work of breathing and oxygenation (by
mitigating pulmonary oedema) and improved cardiac output by
decreasing LV afterload.25 The potential CPAP induced reduction in
cardiac volume could contribute to reductions in atrial stretch, and
help improve overall cardiac function.24
Within the adult population HFNC is becoming a popular treat-
ment to manage patients with ARI due to cardiac failure.25 HFNC is
better tolerated over a wide age range when compared to NIV.13,18
This can be of benefit in the paediatric populationwith cardiac fail-
ure as there is less need for sedation in order tomaintain placement
of an NIV system. As HFNC delivers a similar degree of CPAP the
beneficial effects to cardiac function are maintained without the
negative effects of using other pharmacotherapy to keep NIV in
situ.
In the cases presented our clinical practice in relation to HNFC
is to use 2 L/kg/min of flow and adjust FiO2 to oxygen saturations.
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We determined the level of flow from our own clinical research
and clinical observation of patients commenced on HFNC therapy.
Our practice changed in mid-late 2011 to accommodate delivering
2 L/kg/min flow to all our patients as prior to that we were limited
in our flow delivery by the apparatus used. Importantly there were
no adverse effects of HFNC treatment, such as pneumothorax/air
leak syndrome, nasal trauma or abdominal overdistention in any
of the three cases reported.
Limitations
The physiological effect of HFNC therapy is yet to be fully
examined in paediatric patients in any of the underlying disease
processes presented. We have only hypothesised, from adult and
neonatal studiespublished todate, theeffect thatHFNCmaybehav-
ing on these patients. Case reports and series have limited external
validity however in the absence of higher level research evidence
this provides support for the use of HFNC treatment in paediatrics.
Conclusion
HFNC systems are increasingly being used in intensive care sett-
ings and across a range of patient age groups and conditions. These
case reports highlight a range of conditions in paediatric patients
where HFNC therapy may be beneficial. Our case series suggests
that HFNC therapy is an effective treatment for patients with these
three diagnoses and may prevent invasive ventilation in a variety
of clinical scenarios, improve recovery times and shorten length of
stay in the PICU. However, as with all emergent therapies, further
investigation particularly randomised clinical trials are required to
strengthen the evidence for its use as a recognised and effective
mode of non-invasive respiratory support.
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Chapter 4: Cochrane Review 
4.1 Introduction 
To date, this thesis has examined bronchiolitis, its natural history, sequelae, health service 
response and treatment options. It has also explored the use of HFNC therapy, an 
emergent treatment option, across the patient age span. This chapter will provide a 
systematic review of the literature regarding HFNC use within the paediatric population. 
In 1995, Guyatt et al162 proposed a hierarchy of evidence for assessing study designs and 
the strength of evidence generated, in order to determine the applicability of findings to 
clinical practice. Traditionally systematic reviews of RCTs and meta-analysis form the 
pinnacle of the pyramid.163 Then follow RCTs, other controlled clinical trials, observational 
studies, and finally, lower evidence comprising case studies, anecdote and opinion (Figure 
4.1).  
  
Figure 4.1 – The traditional hierarchy for assessing evidence 
  
The gold standard for systematic reviews is The Cochrane Collaboration. Archie Cochrane 
established the Cochrane Database of Systematic Reviews in the 1980s in an effort to 
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provide a central hub for synthesising evidence from multiple individual trials. The 
Cochrane Collaboration is organised into review groups, based on speciality fields, 
disease or organ classification.164 In embarking on a review, the first step is identifying 
which group to contact. From there, a title registration form is completed and, if registration 
is successful, a protocol is developed, providing both the framework for identifying eligible 
studies and the statistical analysis required to assess the evidence. This then leads onto a 
review (Figure 4.2). Many small studies, such as those in paediatrics, lack the sample size 
and hence power to inform clinical practice changes independently. However, by pooling 
data from homogenous studies into a meta-analysis, statistical significance may be found 
supporting either a positive or negative impact of a treatment, which then informs clinical 
practice. 
The title registration form is a comprehensive outline of what the protocol will entail. It 
includes a title, based on standard Cochrane format (replicates PICO – Population, 
Intervention/Indicator, Comparator/Control, Outcome), motivation for the proposed review, 
and description of the proposal. For a title to progress onto a protocol, each Cochrane 
group requires certain elements to be included in the team undertaking the review, such as 
content expert, methodologist or statistician and experience of co-authors in the Cochrane 
process. It is essential to refer to The Cochrane Collaboration handbook, as this guides 
authors in the conduct of a systematic review and becomes the 'bible' to follow to ensure 
success in producing the highest quality work possible.165 
Once the title is registered, work can begin on the protocol and follows the structure 
outlined in The Cochrane Collaboration handbook. All content is rigorously evaluated by 
each of the Cochrane Group's Editorial team. Once all elements are finalised and 
approved by the editorial team, the protocol is then published.  
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Figure 4.2 – Graphic display of the process for conducting a Cochrane Review 
The protocol gives guidance and outlines intention for the review and subsequent updates. 
For a review into the use of HFNC and bronchiolitis, the Acute Respiratory Infections 
Group was approached to determine whether a proposed title, 'High flow nasal cannula 
therapy for respiratory support of infants with bronchiolitis' could be registered. However, 
the group advised that another team had already registered a title.144 Subsequently, it was 
decided to broaden the review to include all children, regardless of underlying 
pathophysiology, treated with HFNC.  
 The Cochrane Anaesthesia Review Group (CARG) was therefore approached, a title was 
registered, and subsequently a protocol and review were undertaken with CARG's 
guidance and supervision. However, CARG do not review studies involving neonates, who 
comprise pre-term (<37 completed weeks gestation) to one month post-term (44 weeks), 
and because the group of infants from term to one month are disproportionally represented 
in PICUs,166 including them in any review of HFNC is critical. Therefore another title was 
registered, and subsequent protocol and review (pending) were undertaken with the 
Neonatal Review Group.  
When conducting the review, the processes outlined in the protocol are essential and must 
be adhered to, and if not, justification must be forthcoming. For the review conducted with 
the CARG, following input from their editorial team, any studies relating to children with 
bronchiolitis were removed as another group were undertaking this study and it was 
thought to be an unnecessary replication. 
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The CARG staff undertook the literature search (conducted by Karen Hovhannisyan) and 
the 900 results forwarded on. The results were scoured for applicability to the review, 
removing all abstracts that did not meet the outlined criteria. After this stage, the full text of 
remaining published studies were obtained and vigorously analysed for applicability and 
inclusion in the review. The CARG editorial team intensely scrutinise the reviews, ensuring 
the high quality of the resultant publication.  
The Neonatal Review Group employs the same high standard when conducting their 
reviews, and the same rigour was applied to their protocol, and is expected to be applied 
to the review when undertaken (late 2014/early 2015).  
Finally, the reviews are updated every two years, ensuring that clinicians worldwide have 
the most robust statistical summation of all available evidence on current advances in this 
territory. 
4.2 Publication – Cochrane Collaboration Anaesthesia Review Group review 
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A B S T R A C T
Background
Respiratory support is a central component of themanagement of critically ill children. It can be delivered invasively via an endotracheal
tube or non-invasively via face mask, nasal mask, nasal cannula or oxygen hood/tent. Invasive ventilation can be damaging to the lungs,
and the tendency to use non-invasive forms is growing. However, non-invasive delivery is often poorly tolerated by children. High-
flow nasal cannula (HFNC) oxygen delivery is a relatively new therapy that shows the potential to reduce the need for intubation and
be better tolerated by children than other non-invasive forms of support. HFNC therapy differs from other non-invasive forms of
treatment in that it delivers heated, humidified and blended air/oxygen via nasal cannula at rates > 2 L/kg/min. This allows the user to
deliver high concentrations of oxygen and to potentially deliver continuous distending pressure; this treatment often is better tolerated
by the child.
Objectives
To determine whether HFNC therapy is more effective than other forms of non-invasive therapy in paediatric patients who require
respiratory support.
Search methods
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) (2013, Issue 4); MEDLINE via PubMed (January 1966
to April 2013); EMBASE (January 1980 to April 2013); CINAHL (1982 to April 2013); and LILACS (1982 to April 2013). Abstracts
from conference proceedings, theses and dissertations and bibliographical references to relevant studies were also searched. We applied
no restriction on language.
Selection criteria
We planned to included randomized controlled trials (RCTs) and quas-randomized trials comparing HFNC therapy with other forms
of non-invasive respiratory support for children. Non-invasive support encompassed cot, hood or tent oxygen; low-flow nasal cannulae
(flow rates ≤ 2 L/min); and continuous positive airway pressure (CPAP) or bilevel positive airway pressure (BiPAP) delivered via facial
or nasal mask/cannula. Treatment failure was defined by the need for additional respiratory support. We excluded children with a
diagnosis of bronchiolitis.
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Data collection and analysis
Two review authors independently assessed all studies for selection and data extraction. We used standard methodological procedures
expected by The Cochrane Collaboration.
Main results
Our search yielded 922 records. A total of 109 relevant records were retrieved with reference to our search criteria. After duplicates
and irrelevant studies were removed, 69 studies were further scrutinized. Of these, 11 studies involved children. No study matched our
inclusion criteria.
Authors’ conclusions
Based on the results of this review, no evidence is available to allow determination of the safety or effectiveness of HFNC as a form of
respiratory support in children.
P L A I N L A N G U A G E S U M M A R Y
High-flow nasal cannula therapy for support of breathing in children
We reviewed evidence on the effectiveness of high-flow nasal cannula (HFNC) therapy in supporting children’s breathing. We found
11 studies in children.
Background
HFNC therapy delivers a mixture of air and oxygen via tubing that sits just inside the nostrils. For children hospitalized with breathing
difficulties caused by conditions such as pneumonia or trauma or after surgery, HFNC therapy may help to support their breathing.
This may reduce the need for other forms of breathing support such as life support. HFNC therapy can be used within the hospital
ward setting, the emergency department or the intensive care unit. This Cochrane review is important because it assesses available
evidence on the safety and effectiveness of HFNC compared with other forms of respiratory support, to help inform clinicians caring
for children with breathing difficulties.
Search date
We searched medical databases from the 1950s until April 2013.
Study characteristics
We included studies on children from four weeks to 16 years of age. We searched for randomized controlled trials; however we excluded
studies involving infants with bronchiolitis (a respiratory illness affecting infants that typically mimics a common cold) because children
with this condition are included in another Cochrane review.
Results
We found 11 studies involving children; however none matched our criteria.
Conclusion
It is important that good-quality studies are completed to identify indications as to the use and effectiveness of HFNC therapy in
supporting the breathing of ill children.
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B A C K G R O U N D
Description of the condition
Respiratory support is central to the care of critically ill children.
Support may be needed because of underlying disease processes
such as respiratory infection or pneumonia, neuromuscular dis-
orders, cardiac conditions or cardiac failure, and as the result of
other mechanisms such as upper airway obstruction, trauma and
injury or postsurgical interventions. Respiratory support can be
delivered non-invasively in the form of oxygen therapy, continu-
ous positive airway pressure (CPAP) or bilevel positive airway pres-
sure (BiPAP), or invasively via mechanical ventilation. Children
with significant respiratory distress and hypoxaemia often require
the latter. This may result in various forms of trauma to the lungs
and airways, collectively known as ventilator-induced lung injury
(VILI) (Dahlem 2003; The ARDS Network 2000).
Although VILI is the major concern with intubation and mechan-
ical ventilation, other effects on the body need to be considered.
Increased use of sedative drugs may lead to neuropathy or my-
opathy, which can increase recovery time. In turn, cardiovascular
support in the form of drug infusions may be needed to main-
tain blood pressure. These requirements increase the costs of care
provided to the child. Non-invasive methods of ventilation are an
ideal method of providing respiratory support without the need
for intubation and may avoid some of the additional harms asso-
ciated with positive-pressure ventilation, such as ventilator-asso-
ciated pneumonia (VAP) (Glossop 2012).
Non-invasive ventilation can be as simple as oxygen therapy deliv-
ered via face mask, nasal cannula or head box or devices delivering
CPAP/BiPAP via face mask or nasopharyngeal tubes, with pres-
sure generated by a dedicated driver or water column (i.e. bubble
CPAP) (Frey 2001; Frey 2003; Klein 1986). Devices delivering
CPAP/BiPAP can reduce the work of breathing and improve func-
tional residual capacity, potentially avoiding intubation, reducing
VILI and VAP and preventing other possible causes of harm (Reid
1984; Thorsteinsson 2002).
Disadvantages of thismethod of delivery are that it is cumbersome,
and themasks and tubes are poorly tolerated by young children and
infants (McGinley 2009; Spentzas 2009; Yong 2005). Obtaining
an adequate seal around the face of small children can be difficult,
thereby making delivery of CPAP/BiPAP variable and resulting in
ineffective ventilation. This is often due to the limited choice of
face masks developed for children with a wide range of ages and
stages of facial development. The need for a system that can deliver
CPAP while being comfortable and well tolerated by children is
an important consideration in providing non-invasive respiratory
support.
Description of the intervention
High-flow nasal cannula (HFNC) therapy has recently been in-
troduced for a range of patients from preterm infants to adults,
addressing the need for a simple, effective method of providing
respiratory support (Campbell 2006;McGinley 2009;McKiernan
2010; Shoemaker 2007). It offers an advantage over simple oxy-
gen therapy in that the gas mixture can be heated and humidified,
thereby reducing damage to upper airway mucosa, and the con-
centration of inspired oxygen can be titrated as required. This can
prevent inflammatory reactions and the naso-pulmonary bron-
choconstrictor reflex triggered by cold, dry air (Spentzas 2009).
The mixed gas is delivered via a nasal cannula that sits just inside
the nares. The flow rate delivered varies depending on the type of
cannula used but can range from 4 to 70 L/min.
How the intervention might work
It has been shown that delivery of nasal air at high flow rates may
cause incidental delivery of CPAP (Dysart 2009; Spence 2007;
Wilkinson 2008). The effects of this are yet to be fully understood.
It may be that the high flow flushes the dead space of the nasopha-
ryngeal cavity, resulting in alveolar ventilation as a greater fraction
of minute ventilation. It may also assist in the washout of carbon
dioxide, which may then reduce apnoea secondary to hypercapnia
and improve ventilation (Dysart 2009). High flow rates may also
provide some amount of positive pressure and thereby overcome
upper airway obstruction, again improving ventilation (McGinley
2009).
The amount of CPAP generated depends on the flow delivered
relative to the size of the patient, the size of the nasal cannula
used and the potential for leak around the nasal cannula (Kubicka
2008; Lampland 2009; Sreenan 2001). Three retrospective studies
in paediatric populations assessing HFNC therapy have demon-
strated that overall, ventilator days were significantly decreased af-
ter introduction of this therapy when compared with retrospec-
tive historical control groups (McKiernan 2010; Schibler 2011;
Shoemaker 2007).
HFNC therapy has also been reported to be better tolerated by the
patient than other forms of non-invasive ventilation (Roca 2010).
This can reduce the need for the sedation required to help patients
tolerate more invasive or uncomfortable forms of respiratory sup-
port.
Why it is important to do this review
HFNC therapy is an emerging treatment option for the respira-
tory support of children, especially in the intensive care unit. To
date, most findings have been derived from neonatal and adult
studies, with little clinical experience reported in the paediatric
population (McKiernan 2010). Clinical experience in the paedi-
atric population is reported in case reports and observational stud-
ies; few randomized controlled trials are reported (Mayfield 2013;
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McGinley 2009; Spentzas 2009). The Cochrane review of HFNC
therapy from the Cochrane Neonatal Group found only four el-
igible, randomized controlled trials and concluded that evidence
was insufficient to determine effectiveness, and more research was
needed (Wilkinson 2011). Two further reviews of HFNC therapy
are under way: in the adult population (Corley 2012) and in in-
fants with bronchiolitis (Beggs 2012). This review differs in that
it includes studies of children with a broader age range and more
diverse pathophysiologies such as type 1 and 2 respiratory failure,
parenchymal lung disease, neuromuscular disorders, respiratory
drive disorders and airway obstruction.
HFNC therapy has the potential to improve outcomes such as
reduced intubation and invasive ventilation (McKiernan 2010;
Schibler 2011; Wing 2012) in critically ill children. It is readily
applied and is not resource or cost intensive. Staff can easily be
trained in the application of HFNC therapy and in the care of
children using this therapy. It may also reduce the length of intu-
bation, asHFNC holds potential to transition between extubation
and low-flow nasal cannula oxygen delivery. An additional advan-
tage is that children requiring this therapymay be cared for outside
of the paediatric intensive care unit (PICU). However potential
risks are associated with its use, such as air leak syndrome, which
has been described in a case report (Hedge 2013), and other risks
extrapolated from the neonatal population, such as nasal trauma
and abdominal overdistention (Kopelman 2003). These potential
risks and benefits need to be assessed in the paediatric population.
O B J E C T I V E S
To determine whether HFNC therapy is more effective than other
forms of non-invasive therapy in paediatric patients who require
respiratory support.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We included prospective randomized controlled trials (RCTs) and
quasi-randomized studies.
Types of participants
We included paediatric participants from four weeks corrected age
to 16 years of age requiring respiratory support for type 1 and
2 respiratory failure, parenchymal lung disease, neuromuscular
disorders, respiratory drive and airway obstruction. We excluded
a study in children with bronchiolitis.
Types of interventions
What constitutes ’high flow’ has not been well described in the
literature, nor has it been universally determined. Most paediatric
studies have been limited to using devices that deliver flow rates
in infants from 4 to 8 L/min (Arora 2012; Schibler 2011). Older
childrenmay have up to 30L/min delivered (McGinley 2009). For
the purposes of this review, high-flow nasal oxygen was defined as
the delivery of heated, humidified oxygen or blended oxygen with
air via nasal cannula at flow rates greater than 2 L/min. HFNC
therapy was compared with other means of non-invasive respi-
ratory support, such as cot, hood or tent oxygen; low-flow nasal
cannula (flow rates ≤ 2 L/min); and continuous positive airway
pressure (CPAP) or bilevel positive airway pressure (BiPAP).
Types of outcome measures
Primary outcomes
1. Hospital mortality.
2. Intubation rate.
3. Treatment failure (defined as the need for additional
respiratory support).
Secondary outcomes
1. Duration of any form of respiratory support in hours
(mechanical ventilation, non-invasive ventilation, high-flow
nasal cannula).
2. Length of stay in hospital in days.
3. Clinical severity score.
4. Length of paediatric intensive care unit (PICU) stay in days.
5. Complications.
◦ Air leaks (pneumothorax, pneumomediastinum,
pneumopericardium or pulmonary interstitial emphysema
(PIE)) reported individually or as a composite outcome.
◦ Nasal trauma (defined as erythema or erosion of the
nasal mucosa, nares or septum as assessed by a blinded observer).
◦ Barotrauma.
◦ Gastrointestinal distention.
Search methods for identification of studies
Electronic searches
We obtained all relevant studies irrespective of language or pub-
lication status (published, unpublished, in press and in progress)
using the following methods. We applied no limits in terms of
language or year of publication.
We searched Issue 4, 2013 of the Cochrane Central Register of
Controlled Trials (CENTRAL, see Appendix 1); MEDLINE via
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Ovid SP (January 1966 to April 2013, see Appendix 2); EM-
BASE via Ovid SP (January 1980 to April 2013, see Appendix 3);
CINAHL via EBSCO Host (1982 to April 2013, see Appendix
4); and LILACS via the BIREME interface (1982 to April 2013,
see Appendix 5).
We also searched the electronic databases of higher-degree theses
for relevant unpublished trials: Index to Theses (1950 to date),
Australian Digital Theses Program (1997 to April 2013) and Pro-
quest Digital Dissertations (1980 to April 2013).
We then combined our MEDLINE search strategy with the
Cochrane highly sensitive search strategy for identifying RCTs,
as suggested in the Cochrane Handbook for Systematic Reviews of
Interventions (Higgins 2011). We adopted the MEDLINE search
strategy for searching in all other databases.
For ongoing trials, we searched theMetaRegister ofControlledTri-
als (http://www.controlledtrials.com/) and the National Research
Register (http://clinicaltrials.gov/).
Searching other resources
We handsearched citations from included studies.
Data collection and analysis
We used standard methodological procedures expected by The
Cochrane Collaboration.
Selection of studies
We used the search strategy described to obtain titles and abstracts
of studies that may be relevant to the review. Two review authors
(SM and JJ-C) independently performed this screening. Studies
that were not applicable were discarded. We found no ongoing
studies that matched our search criteria.
Data extraction and management
We adapted the standardized Cochrane Anasthesia Review Group
(CARG) data extraction form (Appendix 6) to capture relevant
data specific to this review. We (SM and JJ-C) used this form
independently to extract and collect data from the relevant study.
No disagreements arose.
Assessment of risk of bias in included studies
No studies were eligible for assessment of risk of bias. However,
we planned to assess risk of bias using the following domains with
judgements of high, low or uncertain.
1. Selection bias: incorporating random sequence generation
and allocation concealment.
2. Performance bias: blinding of participants and personnel.
3. Detection bias: blinding of outcome assessment.
4. Attrition bias: incomplete outcome data.
5. Reporting bias: selective reporting.
6. Other bias: other sources of bias.
Measures of treatment effect
No studies were found that could be included in this review. Ex-
cluded studies were tabulated with the reasons for exclusion doc-
umented in the Characteristics of excluded studies.
We planned to manage dichotomous outcome data, such as mor-
tality, by using risk ratios (RRs) to determine effect and by display-
ing them in a table. For continuous data, we planned to collect
means and standard deviations and to display them in a table. If
different scales were used to measure continuous data, we would
have calculated the standardized mean difference. Outcomes from
comparable trials would have used 95% confidence intervals to
estimate treatment effect. We would use forest plots to graphically
compare treatment effect with risk ratio for dichotomous data and
with mean difference for continuous outcomes.
Unit of analysis issues
The unit of analysis was the individual child. We expected to find
parallel-group study designs and no cross-over studies. As none
of the studies included in this review were randomized at cluster
level, unit of analysis was not an issue.
Dealing with missing data
If eligible studies with missing data were found, we planned to
contact the corresponding author.
Assessment of heterogeneity
We planned to analyse heterogeneity using the Chi2 test on N-
1 degrees of freedom, with an alpha of 0.1 used for statistical
significance, along with the I2 statistic (Higgins 2011).
Assessment of reporting biases
We planned to assess publication bias or small-study effects by
preparing a funnel plot. We planned to test for funnel plot asym-
metry if more than 10 studies were included in the meta-analysis.
We planned to obtain published and unpublished studies as a way
of addressing reporting bias.
Data synthesis
We planned to review the summary tables of included trials to
identify clinical heterogeneity amongst trials. If two or more ran-
domized trials had been found with comparable populations un-
dergoing similar interventions, we would have conducted a meta-
analysis with a random-effects model using RevMan 5.2.
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Subgroup analysis and investigation of heterogeneity
No studies were found to permit subgroup analyses or exploration
of heterogeneity (Sutton 2008).
Sensitivity analysis
No studies were found to allow sensitivity analysis.
Summary of findings
We planned to use the principles of the GRADE system (Guyatt
2008) to assess the quality of the body of evidence associated with
the following specific outcomes in our review.
1. Mortality.
2. Intubation.
3. Failure of treatment or escalation to non-invasive
ventilation.
4. Length of PICU stay.
5. Length of time on any form of respiratory support.
6. Oxygenation and respiratory assessment tools.
However, no studies were identified for inclusion.
R E S U L T S
Description of studies
See Characteristics of excluded studies.
Results of the search
Our search yielded 922 records. After duplicates and irrelevant ref-
erences were removed, 69 were further scrutinized. Eleven studies
involved children. No study met our criteria (Figure 1).
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Figure 1. Study flow diagram.
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Included studies
No studies met our inclusion criteria.
Excluded studies
Ten studies did not meet the criteria of being randomized or quasi-
randomized (Abboud 2012; Arora 2012; Hedge 2013; Hough
2011; McGinley 2009; McKiernan 2010; Milesi 2013; Schibler
2011; Spentzas 2009; Wing 2012). One randomized controlled
trial was excluded because it included infants with bronchiolitis
(Hilliard 2012).Details are listed in theCharacteristics of excluded
studies.
Risk of bias in included studies
N/A.
Allocation
N/A.
Blinding
N/A.
Incomplete outcome data
N/A.
Selective reporting
N/A.
Other potential sources of bias
N/A.
Effects of interventions
N/A.
D I S C U S S I O N
Summary of main results
We found no randomized controlled trials of HFNC therapy in
children older than four weeks of age requiring respiratory sup-
port for type 1 or 2 respiratory failure, parenchymal lung disease,
neuromuscular disorders, respiratory drive or airway obstruction.
Overall completeness and applicability of
evidence
N/A.
Quality of the evidence
N/A.
Potential biases in the review process
We believe that any bias in this review is of low probability. We
ensured that language would not be a bias by imposing no re-
strictions on such. We used a well-constructed search strategy to
minimize the chance of missing randomized controlled trials that
fulfilled our inclusion criteria.
Agreements and disagreements with other
studies or reviews
This review supports the conclusion of other studies and re-
views conducted to evaluateHFNC therapy (Lee 2013;Wilkinson
2011) in that evidence of robust quality is insufficient to permit
determination of the superiority of HFNC therapy over other es-
tablished forms of non-invasive ventilation for children withmod-
erate to severe respiratory compromise. Further studies are needed
to quantify this and to identify clinical indicators regarding its use.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
Based on the results of this review, no evidence can be found to
allowdeterminationof the safety or effectiveness ofHFNCtherapy
as a form of respiratory support in children.
Implications for research
It is acknowledged that while the number of retrospective, observa-
tional andphysiological studies surrounding the support ofHFNC
therapy for respiratory support in children is increasing, adequately
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powered randomized controlled trials are needed. HFNC therapy
must be compared with CPAP and other forms of non-invasive
respiratory support. Clinically important outcomes, such as esca-
lation to CPAP or intubation, length of stay and duration of treat-
ment, need to be assessed. With such a broad range of ages and
disease processes in children, an aim of further research should be
to establish which subgroups benefit from HFNC therapy.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Abboud 2012 Retrospective chart review of all patients admitted to intensive care with a diagnosis of viral bronchiolitis from
2006 to 2010. 113 patients met inclusion criteria of < 12 months, initiation of HFNC on admission
Arora 2012 Prospective observational study to measure nasopharyngeal effects of HFNC in infants with bronchiolitis. 25
infants enrolled
Hedge 2013 Case series of three patients with air leak syndrome who were also treated with HFNC
Hilliard 2012 Prospective randomized controlled trial comparing HFNC versus head box oxygen therapy. 19 participants
enrolled, all with viral bronchiolitis
Hough 2011 Prospective physiological study comparing HFNC at different flow rates. 13 participants enrolled, all with
bronchiolitis
McGinley 2009 Prospective observational study of 12 participants with obstructive apnoea-hypopnoea syndrome treated with
nasal insufflation at 20 L/min
McKiernan 2010 Retrospective chart review comparing intubation rates of infants with bronchiolitis admitted before and in the
season after HFNC was implemented. 115 participants included in the review
Milesi 2013 Prospective physiological study of 21 infants < six months with viral bronchiolitis and HFNC therapy. Pharygneal
and oesophageal pressures measured at different flow rates
Schibler 2011 Retrospective chart review of infants < 24 months admitted to PICU between January 2005 and December 2009,
requiring HFNC therapy. 298 infants included in the review
Spentzas 2009 Observational study of all participants (newborn to 12 years) requiring HFNC, admitted between January 2005
and January 2007 to PICU. 46 participants included in the study
Wing 2012 Retrospective chart review of all patients admitted from ED to PICU with acute respiratory insufficiency from
January 2006 to December 2009. Patients admitted before HFNC availability were compared with patients
admitted after HFNC became available (two cohorts, before and after implementation of clinical guidelines).
848 participants included in the review
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D A T A A N D A N A L Y S E S
This review has no analyses.
A P P E N D I C E S
Appendix 1. CENTRAL search strategy
#1 MeSH descriptor Oxygen Inhalation Therapy explode all trees
#2 intubation rates*
#3 (#1 AND #2)
#4 ((high flow (nasal or prong or cannula)) or (nasal near oxygen)):ti,ab
#5 (#3 OR #4)
Search from Issue 4 2013.
Appendix 2. MEDLINE (Ovid SP) search strategy
1. (exp Oxygen Inhalation Therapy/ and intubation rates*.af.) or (high flow adj3 (nasal or prong or cannula)).mp. or (nasal adj3
oxygen).mp.
2. ((randomized controlled trial or controlled clinical trial).pt. or randomized.ab. or placebo.ab. or drug therapy.fs. or randomly.ab. or
trial.ab. or groups.ab.) not (animals not (humans and animals)).sh.
3. 1 and 2
Search from January 1966- April 2013.
Appendix 3. EMBASE (Ovid SP) search strategy
1. (exp oxygen therapy/ and intubation rates*.af.) or (high flow adj3 (nasal or prong or cannula)).mp. or (nasal adj3 oxygen).mp.
2. (randomized-controlled-trial/ or randomization/ or controlled-study/ or multicenter-study/ or phase-3-clinical-trial/ or phase-4-
clinical-trial/ or double-blind-procedure/ or single-blind-procedure/ or (random* or cross?over* ormulticenter* or factorial* or placebo*
or volunteer*).mp. or ((singl* or doubl* or trebl* or tripl*) adj3 (blind* or mask*)).ti,ab. or (latin adj square).mp.) not (animals not
(humans and animals)).sh.
3. 1 and 2
Search from January 1980 to April 2013.
Appendix 4. CINAHL (EBSCO host) search strategy
S1 (((MH “Oxygen Therapy”) and intubation rates*)) OR ((high flow and (nasal or prong or cannula))) OR (nasal and oxygen)
S2 (MM “Randomized Controlled Trials”) OR (MM “Random Assignment”) OR (MH “Clinical Trials+”) OR (MM “Multicenter
Studies”) OR (MM “Prospective Studies”) OR (MM “Placebos”) OR (MM “Double-Blind Studies”) OR (MM “Triple-Blind Studies”)
OR (MM “Single-Blind Studies”)
S3 S1 and S2
Seach from 1982-April 2013.
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Appendix 5. LILACS search strategy
(oxygen therapy and intubation rates$) or (high flow and (nasal or prong or cannula)) or (nasal and oxygen) [Palabras]
Search from 1982 to April 2013.
Appendix 6. Data extraction form
Review title or ID
Study ID (surname of first author and year first full report of study was published e.g. Smith 2001)
Report IDs of other reports of this study (e.g. duplicate publications, follow-up studies)
Notes:
1. General information
Date form completed (dd/mm/yyyy)
Name/ID of person extracting data
Report title
(title of paper/abstract/report from which data are extracted)
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(Continued)
Report ID
(ID for this paper/abstract/report)
Reference details
Report author contact details
Publication type
(e.g. full report, abstract, letter)
Study funding sources
(including role of funders)
Possible conflicts of interest
(for study authors)
Notes:
2. Study eligibility
Study
characteristics
Eligibility criteria
(insert eligibility criteria for each
characteristic as defined in the pro-
tocol)
Yes No Unclear Location in text
(pg & ¶/fig/table)
Type of study Randomized controlled trial
Controlled clinical trial
(quasi-randomized trial)
Participants Paediatric patients from four
weeks corrected to 16 years of
age
Types of inter-
ventions High-flow nasal oxygen (heated/
humidified, flow > 2 L/kg/min)
Comparator: non-invasive respi-
ratory support such as cot/tent/
hood, low-flow oxygen or CPAP
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(Continued)
Types of out-
come measures
Hospital mortality; intubation
rate; treatment failure
Secondary: duration of any form
of respiratory support; length
of hospital stay; clinical severity
score; length of PICU stay; com-
plications-air leak, nasal trauma,
nosocomial sepsis, barotrauma,
gastrointestinal distention
INCLUDE EXCLUDE
Reason for ex-
clusion
Notes:
DO NOT PROCEED IF STUDY EXCLUDED FROM REVIEW.
3. Methods
Descriptions as stated in report/pa-
per
Location in text
(pg & ¶/fig/table)
Aim of study
Design (e.g. parallel, cross-over,
cluster)
Unit of allocation
(by individuals, cluster/groups or
body parts)
Start date
End date
Total study duration
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(Continued)
Ethical approval needed/ob-
tained for study Yes No Unclear
Notes:
4. Risk of bias assessment
See Chapter 8 of the Cochrane Handbook for Systematic Reviews of Interventions (Higgins 2011).
Domain Risk of bias Support for judgement Location in text
(pg & ¶/fig/table)
Low risk High risk Unclear
Random sequence
generation
(selection bias)
Allocation
concealment
(selection bias)
Blinding of partic-
ipants and person-
nel
(performance bias)
Outcome group: all/
(if required) Outcome group:
Blinding of out-
come assessment
(detection bias)
Outcome group: all/
(if required) Outcome group:
Incomplete
outcome data
(attrition bias)
Selective outcome
reporting?
(reporting bias)
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(Continued)
Other bias
Notes:
5. Participants
Provide overall data and, if available, comparative data for each intervention or comparison group.
Description as stated in report/paper Location in text
(pg & ¶/fig/table)
Total no. randomly assigned
(or total population at start of study for
NRCTs)
Clusters
(if applicable, no., type, no. people per cluster)
Withdrawals and exclusions
(if not provided below by outcome)
Age
Sex
Severity of illness
Co-morbidities
Other treatment received (additional to
study intervention)
Subgroups measured
Subgroups reported
Notes:
6. Intervention groups
Copy and paste table for each intervention and comparison group.
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Intervention group 1
Description as stated in report/paper Location in text
(pg & ¶/fig/table)
Group name HFNC
No. randomly assigned to group
(specify whether no. people or clusters)
Description (include sufficient detail for
replication, e.g. content, dose, components)
Duration of treatment period
Timing (e.g. frequency, duration of each
episode)
Delivery (e.g. mechanism, medium, inten-
sity, fidelity)
Co-interventions
Notes:
Comparison group 1
Description as stated in report/paper Location in text
(pg & ¶/fig/table)
Group name Invasive ventilation
No. randomly assigned to group
(specify whether no. people or clusters)
Description (include sufficient detail for
replication, e.g. content, dose, components)
Duration of treatment period
Timing (e.g. frequency, duration of each
episode)
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(Continued)
Delivery (e.g. mechanism, medium, inten-
sity, fidelity)
Co-interventions
Notes:
Comparison group 2
Description as stated in report/paper Location in text
(pg & ¶/fig/table)
Group name Noninvasive ventilation
No. randomly assigned to group
(specify whether no. people or clusters)
Description (include sufficient detail for
replication, e.g. content, dose, components)
Duration of treatment period
Timing (e.g. frequency, duration of each
episode)
Delivery (e.g. mechanism, medium, inten-
sity, fidelity)
Co-interventions
Notes:
7. Outcomes
Copy and paste table for each outcome.
Outcome 1
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Description as stated in report/pa-
per
Location in text
(pg & ¶/fig/table)
Outcome name Hospital mortality
Time points measured
Time points reported
Outcome definition (with di-
agnostic criteria if relevant)
Person measuring/reporting
Unit of measurement
(if relevant)
Scales: upper and lower lim-
its (indicate whether high or low
score is good)
Is outcome/tool validated?
Yes No Unclear
Imputation of missing data
(e.g. assumptions made for ITT
analysis)
Assumed risk estimate
(e.g. baseline or population risk
noted in Background)
Power
Notes:
Outcome 2
Description as stated in report/pa-
per
Location in text
(pg & ¶/fig/table)
Outcome name Intubation rate
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(Continued)
Time points measured
Time points reported
Outcome definition (with di-
agnostic criteria if relevant)
Person measuring/reporting
Unit of measurement
(if relevant)
Scales: upper and lower lim-
its (indicate whether high or low
score is good)
Is outcome/tool validated?
Yes No Unclear
Imputation of missing data
(e.g. assumptions made for ITT
analysis)
Assumed risk estimate
(e.g. baseline or population risk
noted in Background)
Power
Notes:
Outcome 3
Description as stated in report/pa-
per
Location in text
(pg & ¶/fig/table)
Outcome name Treatment failure-escalation to
other form of respiratory support
Time points measured
Time points reported
Outcome definition (with di-
agnostic criteria if relevant)
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(Continued)
Person measuring/reporting
Unit of measurement
(if relevant)
Scales: upper and lower lim-
its (indicate whether high or low
score is good)
Is outcome/tool validated?
Yes No Unclear
Imputation of missing data
(e.g. assumptions made for ITT
analysis)
Assumed risk estimate
(e.g. baseline or population risk
noted in Background)
Power
Notes:
Outcome 4
Description as stated in report/pa-
per
Location in text
(pg & ¶/fig/table)
Outcome name Duration of respiratory support
Time points measured
Time points reported
Outcome definition (with di-
agnostic criteria if relevant)
Person measuring/reporting
Unit of measurement
(if relevant)
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(Continued)
Scales: upper and lower lim-
its (indicate whether high or low
score is good)
Is outcome/tool validated?
Yes No Unclear
Imputation of missing data
(e.g. assumptions made for ITT
analysis)
Assumed risk estimate
(e.g. baseline or population risk
noted in Background)
Power
Notes:
Outcome 5
Description as stated in report/pa-
per
Location in text
(pg & ¶/fig/table)
Outcome name Complications-air leak, nasal
trauma, nosocomial sepsis, baro-
trauma, gastrointestinal distention
Time points measured
Time points reported
Outcome definition (with di-
agnostic criteria if relevant)
Person measuring/reporting
Unit of measurement
(if relevant)
Scales: upper and lower lim-
its (indicate whether high or low
score is good)
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(Continued)
Is outcome/tool validated?
Yes No Unclear
Imputation of missing data
(e.g. assumptions made for ITT
analysis)
Assumed risk estimate
(e.g. baseline or population risk
noted in Background)
Power
Notes:
Outcome 6
Description as stated in report/pa-
per
Location in text
(pg & ¶/fig/table)
Outcome name Length of hospital stay
Time points measured
Time points reported
Outcome definition (with di-
agnostic criteria if relevant)
Person measuring/reporting
Unit of measurement
(if relevant)
Scales: upper and lower lim-
its (indicate whether high or low
score is good)
Is outcome/tool validated?
Yes No Unclear
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(Continued)
Imputation of missing data
(e.g. assumptions made for ITT
analysis)
Assumed risk estimate
(e.g. baseline or population risk
noted in Background)
Power
Notes:
Outcome 7
Description as stated in report/pa-
per
Location in text
(pg & ¶/fig/table)
Outcome name Clinical severity score
Time points measured
Time points reported
Outcome definition (with di-
agnostic criteria if relevant)
Person measuring/reporting
Unit of measurement
(if relevant)
Scales: upper and lower lim-
its (indicate whether high or low
score is good)
Is outcome/tool validated?
Yes No Unclear
Imputation of missing data
(e.g. assumptions made for ITT
analysis)
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Assumed risk estimate
(e.g. baseline or population risk
noted in Background)
Power
Notes:
Outcome 8: secondary outcome
Description as stated in report/pa-
per
Location in text
(pg & ¶/fig/table)
Outcome name Length of PICU stay
Time points measured
Time points reported
Outcome definition (with di-
agnostic criteria if relevant)
Person measuring/reporting
Unit of measurement
(if relevant)
Scales: upper and lower lim-
its (indicate whether high or low
score is good)
Is outcome/tool validated?
Yes No Unclear
Imputation of missing data
(e.g. assumptions made for ITT
analysis)
Assumed risk estimate
(e.g. baseline or population risk
noted in Background)
Power
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Notes:
8. Results
Copy and paste the appropriate table for each outcome, including additional tables for each time point and subgroup as required.
Dichotomous outcome
Outcome HFNC Invasive ventilation Non-invasive ventilation Details
No. with
event
No. without
event
No. with
event
No. without
event
No. with
event
No. without
event
Intubation
Failure of
treatment
Hospital mor-
tality
Complica-
tions
Continuous outcome
Out-
come
Unit of
mea-
sure-
ment
HFNC group Invasive ventilation
group
Non- invasive
group
Details
n M SD n M SD n M SD
Length
of PICU
stay
Clini-
cal sever-
ity score
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(Continued)
Dura-
tion of
respira-
tory sup-
port
LOS-
hospital
9. Applicability
Have important populations been ex-
cluded from the study? (consider disadvan-
taged populations and possible differences in
the intervention effect)
Yes No Unclear
Is the intervention likely to be aimed at
disadvantaged groups? (e.g. lower socioeco-
nomic groups)
Yes No Unclear
Does the study directly address the re-
view question?
(any issues of partial or indirect applicability)
Yes No Unclear
Notes:
10. Other information
Description as stated in report/paper Location in text
(pg & ¶/fig/table)
Key conclusions of study authors
References to other relevant studies
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Correspondence required for further
study information (from whom, what and
when)
Notes:
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Conceiving of the review: Sara Mayfield (SM).
Co-ordinating the review: SM.
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Screening search results: SM and Jacqui Jauncey-Cooke (JJ-C).
Organizing retrieval of papers: SM.
Screening retrieved papers against inclusion criteria: SM and JJ-C.
Appraising quality of papers: SM, JJ-C and Judith L Hough (JH).
Abstracting data from papers: SM and JJ-C.
Writing to authors of papers for additional information: SM.
Providing additional data about papers: SM.
Obtaining and screening data on unpublished studies: SM.
Managing data for the review: SM, JJ-C and Fiona Bogossian (FB).
Entering data into Review Manager (RevMan 5.2): SM.
Interpreting data: SM, JJ-C, FB, JH and Andreas Schibler (AS).
Making statistical inferences: SM, JJ-C, FB and Kristen Gibbons (KG).
Writing the review: SM.
Serving as guarantor for the review (one author): FB.
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4.3 Conclusion 
At the time of preparing this thesis (mid-2014), the protocol (Appendix 1) and review have 
been completed and published with CARG as evidenced above. The protocol with the 
Neonatal Review Group is published and the review is expected to be completed late 
2014/early 2015. Following that, both reviews are scheduled for revision in two years. 
The following chapter will detail the methodology for a pilot study, undertaken in the 
paediatric ward setting, using HFNC in the management of infants with bronchiolitis. 
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Chapter 5: Pilot study methodology  
5.1 Introduction 
The previous chapters of this thesis outlined bronchiolitis – its history, sequelae, health 
service response, and the various pharmacological and non-pharmacological treatment 
options; and HFNC oxygen therapy – mechanism of action, current evidence available, 
and a case series of its use in the intensive care setting. The previous chapters also 
presented a Cochrane Review examining the evidence for HFNC. 
To advance understanding and raise the level of evidence for using HFNC therapy beyond 
the ICU, experimental studies are required. This chapter reports the methodology of the 
pilot study, which aimed to assess the safety and efficacy of HFNC therapy outside 
intensive care. The pilot study used a paediatric ward setting and, in the absence of a 
specific reporting framework for pilot studies, it used the TREND guidelines and 
checklist167 to guide reporting where appropriate.  
5.1.1 Background 
Bronchiolitis is the leading cause of paediatric hospitalisation in Australia accounting for 
approximately 16,000 admissions annually.42 Treatment of bronchiolitis is controversial, 
and many RCTs have been conducted without showing a clear benefit for any specific 
treatment. Most of these trials attempted to reduce either the inflammatory response 
(using steroids) or smooth muscle relaxation of the small airways (using adrenaline, 
salbutamol). No studies, however, provide data investigating whether reducing the work of 
breathing through moderate respiratory support improves length of stay, reduces 
admission rates to PICU, or the need for intubation. 
5.2 Research questions 
HFNC is a rapidly emerging clinical therapy used in the intensive care setting to treat 
respiratory distress in populations from neonates to adults. Based on the observed high 
efficacy and practicality of using HFNC in PICUs, there is a desire to implement its use in 
general paediatric wards. However, several unanswered questions remain before HFNC 
can become standard practice for delivering oxygen to patients with respiratory distress in 
the general paediatric ward: 
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• Is safety of HFNC treatment in a general paediatric ward similar to in PICU?  
• Does HFNC treatment reduce the hospital length of stay (LOS)?  
• Does the early use of HFNC reduce the number of PICU admissions?  
• Does the early use of HFNC reduce the need to use non-invasive and invasive 
ventilation? 
5.3 Study aim 
This pilot study aimed to assess the safety and efficacy of managing infants with 
bronchiolitis on a paediatric ward with HFNC therapy. The measures used as surrogates to 
determine safety and efficacy were admission to PICU, physiological response to HFNC, 
adverse events (bradycardia, pneumothorax, cardiopulmonary arrest and emergency 
intubation), and hospital and PICU length of stay.  A secondary aim was to determine a 
sample size for a future, large multi-centred RCT. 
5.4 Outcome measures 
The primary outcome measure was admission to PICU. This was readily tracked 
prospectively as every study participant was visited on a daily basis, Monday to Friday.  
Secondary outcome measures encompassed physiological response to HFNC therapy 
and were collected on the HiFOD form. These measures included respiratory, 
cardiovascular and overall HiFOD score. Adverse events (including bradycardia, 
pneumothorax, cardiopulmonary arrest and emergency intubation) were also defined as 
outcome measures and were collected prospectively for all patients. Other outcome 
measures collected were the need for non-invasive ventilation and/or intubation for those 
patients admitted to PICU, as well as hospital and PICU length of stay.  
5.5 Study design 
Pilot  designed studies are a useful way to determine processes, resources, management 
and assessment of treatment safety that influence and govern large, multi-centred 
RCTs.168,169 For this study, a pilot design was chosen to explore the safety and efficacy of 
implementing HFNC therapy in the paediatric ward environment.   
The pilot study encompassed three stages: the education and training of staff involved in 
the pilot; the recruitment and clinical course of study patients; and data collection and 
analysis. 
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5.6 Study setting  
The study was located in the PED and the Babies Ward (8 South) of the Mater Children's 
Hospital (MCH), Brisbane, Australia. In 2009, the Babies Ward had approximately 5580 
occupied bed-days. This comprised infants aged less than 12 months, with a case mix 
including all paediatric medical and surgical specialities, excluding cardiac. The standard 
nurse to patient ratio is 1:3. For the purpose of the study, nurse to patient ratios remained 
at 1:3 for study patients. Nursing staff mix per shift comprises at least two clinical nurses 
(with one designated as team leader), senior registered nurses, junior registered nurses 
and 1–2 graduate nurses. On week days, a Nurse Unit Manager and Clinical Nurse 
Educator (CNE) are also present, who provide further managerial and educational support 
to the nursing team. 
5.7 Participants 
Potential patients were screened in the PED for inclusion in the study, either at triage or in 
the acute observation area. The author conducted the initial recruitment of patients from 
9am–5pm, Monday to Friday, with PED staff trained to recruit patients outside of these 
hours.  
5.7.1 Inclusion criteria 
Infants were considered for study inclusion if they met the following criteria: 
• age less than 12 months 
• clinical diagnosis of bronchiolitis  
• an oxygen requirement, based on oxygen saturations <94% in room air. 
Inclusion criteria were selected on the basis that bronchiolitis is the leading cause of 
hospitalisation in infants less than 2 years of age.41  To maximise homogeneity of included 
participants and to focus the study in one ward of the hospital only infants aged less than 
12 months of age were to be included.   
5.7.2 Exclusion criteria 
Infants were excluded from the study if they met any of the following criteria: 
• craniofacial malformations 
• upper airway obstruction  
• home oxygen therapy for pre-existing lung disease 
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• impending PICU admission due to decreasing level of consciousness, apnoeas, 
need for increased respiratory support (non-invasive or invasive ventilation) 
• no oxygen requirement. 
5.8 Intervention 
5.8.1  Education and training  
The education program followed the Mater Education Centre (MEC) Governance & 
Management Framework. This framework aims to maintain a 'commitment to safe and 
compassionate care', applying high standards in education, delivered in a strategic, 
coordinated and collaborative manner to develop capable and safe staff. To ensure the 
remit of the MEC was adhered to and maintained, funding was applied to employ a part-
time CNE to assist in educating staff involved with the study, and to liaise with the MEC, 
ensuring the proper processes were followed.  
The education program consisted of group and individual teaching sessions and 
commenced a month before the study commenced recruitment. It concentrated on medical 
and nursing staff in PED, and the ward. It was anticipated that the program would also be 
a continuous process throughout the recruitment period.  
The features of the education program included: 
• A focus on two departments in the MCH: PED and the Babies Ward. 
• Use of the approved education MEC Governance & Management Framework. 
• A structured approach in delivering education, using presentations and utilising set 
and opportunistic times for education, to ensure staff in the two departments had 
the knowledge and skills to adhere to the study protocol, and provide the standard 
care (in accordance with hospital policy) for the infant admitted with bronchiolitis. 
• External support from the MCH Acting Nursing Director and the Nurse Unit 
Managers, and internal support from registered nurses and clinical nurses, ensuring 
practice change was successfully adopted. 
The supported education was essential to the successful completion of the study. It 
encompasses not only the use of the equipment and the protocol, but using the study's 
key documentation format: the high flow oxygen data collection form (HiFOD) (Figure 5.1). 
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5.8.2 Data collection 
5.8.2.1 HiFOD data collection form 
When considering how to capture physiological data in the initial planning phases of the 
protocol, it was suggested that the Respiratory Distress Assessment Instrument (RDAI) 
(Table 5.1) be used to rate respiratory distress as a measure of severity of bronchiolitis. 
This instrument has been widely used in papers quantifying the severity of 
bronchiolitis.54,170–172 The RDAI validity was established by comparing chest wall 
retractions with other work-of-breathing markers, such as breath sounds, grunting, and 
nasal flaring.173 However, this tool had not been used at MCH in any clinical inpatient area, 
and other available tools were more comprehensive and could have better suited this 
study. 
Figure 5.1 – High flow oxygen data collection form (HiFOD)
HiFOD Scoring Form
URN:
>55 3 >55
50 2 50 Family Name:
45 1 45
40 0 40 Given name(s):
35 0 35
30 0 30 Date of birth: Sex: □ M □ F □ I
25 0 25
20 0 20
15 2 15
10 3 10
E <10
Severe 3 Severe HiFOD Score
Moderate 2 Moderate
Mild 1 Mild If an observation moves into one of the shaded areas, add up
Nil 0 Nil the patients full HiFOD score and take action as described in the actions
box below
>60% 2 >60%
30-60% 1 30–60% Score 0
<30% 0 <30%
High Flow (L/min)
Score 1
>94 0 >94 1
90-93 1 90-93
86-89 2 86-89 Score 2
<85 3 <85 2
Probe Change
Score 3
40.5 40.5 3
40 2 40
39.5 39.5
39 39
Temperature 38.5 38.5 Place emergency call
°C 38 1 38 E
37.5 0 37.5
37 0 37
36.5 0 36.5
36 0 36
35.5 0 35.5 Actions
<35.5 2 <35.5
HiFOD Action
190 3 190 Obtain full score 
180 2 180 1 to 3 Carry out and document appropriate interventions 
170 170 as prescribed
160 1 160 Increase frequency of observations
Heart Rate 150 0 150 Manage pain/fever/anxiety
(beats/min) 140 0 140 Review oxygen requirement
130 0 130 Inform Team Leader as appropriate
120 0 120
110 0 110 Ward doctor to reveiw within 30 minutes
100 0 100 4 to 5 Notify Team Leader
90 1 90 Obtain full score after interventions
80 2 80 If no review within 30minutes escalate to registrar review
70 3 70
60 60 6 to 7 Registrar to review patient- response within 15 minutes
E
If no review, or clinically concerned place SERT call
>120 2 >120 Obtain a full score after any interventions
115 0 115 Registrar to ensure consultant is notified
110 0 110 Ward doctor to attend
105 0 105
Systolic Blood Pressure 100 0 100 8+ Place SERT call
95 0 95 Registrar to attend
    (mmHg) 90 0 90 Ensure consultant is notified
85 0 85
80 0 80
75 0 75
70 1 70
65 65
60 2 60
55 55
50 3 50
45 E 45
Capillary Refill Time >2sec 1 >2sec
<2sec 0 <2sec Place emergency call if any of the following:
: airway threat
Alert 0 Alert : apnoea
Level of Consciousness Verbal 1 Verbal : seizure
Pain 3 Pain : you are worried about the patient
Unresponsive E Unrespon. : any observation in the violet area
Total HiFOD Score
H
i
F
O
D
 
S
t
u
d
y
Date
Time
FiO2 on blender
O2 Saturation
(%)
(Affix patient identification label here)
< 1
YEAR
Respiratory Rate
(breaths / min)
Respiratory distress
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Table 5.1 – Respiratory Distress Assessment Instrument 
 
  
Since a 'new' tool was required to capture the physiological data, paediatric early warning 
tools were considered. These early warning tools were originally developed and embraced 
as a consequence of poor identification of – and response to – deteriorating patients, in 
both adult and paediatric populations. The vast majority of adverse events do not occur 
through malice or incompetence; in fact, deficiencies in the structure of healthcare systems 
in the developed world have been identified as the culprit. Some of these systems issues 
identified in the literature174–176 include: 
• inability of medical and nursing staff at all levels to recognise critical illness and the 
deteriorating patient174 
• inexperience of doctors reviewing the patient175 
• lack of empowerment of junior staff to speak up, or seek senior assistance174 
• communication issues between staff176 
• errors in diagnosis, delays in instituting therapy, and an inadequate level of 
intervention.175 
As a consequence, the relationship between physiological abnormalities and the 
occurrence of serious adverse events was considered. Systems that 'track and trigger' 
have been increasingly researched,177 based on the periodic measurement of vital signs 
(track), with a pre-determined response (trigger) at a certain threshold.14 
Before the pilot study, MCH had no paediatric warning system in place for the early 
detection of the deteriorating child. However, as of 2010, five early warning systems 
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existed designed for children, four of which use scoring tools to aid in detecting the 
deteriorating child.178–181 While one of these systems does not use a specific scoring tool, 
it does provide guidelines for activating medical emergency teams (METs). These METs 
can be activated by any member of staff, either from a change in clinical state of the 
patient or simply because the staff are concerned. The system is not dependent on 
traditional hierarchical medical structures to instigate a review.178  
One study identifies that, of the systems using a scoring tool, 78% of "code blue" 
emergency call patients were recognisable at least one hour before the emergency call.179 
Other studies have also commented on the improved confidence of the attending staff, and 
overall staff perceived that they were better able to care for their patients.180,181  
Three of the four tools considered have been published.179–181 They vary considerably in 
the way physiological variables are collected and scored (Tables 5.2–5.4). And while they 
all assess the respiratory and cardiovascular system, they also vary in assessing 
neurological function, oxygen requirement and airway obstruction. Only one has 
differentiated between paediatric age groups.179 What is similar is that each component 
generates a score, and the overall score determines the clinician's level of intervention, 
whether it be obtaining a medical review in a pre-determined time, or instigating an 
emergency call. 
Table 5.2 – Brighton Paediatric Early Warning Score181 
  1 2 3 Score 
Behaviour Playing/appropriate Sleeping Irritable 
Lethargic/confused. 
Reduced response 
to pain. 
 
Cardiovascular Pink or capillary refill 1–2 seconds 
Pale or 
capillary refill 
3 seconds 
Grey or 
capillary refill 
4 seconds 
Grey and mottled 
or capillary refill 
5 seconds or 
above. Tachycardia 
of 30 above normal 
rate or bradycardia. 
 
Respiratory 
Within normal 
parameters, no 
tracheal tug 
>10 above 
normal 
parameters, 
using 30+% 
FiO2 or 
4+ L/min 
Tachycardia of 
20 above 
normal rate 
parameters 
recessing, 
tracheal tug. 
40+% FiO2 or 
6+ L/min 
5 below normal 
parameters with 
sternal recession, 
tracheal tug or 
grunting. 50% FiO2 
or 8+ L/min 
 
Score 2 extra for 1/4 hourly nebulisers or persistent vomiting following surgery 
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Table 5.3 – Bedside Pediatric Early Warning System Score (PEWSS)179 
 
 Age group 
Item sub score 
0 1 2 4 
Heart rate 
(bpm) 
0 to <3 months >110 and <150 
≥150 or 
≤110 
≥180 or 
≤90  ≥190 or ≤80 
3 to 
<12 months 
>100 and 
<150 
≥150 or 
≤100 
≥170 or 
≤80 
 ≥180 or 
≤70 
1–4 years >90 and <120 ≥120 or ≤90 ≥150 or ≤70 ≥170 or ≤60 
>4–12 years >70 and <110 ≥110 or ≤70 ≥130 or ≤60 ≥150 or ≤50 
>12 years >60 and <100 ≥100 or ≤60 ≥120 or ≤50 ≥140 or ≤40 
Systolic 
blood 
pressure 
(mmHg) 
0 to <3 months >60 and <80 ≥80 or ≤60 ≥100 or ≤50 ≥130 or ≤45 
3 to <12months >80 and <100 ≥100 or ≤80 ≥120 or ≤70 ≥150 or ≤60 
1–4 years >90 and <110 ≥110 or ≤90 ≥125 or ≤75 ≥160 or ≤65 
>4–12 years  >90 and <120 ≥120 or ≤90 ≥140 or ≤80 ≥170 or ≤70 
>12 years >80 and <100  >100 and <130 
≥130 or 
≤100 
≥150 or ≤85 
≥190 or ≤75 
Capillary 
refill time   <3 seconds    ≥3 seconds 
Respirator
y rate 
(breaths/ 
min) 
0 to <3 months >29 and <61 ≥61 or ≤29 ≥81 or ≤19 ≥91 or ≤15 
3 to <12months >24 or <51 ≥51 or ≤24 ≥71 or ≤19 ≥81 or ≤15 
1–4 years >19 or <41 ≥41 or ≤19 ≥61 or ≤15 ≥71 or ≤12 
>4–12 years >19 or <31 ≥31 or ≤19 ≥41 or ≤14 ≥51 or ≤10 
>12 years >11 or <17 ≥17 or ≤11 ≥23 or ≤10 ≥30 or ≤9 
Respirator
y effort  Normal 
Mild 
increase 
Moderate 
increase 
Severe 
increase / 
any apnoea 
Oxygen 
saturation 
(%)   
>94 91 to 94 ≤90  
Oxygen 
therapy   Room air  
Any to 
<4 L/min 
or <50% 
≥4 L/min or 
≥50% 
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Table 5.4 – Bristol Paediatric Early Warning Tool180 
A Acute airway obstruction 
(1)  Child has required nebulised adrenaline 
(2)  Clinically tiring or impending complete airway obstruction 
B Breathing 
(1)  SaO2 ≥92% in any amount of oxygen 
(2)  SaO2 ≥75% in any amount of oxygen (cyanotic heart disease) 
(3)  Persistent tachypnoea (RR≥70 under 6 months; ≥60 6–12 months; ≥40 1–5 
years; ≥25 over 5 years) 
(4)  Apnoea±bradycardia (HR≥95 in children under 5 years) 
C  Circulation  
(1)  Persistent tachycardia following one bolus of 10 ml/kg fluid (HR≥150 under 
5 years; HR≥120 5–12 years; HR≥100 over 12 years) 
(2)  Signs of shock, e.g. prolonged capillary refill (3 s); poor perfusion; ±low BP 
D   Disability  
(1)  GCS≥11 or unresponsive or responding only to pain 
(2)  Convulsion unresponsive to anticonvulsant therapy (lasting ≥30 min) 
E  Others 
(1)  Hyperkalaemia − K+ ≥6.0 mmol/L 
(2)  Any child with suspected meningococcal disease 
(3)  Any child with diabetic ketoacidosis (DKA) 
(4)  Any child whose condition is worrying 
 
The fourth tool considered has not been published, however is in use throughout 
Queensland Health hospitals. The Children's Early Warning Tool (CEWT, Appendix 3) is 
very similar to the Bedside PEWSS, and has been developed for differing ages groups in 
paediatrics. It highlights physiological variables that are abnormal for the age group by 
giving the variable a score and colour code. This allows attending staff to rely on the tool 
instead of carrying reference cards, or remembering 'normal for age' physiological 
variables. Colour bands are also key visual prompts that a physiological variable is 
worsening. 
The benefit in using these scoring tools underpinned the decision to use a similar tool for 
collecting physiological data on the pilot study patients. A scoring tool would provide staff 
confidence in their decision making, especially as they would be caring for patients 
differently from usual practice (in using HFNC). In addition, as the MCH Executive were to 
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roll out the CEWT throughout the hospital in late 2011 – early 2012, it made sense to use 
this tool to collect relevant data from the study patients.  
However, the CEWT does not capture FiO2 or apparatus flow rate – only oxygen flow rate 
– hence, the tool was modified to incorporate these two factors. The name of the tool was 
changed to High Flow Oxygen Data (HiFOD). All other parameters remained unchanged 
from CEWT, and the HiFOD was printed in colour on A3 paper. 
Education on using HiFOD, its components and actions, occurred in the months preceding 
the study, with 100% of nurses in the emergency department and paediatric ward planned 
to undergo training. Laminated cards were visibly displayed on all the study equipment and 
incorporated the use of HiFOD. Follow up education was also undertaken throughout the 
study period to mitigate any concerns over the use of the HiFOD form and the resultant 
scoring. 
5.8.2.2 Other data collection tools and systems 
A data collection tool was also developed to collect not only demographics but information 
such as prematurity, co-morbidities and respiratory virus identified from the 
nasopharyngeal aspirate (as reported on the hospital clinical laboratory interface: Kestral 
Computing Pty Ltd 1997–2013). Every patient's admission and discharge times, and 
interhospital transfers, were able to be tracked from the hospital patient information 
system: iPM™ (CSC Version 1.86.5 Build 002). All PICU admissions were tracked and 
clinical information obtained from the PICU clinical information system (PiCIS™, Spain). A 
screening log was kept of all potentially eligible patients during the study period. These 
patients were identified from the PED database: EDIS™ (iSOFT, Sydney, Australia). 
Data for those patients who were not eligible (>12 months of age, and those not admitted 
to the ward), was logged. This screening log allowed potentially missed patients to be 
identified. 
5.8.3 Pre-intervention preparations 
Equipment for the study consisted of three 'G' sized medical air cylinders (BOC Limited, 
Australia) in PED areas with no piped air (Figure 5.2), and 5 HFNC set-ups consisting of:  
• a humidification base (MR850, Fisher & Paykel Healthcare, Auckland, New 
Zealand) 
• flow meter, 0–15 L capacity  
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• Bird® Air-Oxygen Blender (CareFusion, California, USA) 
• air and oxygen hoses 
• circuit (RT329, Fisher & Paykel Healthcare, Auckland, New Zealand) 
• sterile water bag (Baxter Healthcare, Toongabbie, Australia). 
All equipment was attached to a mobile pole (Figure 5.3).  
   
  
Figure 5.2 – 'G' size air cylinder Figure 5.3 – HFNC set-up 
5.8.4 Intervention procedure 
Potential patients were screened in the PED and, if they met the inclusion criteria and if no 
exclusion criteria applied, the author was notified. Parents of eligible patients were then 
approached for consent and, if given, they were enrolled into the study. Ward staff were 
informed of the admission of a study patient. 
Recruited patients were fitted with the appropriately sized nasal cannula to interface with 
the HFNC unit (BC2745 or BC3780, Fisher & Paykel Healthcare, Auckland, New Zealand) 
and this was secured with Fixomull® Stretch 10x10 (BSN Medical, Hamburg, Germany) 
tape to the face (Figure 5.4). Observations were recorded on the HiFOD form before 
starting HFNC treatment, and then at least hourly, as per hospital policy for managing a 
patient receiving oxygen therapy. Nasopharyngeal aspirates (sputum trap by ConvaTec 
Limited, Deeside, United Kingdom) were collected as soon as practicable, either in the 
BC 2745 or 
3780 prongs 
 
 
Air/O2 blender 
and 0–15Lt 
flow meter 
 
 
 
RT 329 circuit 
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PED or the ward. A nasogastric tube (Argyle 6-8Fr, Covidien Healthcare, NSW, Australia) 
was inserted at the time of nasal cannula fitting to aid in decompressing the stomach, and 
if required for enteral feeding.  
 
Figure 5.4 – Nasal cannula secured with Fixomull® Stretch tape 
To initiate HFNC treatment, the FiO2 was set to 0.6 on the blender, and the flow increased 
to 2 L/kg/min, or a maximum of 10 L/min over a few minutes. The FiO2 was then 
decreased to maintain oxygen saturations of 94–98%. Oxygen saturation, heart rate and 
respiratory rate in the PED were monitored on the Infinity® Delta (Drager, Germany) 
(Figure 5.5) multiparameter monitor using a MasimoSET® LNOP® Inf-L SpO2 adhesive 
sensor (Masimo, USA) (Figure 5.6). On the ward, the MasimoSET® Radical® (Masimo, 
USA) portable oxygen saturation monitor were used to monitor SpO2 and heart rate 
(Figure 5.7). When the patient was ready to be admitted to the ward, two 'C' sized portable 
cylinders (medical oxygen, medical air, BOC Limited, Australia) were used during the 
patient transfer so that gas flow was maintained. The humidifier, however, was off during 
transfer as there was no battery back-up for this equipment. On arrival to the ward, the gas 
cables were transferred over to 'wall' piped medical oxygen and air, and the humidifier 
plugged into mains power and turned on.  
  
Figure 5.5 – Infinity® Monitor Figure 5.6 – Masimo LNOP® Inf-L sensor 
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Figure 5.7 – Masimo Radical® portable SpO2 monitor 
 
A simplified study protocol instruction sheet was attached to each HFNC set-up, with a 
flow chart for both PED staff and for ward staff (Figure 5.8 and Figure 5.9). The protocol 
required oxygen saturations to be maintained at 94–98%, therefore if saturations were 
consistently >98%, the FiO2 would be weaned. If saturations fell below 94%, then the FiO2 
would be increased. The aim was to wean oxygen to 21% (room air) with flow continuing. 
Once the patient's condition was stable, the flow would be turned off. If the patient then 
desaturated below 94%, flow would be reinstated at the previous flow rate, and if no 
improvement occurred, FiO2 was to be increased until the desired SaO2 of ≥94% was 
achieved. If, however, a FiO2 of >0.6 was required, or there were apnoeic episodes, or if 
the bedside nurses had any concerns, then medical staff were to review the patient.  
Infants were admitted to PICU on review by a paediatric consultant and PICU 
registrar/consultant. All other clinical management of infants with bronchiolitis remained as 
per hospital policy and paediatrician discretion. Pharmacological treatments remained as 
per treating physicians' orders. All clinical care, including positioning of the infants, 
remained as per normal ward management. Observations were to be collected on the 
HiFOD form until the infant was discharged from the ward.  
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Figure 5.8 – Flow chart for PED 
Diagnosis 
Bronchiolitis 
 
Eligible? NO YES 
Exclusion Criteria 
* No oxygen requirement 
* Home oxygen Tx for lung 
disease 
* Upper airway obstruction 
* Craniofacial malformation 
* Severe respiratory distress 
requiring other means of 
support such as NIV/INV 
and PICU admission 
Inclusion 
criteria 
* O2 
requirement 
to keep 
SaO2 >94% 
* given via 
face mask or 
nasal prongs 
Call study staff 
for consent 
No further 
action 
 
NO 
YES 
Initiate HFNP 
 
- 2 L/kg/min, max10 L 
- FiO2 60% 
Record obs on HiFOD 
Scoring Form. 
Frequency as per PED 
 
Transfer to ward as per 
PED policy 
IF: 
- FiO2 > 60% 
needed to 
maintain SaO2 > 
94% 
- score >6 
- nurse concerns 
NOTIFY RMO 
AND TREAT AS 
CLINICALLY 
INDICATED 
Take Baseline 
Observations, with and 
without O2 in situ 
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Figure 5.9 – Flow chart for ward 
 
Patient arrives on ward fromP ED 
Ensure equipment set up correctly, 
humidifier plugged in, set to ETT mode, 
water insitu 
Record observations on HiFOD Scoring Form 
– frequency of observations as per ward policy 
 
All clinical treatments and investigations as per ward policy 
May be breast/bottle/nasogastrically fed as per standard ward practice 
 
Adjustment of HFNP 
1st – reduce FiO2 to 
maintain SaO2 
between 94–98% 
Avoid SaO2 100% 
for too long unless 
FiO2 is 21% 
When FiO2 is 21%, turn 
flow OFF. The patient is 
now breathing room air. 
Continue observations as per ward 
policy, document on HiFOD form. 
IF RESPIRATORY DISTRESS RE-OCCURS AND SaO2 DROPS <94% 
Start flow at 2 L/kg/min to 
max 10 L/kig/min 
If SaO2 remains <94%, 
adjust FiO2 till Sats 94–98 
% achieved 
If FiO2 >60% required to maintain 
SaO2 >94%, SEEK MEDICAL 
REVIEW 
Notify medical officer if:- 
                                       : FiO2 on blender >60% 
                                       : apnoeas 
                                       : need for SERT call 
                                       : concern of bedside nurse/TL about wellbeing of child 
MEDICAL OFFICER TO MANAGE PATIENT AS CLINICALLY INDIACTED MAY NEED PICU 
ADMISSION 
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5.9 Sample size 
While pilot study designs are often used to assess proposed procedures of an intervention, 
or to plan a larger study , preliminary pilot data may still be both statistically and clinically 
significant, even with small sample sizes.169,182,183 However, determining how many 
participants are required for a pilot study is somewhat nebulous. Depending on the 
outcomes and intention of a pilot, the sample size can range from 10–40 participants, and 
is often determined by cost and realistic time frames.183 When determining sample size for 
studies such as RCTs, it is necessary to consider the size in relation in the power required 
to detect the effect being considered. Determining sample size uses the concepts of 
standard error and confidence interval to quantify how many participants are included, and 
are often based on previous data or by carrying out a pilot study.184 
For this pilot study, determining the sample size required considering a number of factors. 
In previous RCTs investigating the role of bronchodilators or corticosteroids in 
bronchiolitis, approximately 400 patients needed to be recruited. This number was based 
on a treatment effect of reducing admission rates and LOS by 20%. The Mater Children's 
Hospital admits approximately 660 patients per year via the PED with bronchiolitis. Annual 
PICU admissions of patients with bronchiolitis (from PED, paediatric wards and 
externally166) are about 140 patients. A study by Schibler et al15 and the success rate of 
HFNC treatment in the Mater Children's PICU indicated that a 10% reduction in PICU 
admission may be feasible. Therefore, enrolling 60 patients was deemed sufficient to 
demonstrate a reduction in the primary outcome (that is, admission to PICU) and inform 
both a sample size estimate, and clinical and admission criteria for the future RCT.  
5.10 Blinding 
Due to the nature of the study and the HFNC device, study staff were unable to be blinded. 
5.11 Statistical methods 
All data from a study patient's HiFOD forms was manually entered into Excel 
(Microsoft® Excel 2010) spreadsheets. Data were then selected at set clinical points in 
time, namely: pre-oxygen use, post-oxygen (i.e. face/nasal cannula oxygen therapy, and at 
1, 3, 6, 12, 24, and 48 hours post–HFNC), pre-PICU admission (if applicable), pre-HFNC 
cessation, and 4 hours post-HFNC cessation. These were entered into an Excel workbook 
which also included other demographic data, such as gender, age, prematurity, hospital 
LOS, PICU LOS, length of treatment (HFNC or standard oxygen treatment), respiratory 
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virus, co-morbidity, and any treatments such as antibiotics, salbutamol and steroids as 
collected on the data collection tool. 
Following this, the data were imported into the statistical software program SPSS™ 15.0 
(SPSS Inc., Chicago, IL). Data were manually checked for accuracy. Demographic and 
clinical data were compared between the expectant HFNC failure and success group using 
Fisher's exact test and independent T-test where appropriate. Mean and 95% confidence 
intervals (CI) were used for continuous variables with a parametric distribution.  Median 
and interquartile range (IQR) were used for non-parametric variables. For the relationship 
between physiological data and time among the different patient groups, a generalised 
linear model (GLM) was used. To describe the change in physiological data over time 
between the groups, an analysis of variance (ANOVA) for repeated measurements with 
Bonferoni correction was used. In order to determine the sample size for a larger RCT, a 
power of 90% and type 1 error 0.05 will be adopted. 
5.12 Ethical considerations 
Children and young people are defined by the National Statement on Ethical Conduct in 
Human Research185 as a vulnerable population, and additional vigilance is required to 
ensure that they are protected in the conduct of studies. Ethical approval was sought from 
the Mater Health Services' Human and Research Ethics Committee (HREC) and the 
Medical Research Ethics Committee of The University of Queensland. All documentation 
for the Mater HREC was completed for the study and included: 
• study protocol  
• parent consent and information form (Appendix 2) 
• staff information sheet  
• simplified protocol sheet for the two departments 
• budget proposal  
• excerpt of PICU guidelines for high flow set-up  
• CEWT tool (Appendix 3). 
Parents were provided with a copy of the parent consent and information form, and 
participation was documented in the medical chart. All requirements for the Mater HREC 
were to be met during the study period, including annual and final reports, and data 
monitoring and safety committee (DMSC) reports. Any adverse events of deaths during 
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the study period were to be reported to the DMSC immediately, and could have resulted in 
early termination of the study due to safety considerations.  
5.13 Storage of data collection sheets and electronic data 
Data collection sheets, photocopied HiFOD forms and signed parental consent forms were 
stored in a locked cabinet, in a swipe card-accessed area of the PICU. Electronic files 
were stored on a password-protected computer located within this same area, on the 
Mater Hospital secured drive, and within a restricted folder. 
5.14 A priori amendments to protocol  
In the initial conception of the study, there were a number of elements that were 
considered and written into the protocol.  These were: a randomised controlled trial design, 
inclusion criteria up to age 2 years (as bronchiolitis is most common up to this age), and 
conducted within two wards at MCH.  In further consultation with key stakeholders, these 
elements were required to be amended (see Chapter 7.4.2.1) and the final protocol 
submitted for ethical approval consisted of a pilot study design, inclusion criteria to 12 
months of age and conducted within one ward at MCH. 
5.15 Other amendments to protocol and ethics 
 
To fully describe the population cohort, recruitment monitoring in the initial five months of 
the study revealed that potentially eligible study participants were not being screened and 
identified for recruitment. Recognising the value of these patients as a comparison group, 
the protocol was amended for this group to be further assessed for eligibility. Potentially 
eligible patients were assessed and, if they met the study's enrolment criteria, their data 
were collected prospectively from medical records and entered into Excel workbooks at 
their point of entry into the study. The same inclusion and exclusion criteria used for the 
HFNC intervention patients were applied to this group.  
Consequently, an amendment was obtained from Mater HREC to access the medical 
charts of this potential comparison group (Appendix 6). A waiver of consent was sought for 
this group, allowing the course of these patients (the comparison group) to be compared to 
the intervention (HFNC) group. The same statistical analysis techniques outlined in the 
protocol were applied to this group, and comparisons made between each group 
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accordingly. Their details, such as date of birth and admitting ward, were noted on the 
screening log form, and subsequently transcribed into an Excel workbook.  
5.16 Conclusion 
This chapter has presented the protocol and methodology for the HFNC pilot study, 
including the study design and choice of physiological data collection tool. The protocol 
has been specified to the extent required for future replication studies. Additionally, the 
variation to the original design, which resulted in the inclusion of a comparison group, has 
been explained and detailed. The following chapter will present the results of this pilot 
study. 
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Chapter 6: Results 
6.1 Introduction 
In previous chapters the literature surrounding bronchiolitis and HFNC therapy have been 
described. The preceding chapter presented the methodology for the pilot study, and this 
chapter presents the results, including the resulting publication. Results are reported as 
consistent with the TREND guidelines.167 Before commencing the study, full ethical 
approval and governance considerations were obtained from both Mater HREC (Appendix 
4) and the University of Queensland HREC (Appendix 5). 
6.2 Participant flow 
A total of 1111 patients were screened in the PED of the MCH, between July 2011 and 
May 2012. During that time, 94 patients satisfied the study's eligibility criteria and of those, 
61 were consented and enrolled for HFNC treatment (intervention group). The remaining 
33 eligible patients had not been approached for recruitment. They were identified and 
formed the comparison group who received standard treatment (Figure 6.1).   Eighty-one 
patients were admitted who did not meet the inclusion criteria, that is, they had no oxygen 
requirement, had craniofacial malformations, had pre-existing home oxygen requirement 
or upper airway obstruction, or were commenced on oxygen therapy despite having 
oxygen saturations >94% on room air. These patients were excluded from the trial. 
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Figure 6.1 – Screening flow chart from the paediatric emergency department 
 
6.3 Baseline data HFNC vs comparison group 
6.3.1 Demographic data 
Demographic data, specifically age and gender, were collected for each participant on 
admission, as summarised in Table 6.1. Gender was equally distributed between the 
groups with the HFNC group having 64% males and 36% females, and the comparison 
group having 58% males and 42% females. Ages were also similar with the mean [95% 
CI] for the HFNC group 157 days [128–187] and the comparison group 146 days [104–
188].  
1017 patients excluded: 
• 577 (52%) discharged home 
• 121 (11%) transferred to other 
facilities 
• 232 (21%) >12 months of age 
• 6 (0.5%) directly admitted to 
PICU 
• 81 (7%) admitted but not 
fulfilling inclusion criteria  
Screened for 
eligibility in the 
Emergency 
Department 
n=1111 
July 2011–May2012 
Identified as eligible 
n= 94 
Recruited to study 
HFNC Group 
n=61 
Not recruited to study 
Comparison Group 
n=33 
HFNC 
Non-Responders 
(required PICU admission) 
n=8 
HFNC 
Responders 
(managed on ward) 
n=53 
Comparison 
Non-Responders  
(required PICU admission) 
n=10 
Comparison 
Responders  
(managed on ward) 
n=23 
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6.3.2 Clinical data 
Clinical data collected for each participant comprised weight, prematurity and co-morbidity. 
Weight was comparable between the two groups with mean [95%CI] of the HFNC group at 
6.8 kg [6.1–7.5] and the comparison group at 6.6 kg [5.6–7.7]. Prematurity was described 
as gestation of less than 37 completed weeks, with 31% premature in the HFNC group 
and 18% in the comparison group. Co-morbidities encompassed infants with Trisomy 21, 
tracheomalacia, and repaired/unrepaired cardiac anomalies – 5% in the HFNC group and 
6% in the comparison group had these conditions. No statistical differences were identified 
on any of these characteristics between the HFNC and comparison groups (Table 6.1). 
6.3.3 Physiological data 
Physiological assessment of heart rate, respiratory rate, oxygen saturation (SpO2) and 
HiFOD score did not differ significantly between groups on admission. The mean [95% CI] 
heart rate for the HFNC group on admission was 158 bpm [153–163] and 159 bpm [152–
166] in the comparison group. Mean respiratory rate was also comparable, being 54 rpm 
[51–57] in the HFNC group and 53 rpm [50–57] in the comparison group. The admission 
SpO2 was almost identical with the HFNC group mean 89% [88–90] and the comparison 
group 90% [89–92]. Finally, the mean HiFOD score in the HFNC group was 6 [5–8] with 
the comparison group being 5.5 [4–7] (Table 6.1).   
Nasopharyngeal aspirates revealed respiratory viruses, namely: respiratory syncytial virus 
(RSV), influenza, rhino/enterovirus, adenovirus, human metapneumovirus (HMPV), or 
combinations of these. The most predominant single viral infection was RSV (48%) (Figure 
6.2) and overall, 60% of viral infections incorporated RSV. There were no statistically 
significant differences between the two groups in rate of respiratory infection as 
determined by nasopharyngeal aspirate, p=0.54.  
Day of illness (the number of days the participant was ill prior to PED presentation) was 
also not statistically different between the groups, with the HFNC group presenting at a 
mean [95%CI] of 3.0 days [1–5] and the comparison group at 2.9 days [2–3.5]. 
6.3.4 Treatment data 
Treatment modalities such as steroid use (12% each group), salbutamol nebulisers (26% 
and 24%) or antibiotics (20% and 24%) likewise did not exhibit statistically significant 
differences between the HFNC group and comparison group respectively.  
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6.3.5 Length of stay 
The hospital length of stay was calculated as a median with interquartile ranges, and was 
almost identical between the groups. The HFNC group was 92 hours (59–141) and the 
comparison group 92 hours (48–124), p=0.56.  
Table 6.1 – Demographic, physiological, clinical and treatment characteristics between HFNC group 
and comparison group  
Characteristics Variable 
HFNC Group 
n=61 
n = (%) 
mean [95% CI] 
 
Comparison 
Group n=33 
n= (%) 
mean [95% CI] 
P 
value 
Demographic 
Male 39 (64%) 19 (58%) 0.66 
Female 22 (36%) 14 (42%)  0.66 
Age (days) 157 [128–187] 146 [104–188] 0.66  
Physiological 
Weight (kg) 6.8 [6.1–7.5] 6.6 [5.6–7.7] 0.78 
Ex-prematurity 19 (31%) 6 (18%) 0.23 
Other co-morbidity 3 (5%) 2 (6%) 0.58  
Clinical 
Heart rate (bpm) 158 [153–163] 159 [152–166] 0.75 
Respiratory rate (rpm) 54 [51–57] 53 [50–57] 0.78 
SpO2 (%) 89 [88–90] 90 [89–92] 0.17 
HiFOD Score 6 [5–8] 5.5 [4–7] 0.64 
NPA positive 55 (95%) 32 (97%) 0.54 
Day of Illness 3.0 [1–5] 2.9 [2–3.5] 0.68 
Treatment 
Steroids (Tx) 7 (12%) 4 (12%) 0.93 
Salbutamol (Tx) 16 (26%) 8 (24%) 0.83 
Antibiotics (Tx) 12 (20%) 8 (24%) 0.60 
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Figure 6.2 – Percentage of respiratory viruses (*rhino/entero virus, influenza, HMPV, adenovirus & 
combinations of these) 
6.4 Primary outcome 
The primary outcome measure was admission to the PICU. Within each group, those 
admitted to PICU were classified as Non-Responders, with those managed successfully 
on the ward classified as Responders. 
Of the 61 patients in the HFNC group, 8 (13%) were admitted to the PICU and therefore 
labelled HFNC Non-Responders. This is compared to 53 (87%) who remained on the 
paediatric ward and labelled HFNC Responders. In the comparison group, 10 (31%) 
required PICU admission (comparison Non-Responders) and 23 (69%) remained on the 
paediatric ward (comparison Responders). When compared, those in the intervention 
group (HFNC) were significantly less likely to be admitted to PICU than those in the 
comparison group [OR 4.086, 95% CI 1.0–8.2, p=0.04].  
6.4.1 Demographic and physiological characteristics of Responders vs Non-
Responders on admission 
Further analysis was necessary to determine whether there were differences in 
demographic or physiological characteristics at admission between the Non-Responders 
and Responders that may have unduly skewed the outcome (Table 6.2). Demographic 
data were not statistically significant between the Non-Responders and Responders of 
each group. Mean [95% CI] for Non-Responders (HFNC and comparison) for age (in days) 
were 170 [70–270] and 115 [40–190], and for Responders (HFNC and comparison) 157 
47% 
24% 
2% 
26% 
1% 
RSV only
RSV + 1 other virus
RSV + 2 other virus
All other virus*
Nil virus
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[121–186] and 160 [111–206]. Weight (in kg) was also similar between each Non-
Responder and Responder group. 
No differences were found in percentages of premature infants (12% and 10% in the Non-
Responders (HFNC and comparison); 34% and 22% in the Responders (HFNC and 
comparison)) or those with co-morbidities (12% and 20%; 4% and 0% respectively).  
6.4.2 Clinical characteristics of Responders vs Non-Responders on admission 
Differences in physiological data (heart rate, respiratory rate, SpO2, and HiFOD score) 
were not statistically significant. On admission, the mean [95% CI] heart rate of the Non-
Responders were 159 bpm [142–176], 161 bpm [171–151], HFNC and comparison group, 
respectively. The Responders were 157 bpm [151–163], 159 bpm [151–167], HFNC and 
comparison group, respectively. Admission mean respiratory rate for the Non-Responders 
was 54 rpm [47–61], 58 rpm [53–63], HFNC and comparison respectively. The 
Responders group was 54 rpm [51–57], 52 rpm [48–56], HFNC and comparison 
respectively. The SpO2 for the Non-Responders on admission was 88% [86–92], 91% [85–
94], HFNC and comparison respectively. The Responders also had very similar SpO2, 
89% [88–90], 90% [89–91]. Finally, the HiFOD score was almost identical between the 
Non-Responders, 7 [6–8], 7 [6–8.5], and within the Responders groups, 6 [4–8], 5 [4–7], 
HFNC and comparison respectively. 
Infection with a respiratory virus was also not statistically significant between any of the 
groups. Non-Responders had 87% and 90% (HFNC and comparison) infections, with 
Responders 90% and 100%. RSV continued to be the most prevalent cause of respiratory 
viral infection amongst all the groups, attributable to 75% and 80% of infections in the Non-
Responders (HFNC and comparison; Figure 6.3 and Figure 6.4), and 52% and 61% in the 
Responders (Figure 6.5 and Figure 6.6). 
Day of illness on admission was also not statistically significant between any of the groups. 
Non-Responders presented on, HFNC and comparison respectively, day 3.0 [2–4] and 2.5 
[2–3] and Responders on day 3 [2.5–3.5] and 3 [2–4]. 
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Figure 6.3 – Virus types of Non-Responders 
HFNC group 
Figure 6.4 – Virus types of Non-Responders 
comparison group 
  
Figure 6.5 – Virus types of Responders HFNC 
group      
Figure 6.6 – Virus types of Responders 
comparison group 
6.4.3 Length of treatment 
The length of treatment (in hours) of either HFNC or oxygen therapy between the Non-
Responders and Responders was not statistically significant. Median (with interquartile 
ranges) for the Non-Responders was 7 hours (4.5–12) for the HFNC group and 4 hours 
(2–7) for the comparison group before they were admitted to PICU, p=0.07. For the 
Responders, it was 53 hours (26–101) for the HFNC group, 40 hours (24–63) for the 
comparison group, p=0.32. 
 
50% 
25% 
12% 
13% 
RSV & Rhino/Entero Virus RSV HMPV  not done
10% 
80% 
10% 
Rhino/Entero Virus RSV Nil
41% 
22% 
2% 
2% 
2% 
7% 
6% 
6% 
4% 
4% 2% 
2% 
RSV
Rhino/Entero Virus
Adeno & Rhino/Entero
Virus
HMPV
 Influenza
RSV & Rhino/Entero
Virus
Influenza &
Rhino/Entero Virus
Nil
 not done
RSV & Adeno &
Rhino/Entero Virus
Adeno & HMPV
Rhino/Entero Virus &
HMPV
52% 
5% 
22% 
9% 
4% 
4% 4% 
RSV
Rhino/Entero
Virus
Adeno &
Rhino/Entero
Virus
 Human
metapneumovir
us
 Influenza
RSV,
HMPV&Rhino/E
ntero Virus
RSV, Influ&
Rhino/Entero
Virus
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Table 6.2 – Demographic, physiological and clinical characteristics of Responders and Non-Responders in HFNC and comparison groups at admission 
Characteristics  Variable 
HFNC 
Non-Responders 
n=8 
 
n= (%) 
mean [95% CI] 
Comparison 
Non-Responders 
n=10 
 
n= (%) 
mean [95% CI] 
p 
value 
HFNC 
Responders 
n=53 
 
n= (%) 
mean [95% CI] 
Comparison 
Responders 
n=23 
 
n= (%) 
mean [95% CI] 
p 
value 
Demographic Age (days) 170 [70–270] 115 [40–190] 0.34 157 [121–186] 160 [111–206] 0.77 
Physiological 
Weight (kg) 6.9 [4.8–9.0] 6.3 [4.0–8.6] 0.70 6.7 [(5.9–7.4] 6.6 [5.7–7.8] 0.66 
Ex-prematurity 
 1 (12%) 1 (10%) 0.26 18 (34%) 5 (22%) 0.26 
Other co-
morbidity 1 (12%) 2 (20%) 0.08 2 (4%) 0 0.08 
Clinical 
Heart Rate 
(bpm)  159 [142–176] 161 [171–151] 0.98 157 [151–163] 159 [151–167] 0.75 
Respiratory 
Rate (rpm)  54 [47–61] 58 [53–63] 0.66 54 [(51–57] 52 [48–56] 0.77 
SpO2 (%) 
 88 [86–92] 91 [85–94] 0.39 89 [88–90] 90 [89–91] 0.17 
HiFOD Score 7 [6–8] 7 [6–8.5] 0.60 6 [4–8] 5 [4–7] 0.64 
NPA  
Positive 7 (87%) 9 (90%) 0.47 43 (90%) 23 (100%) 0.47 
Day of Illness 3.0 [2–4} 2.5 [2–3] 0.42 3 [2.5–3.5] 3 [2–4] 0.68 
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6.5 Secondary outcomes 
Secondary outcome measures encompassed physiological parameters such as respiratory 
and heart rate, and the overall HiFOD score. Other outcome measures comprised adverse 
events, which include bradycardia, pneumothorax, cardiopulmonary arrest and emergency 
intubation; and for those patients admitted to PICU, non-invasive ventilation and/or 
intubation.  
6.5.1 Physiological parameters  
A GLM was used to analyse differences in heart rate, respiratory rate and HiFOD score 
over time. ANOVA was used to determine the difference between the means of the 
groups, with the p-value set at <0.05 for significance. Responders to therapy, whether in 
the HFNC group or undergoing standard treatment, had clinically significant differences at 
60 minutes post-initiation of intervention/standard treatment compared to Non-Responders 
(Table 6.3 & 6.4). Responders to HFNC showed a reduction of 15–20% in the baseline 
heart rate on admission, otherwise quantified as a reduction in heart rate of 15 bpm.  
Table 6.3 – Clinical parameters of HFNC group at 60 minutes of treatment  
 
Responders 
n= 53 
mean 
[95%CI] 
Non-
Responders 
n= 8 
mean [95%CI] 
p-valve 
Heart rate (bpm) 144 [138–150] 
162 
[152–171] 0.02 
Respiratory rate 
(rpm) 
51 
[48–54] 
58 
[48–69] 0.07 
HiFOD score 4.5 [4–5.5] 
6.5 
[5–8] 0.006 
 
Table 6.4 – Clinical parameters of comparison group at 60 minutes of treatment 
 
Responders 
n= 23 
mean 
[95%CI] 
Non-
Responders 
n= 10 
mean [95%CI] 
p-value 
Heart rate (bpm) 141 [131–150] 
160 
[136–183] 0.06 
Respiratory rate 
(rpm) 
45 
[41–49] 
51 
[44–45] 0.16 
HiFOD score 3 [2–4] 
6.5 
[5–8] 0.00 
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6.5.1.1 Heart rate 
Overall between the four groups there was a significant difference in heart rate over time 
from admission, p<0.001 (Figure 6.7). Heart rate in infants remaining in the paediatric 
ward (Responders) for both HFNC group and comparison group dropped significantly 
within the first 60 minutes. In infants requiring PICU admission (Non-Responders) heart 
rate either remained unchanged or increased after admission. The heart rates for 
Responders in the HFNC group reduced significantly (p=0.02) within 60 minutes from a 
mean [95% CI] of 157 bpm [151–163] to 144 bpm [138–150] whereas the heart rate of the 
Non-Responders increased slightly from 159 bpm [142–176] to 162 bpm [152–171]. 
 
 
Figure 6.7 – Change in heart rate in intervention and comparison groups after inclusion in the study 
 
6.5.1.2 Respiratory rate 
Between the four groups there was also a significant difference in respiratory rate over 
time from admission, p=0.05 (Figure 6.8).The respiratory rate in the HFNC Non-
Responders group remained high but in the comparison Non-Responders group 
decreased after admission. At 60 minutes, the Responders in the HFNC group dropped 
their respiratory rate from a mean [95% CI] of 54 rpm [51–57] to 51 rpm [48–54] with the 
Non-Responders increasing from 54 rpm [47–61] to 58 rpm [48–69], p=0.07. While the 
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differences were not statistically significant at 60 minutes, they were statistically and 
clinically significant at 180 minutes post-treatment initiation, p<0.05.   
 
 
Figure 6.8 – Change of respiratory rate in intervention and comparison group after inclusion in the 
study 
 
6.5.1.3 HiFOD score 
The HiFOD score as a composite of physiological data changed significantly between the 
groups after admission, p< 0.001 (Figure 6.9). HiFOD score decreased for the HFNC 
Responders and comparison Responders significantly 60 minutes after admission, but 
remained high in infants requiring PICU admission. The Responders in the HFNC group 
dropped their HiFOD score from a mean [95% CI] of 6 [4–8] to 4.5 [4–5.5], with the Non-
Responders slightly decreasing their HiFOD score from 7 [6–8] to 6.5 [5–8] at 60 minutes. 
109 
 
 
 
Figure 6.9 – Change in HiFOD score in intervention and comparison group after inclusion in the 
study 
 
6.5.1.4 Post-hoc analysis – Physiological data 
Receiver operator characteristic (ROC) curves are usually applied in diagnostic statistics. 
This analytical procedure uses sensitivity and specificity to determine the likelihood of 
having or not having a particular disease.184 Logically, this same test can be applied to 
predictors of physiological parameters to determine the sensitivity and specificity for 
predicting treatment failure.  
Area under the curve ROC (AUROC) was applied to heart rate, respiratory rate and 
HiFOD score and were found to be statistically significant in the HFNC group to predict 
PICU admission, p<0.001 (Figure 6.10). The sensitivity of heart rate to predicting PICU 
admission was 0.74 [95% CI 0.66–0.83]. Respiratory rate was also sensitive, 0.73 [95% CI 
0.65–0.81], as was HiFOD score, 0.80 [95% CI 0.73–0.88].  
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Figure 6.10 – Receiver operator characteristics for HFNC group 
 
6.5.2 Adverse events 
No serious adverse events (such as bradycardia, pneumothorax, cardiopulmonary arrest 
or need for emergency intubation) occurred during the study in either the HFNC group or 
through retrospective chart audit in the comparison group.  
6.5.3 PICU clinical course 
Of those infants admitted to PICU (n= 18), one infant in the HFNC group and three in the 
comparison group required a period of non-invasive ventilation (NIV). Within the PICU, NIV 
is given via an appropriately fitting face mask using the Evita®XL ventilator (Drager, 
Germany) in pressure support mode. The remaining infants admitted to PICU received 
HFNC treatment at 2 L/kg/min. None of the infants required intubation in the PICU.  
6.5.4 Post-hoc outcomes 
A further aim was to determine a sample size for a multicentre RCT.  Under consultation 
with a statistician, with the power set at 90% and type 1 error of 0.05, based on PICU 
admission rates of 13% for HFNC therapy group and 33% for standard therapy group, 
1 - Specificity
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there would need to be 121 participants in each group.  However, it is feasible that a 10% 
reduction in PICU admission rate is achievable. Therefore 392 participants in group one 
(standard therapy) and 392 in group two (HFNC therapy) achieves 90% power to detect an 
absolute difference between the group proportions of 10%.  The proportion of participants 
admitted to PICU in the HFNC group is assumed to be 30% under the null hypothesis and 
20% under the alternative hypothesis.  The proportion in the standard therapy group is 
30%.  The test statistic used is the two-sided Z test with pooled variance.  The significance 
level of the test is targeted at 0.05.   
Although the study did not intend to consider feeding in the initial analysis and outcome 
measures, it emerged to be an issue worthy of exploring. Post-hoc analysis of feeding in 
the HFNC patients during the study revealed they were fed via nasogastric tube, orally or 
intravenous infusion, or a combination of these (Figure 6.8). No orally fed HFNC patient 
was admitted to PICU. Those admitted to PICU (Non-Responders) were either nasogastric 
fed or had fluids delivered via intravenous infusion (Table 6.5). There were no reports of 
adverse events such as abdominal overdistention, nasal trauma or aspiration from oral 
feeds.  
 
Figure 6.11 – Feeding mode in HFNC patients 
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Table 6.5 – Feeding mode in HFNC Responders and Non-Responders 
Mode of feeding HFNC Responders n=53 
HFNC Non-Responders 
n=8 
Oral only 21  (40%) 0 
Nasogastric (NG) only 13  (24%) 
6  
(75%) 
Combination NG/Oral 19  (36%) 0 
Intravenous 0 2  (25%) 
P=0.000 
 
 
Infant positioning was not recorded formally during the study period nor collected on the 
comparison group. However, the study protocol did not stipulate any particular way to 
position the patient. This was left to standard ward protocol for managing infants with 
bronchiolitis. It is likely that there was no difference in the way infants were positioned 
between the HFNC group and comparison group, however no data exists to support this.  
6.6 Summary 
This chapter detailed the findings of the pilot study. The key results from instituting HFNC 
in a ward setting suggest that: PICU admissions may be significantly reduced; 
physiological parameters such as heart rate, respiratory rate and HiFOD score (as a 
composite of physiological variables) could be used, either singularly or combined, to 
determine potential PICU admission; instituting HFNC therapy following this protocol was 
feasible and gave a reasonable indication of success within 60 minutes of 
commencement; factors such as age, weight, gender, prematurity and co-morbidity did not 
play a significant role in predicting treatment failure; use of HFNC therapy did not increase 
hospital length of stay; and there was no apparent association between oral feeding whilst 
on HFNC and admission to PICU. 
The following chapters will discuss the results and what they may mean for clinicians, 
elaborate on the limitations to the study and thesis, and explore further areas of 
investigation. 
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High-flow nasal cannula oxygen therapy for infants with
bronchiolitis: Pilot study
Sara Mayfield,1,2 Fiona Bogossian,2 Lee O’Malley1 and Andreas Schibler1,3
1Paediatric Critical Care Research Group, PICU, Mater Children’s Hospital, and Schools of 2Nursing and Midwifery and 3Medicine, The University of Queensland,
Brisbane, Queensland, Australia
Aim: To obtain data on the safety and clinical impact of managing infants with bronchiolitis on the ward with high-flow nasal cannula (HFNC)
treatment.
Methods: A prospective pilot study was conducted of 61 infants aged <12 months with bronchiolitis and oxygen requirement presenting to
the emergency department. HFNC was commenced at 2 L/kg/min, and fraction of inspired oxygen was titrated to oxygen saturation > 94%. A
standard-treatment group (n = 33) managed with standard low-flow subnasal oxygen during the same time period was retrospectively identified.
Results: Admission demographics, heart rate (HR) and respiratory rate (RR) were similar in test and standard-treatment groups. Responders
and non-responders to HFNC were identified within 60 min of treatment. Non-responders to HFNC requiring paediatric intensive care unit (PICU)
admission showed no change in HR and RR, whereas responders showed decreases in HR and RR (P < 0.02). Patients receiving HFNC were four
times less likely to need PICU admission than the standard treatment group (OR 4.086, 95%CI 1.0–8.2; P = 0.043). No adverse events such as
pneumothorax, bradycardia, bradypnoea, emergency intubation or cardiopulmonary resuscitation were observed. No patients admitted to the
PICU required intubation.
Conclusions: HFNC treatment in the paediatric ward is safe. Non-responders requiring PICU admission can be identified within the first hour
of HFNC treatment by monitoring HR and RR. It is feasible to undertake a randomised controlled trial based on this pilot with the aim of
decreasing PICU admissions.
Key words: bronchiolitis; high-flow nasal cannula; infant.
What is already known on this topic
1 High-flow nasal cannula (HFNC) treatment is in use throughout
many neonatal, adult and paediatric intensive care units (ICUs).
2 It is thought to provide incidental continuous positive airway
pressure and reduce intubation rates.
3 There is potential for its use outside the ICU environment.
What this paper adds
1 Evidence is presented to guide a larger randomised controlled
trial for the safety and feasibility of HFNC treatment use in
the paediatric ward environment for the management of
bronchiolitis.
2 HFNC treatment on the ward is safe.
3 Non-responders to HFNC can be identified early.
Bronchiolitis in infants is the most common reason for non-
elective hospital admissions. Within Australia it accounts for an
estimated 8000–9000 admissions per year. In 2011 the Austral-
ian and New Zealand Paediatric Intensive Care Registry reported
858 admissions of bronchiolitis to paediatric intensive care units
(PICUs), reflecting approximately 10% of all bronchiolitis
hospital admissions.1 There is a general trend in bronchiolitis
management towards reduced intubation and ventilation and
an increased use of non-invasive ventilation (NIV).2 The latest
addition to the respiratory management of bronchiolitis is the
use of high-flow nasal cannula (HFNC) therapy. Studies in neo-
nates and recently in infants have shown that HFNC therapy
delivers inadvertent continuous positive airway pressure
(CPAP)3 and improves work of breathing (WOB).4–8 Since the
introduction of HFNC treatment, a significant reduction in the
need for mechanical respiratory support other than HFNC has
been demonstrated.9–11 The striking advantage and efficacy of
HFNC may be based on its simple application and minimal
interference with patient comfort. However, the uptake of
HFNC treatment in paediatrics has been sporadic. This is, in part,
due to a lack of guidelines on ‘best practice’.
For the purpose of gaining some clinical data on the safety
and clinical impact of HFNC use in a regular paediatric ward, we
performed a case control study in infants with bronchiolitis aged
less than 12 months of age. Secondary outcomes of this pilot
study were to demonstrate a proof of concept for a future
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randomised controlled trial (RCT) and to present data on the
decreased prevalence of respiratory deterioration and require-
ment for PICU admission.
Methods
Study design
A prospective pilot study was conducted, investigating the use of
HFNC treatment in a paediatric ward setting. The use of an RCT
design for this study was denied by the institutional ethics
board, as there are no convincing data yet available for safety of
HFNC use in regular ward settings. Inclusion of case controls
who were admitted during the same period was retrospectively
allowed by the ethics board for the purpose of comparison.
These patients received standard oxygen therapy and are
referred to as the standard-treatment group.
Study protocol
Prior to the study, staff education on the protocol and equip-
ment was implemented utilising a structured education plan.
The plan targeted both medical and nursing staff in the emer-
gency department (ED) and paediatric ward. ED staff education
focused on recognition and identification of candidates meeting
inclusion and exclusion criteria, adherence to study protocol,
notification to study investigator, understanding correct selec-
tion and application of equipment, commencement of HFNC
treatment and ongoing assessment of the patient. Ward staff
education focused on ongoing respiratory care, adherence to the
study protocol, and understanding and recognition of deterio-
rating and improving infants.
Patients were screened from July 2011 to May 2012 in the ED
of Mater Children’s Hospital, Brisbane, Queensland, Australia,
for the following inclusion criteria: age <12 months, clinical
diagnosis of bronchiolitis and oxygen requirement (SpO2 < 94%
in room air). Exclusion criteria were the following: craniofacial
malformation, upper airway obstruction (stridor), and impend-
ing PICU admission based on severity of illness (impending
intubation, NIV, low level of consciousness, apnoea) or transfer
elsewhere. Informed consent to the study was obtained for all
patients receiving HFNC treatment.
Patients for the standard-treatment group were identified retro-
spectively through chart review and included all infants with the
same inclusion and exclusion criteria as the study patients who
were admitted during the same time period to the same paediatric
ward. Informed consent was waived for this group.
HFNC intervention
After consent was provided by the parents or guardians, the
infants had the appropriate-sized nasal cannula applied, and flow
was commenced through a circuit (RT329, BC3780 and BC2745;
Fisher & Paykel Healthcare, Auckland, New Zealand) at 2 L/kg/
min to a maximum of 10 L/min. Fraction of inspired oxygen
(FiO2) was titrated (Bird Air–Oxygen Blender, CareFusion, Yorba
Linda, CA, USA) to maintain oxygen saturation between 94%
and 98%, and the humidifier (Fisher & Paykel Healthcare
MR850) was auto-set at 37°C. All other areas of nursing and
medical management for bronchiolitis remained unchanged for
the study purpose according to standard hospital protocol and
consultant directive. Patients were transferred to the paediatric
ward after commencement of HFNC treatment. Once FiO2 could
be reduced to 0.21, and oxygen saturations remained at 94% or
higher, flow was turned off. If SpO2 dropped below 94%, flow
returned at the same rate. If SpO2 did not improve, then FiO2 was
increased and titrated to achieve SpO2 of 94% or higher. This
weaning procedure was repeated until the patient was able to
remain off HFNC treatment.
Measures
Physiological parameters including heart rate (HR), respiratory
rate (RR), SpO2, temperature and a respiratory score for WOB
were documented (from no distress to severe distress in three
levels). Observations were recorded on admission and at regular
time points until discharge. Hospital length of stay (LOS) and
length of treatment (LOT) of either HFNC treatment or low-flow
subnasal oxygen treatment were measured. Demographic data
and comorbidities such as prematurity, chromosomal abnormal-
ity and repaired/unrepaired cardiac anomaly were recorded.
Serious adverse events, as a measure of safety, were defined as
cardiopulmonary arrest, pneumothorax, bradypnoea, bradycar-
dia, requirement for CPR or emergency intubation in the ward/
PICU. Criteria for admission to PICU were the following:
requirement for escalation of care, including cases of SpO2 <
92% despite 2 L/min O2 in the control group or FiO2 > 60% in
the HFNC group; inability to manage the patient on the ward
(nursing); and deterioration in physiological parameters (persis-
tent tachypnoea (>60 breaths/min) and tachycardia (>180
beats/min) ). PICU admission in such cases was discussed and
determined between the paediatric consultant and PICU
registrar/consultant after patient review.
Statistical analysis
Demographic and clinical data, the number of adverse events
and the number of PICU admissions were compared between
the HFNC and standard-treatment groups using Fisher’s exact
test and the independent-samples t-test where appropriate. For
the relationship between physiological data and time among the
different groups, a generalised linear model (GLM) was used. To
describe the change of physiological data over time, an ANOVA
for repeated measurements with Bonferroni correction was
used (SPSS 15.0, SPSS Inc, Chicago, IL, USA). Data are pre-
sented as mean and 95% confidence interval (CI), and a P value
< 0.05 was considered significant.
Results
A total of 1111 patients were screened in the ED between July
2011 and May 2012, and 61 patients were enrolled for HFNC
treatment. Subsequently, 33 patients were identified retrospec-
tively as meeting the inclusion criteria and included in the
standard-treatment group (Fig. 1). There were no statistically
significant differences in the demographic and physiological
characteristics of patients in the HFNC and standard-treatment
groups on admission (Table 1).
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There were no serious adverse events observed during the
study in either group, and importantly, no emergency pro-
cedures such as intubation and mechanical ventilation were
required.
Overall, among the four patient groups, there was a signifi-
cant difference in the change of HR over time (P < 0.001, GLM)
from admission (Fig. 2). The HR in patients remaining in the
paediatric ward for both HFNC and standard-treatment groups
dropped significantly within the first 60 min (responders). In
patients requiring PICU admission, the HR remained unchanged
and even increased after admission (non-responders). Respond-
ers to care could be identified by their HR dropping by 15 beats
(or 15–20%) from their baseline at admission. In the responders
in the HFNC group, mean HR changed significantly within
60 min from 158 beats/min (95% CI 154–164) to 144 beats/min
(95% CI 138–150), whereas the mean HR of the non-
responders increased slightly from 159 beats/min (95% CI 144–
173) to 162 beats/min (95% CI 152–171) (P = 0.02).
1017 patients excluded:
• 577 (52%) discharged home
• 121 (11%) transferred to other 
facilities
• 232 (21%) >12 months of age
• 6 (0.5%) directly admitted to PICU
• 81 (7%) admitted but not fulfilling 
inclusion criteria
Screened for eligibility 
in the emergency 
department
n = 1111
July 2011−May 2012
Identified as eligible
n = 94
Recruited to study
HFNC group 
n = 61
Not recruited to study†
Standard-treatment group 
n = 33
HFNC
Non-responders 
(required PICU admission)
n = 8
HFNC
Responders 
(managed on ward)
n = 53
Standard-treatment
Non-responders 
(required PICU admission)
n = 10
Standard-treatment
Responders 
(managed on ward)
n = 23
Fig. 1 Screening flow chart from the emer-
gency department (ED). †Patients were eligible
but not approached, as ED staff did not alert
study staff. HFNC, high-flow nasal cannula; PICU,
paediatric intensive care unit.
Table 1 Demographic and physiological characteristics of high-flow nasal cannula and standard-treatment groups at admission
HFNC group (n = 61) Standard-treatment group (n = 33) P value
Male, n (%) 39 (64) 19 (58) 0.66
Female, n (%) 22 (36) 14 (42) 0.66
Age (days), mean (95% CI) 157 (128–187) 146 (104–188) 0.66
Weight (kg), mean (95% CI) 6.8 (6.1–7.5) 6.6 (5.6–7.7) 0.78
Ex-prematurity (<37 weeks gestation), n (%) 19 (31) 6 (18) 0.23
Other comorbidity, n (%)† 3 (5) 2 (6) 0.58
NPA-positive, n (%)‡ 55 (95) 32 (97) 0.54
Heart rate (beats/min), mean (95% CI) 158 (153–163) 159 (152–166) 0.75
Respiratory rate (breaths/min), mean (95% CI) 54 (51–57) 53 (50–57) 0.78
SpO2 (%), mean (95% CI) 89 (88–90) 90 (89–92) 0.17
Hospital length of stay (h), median (IQR) 92 (59–141) 92 (48–124) 0.60
Salbutamol therapy, n (%) 16 (26) 8 (24) 0.83
Steroid therapy, n (%) 7 (12) 4 (12) 0.93
Antibiotic therapy, n (%) 12 (20) 8 (24) 0.60
†Includes trisomy 21, repaired and unrepaired cardiac anomaly, and tracheomalacia. ‡Viruses including respiratory syncytial virus, influenza, rhinovirus,
enterovirus, adenovirus and human metapneumovirus. Fisher’s exact test and independent-samples t-test have been used as appropriate. CI, confidence
interval; HFNC, high-flow nasal cannula; NPA, nasopharyngeal aspirate.
High-flow nasal cannula in bronchiolitisS Mayfield et al.
Journal of Paediatrics and Child Health (2014)
© 2014 The Authors
Journal of Paediatrics and Child Health © 2014 Paediatrics and Child Health Division (Royal Australasian College of Physicians)
3
Similarly, the change in RR after admission was significantly
different between the groups over time (P = 0.05, GLM) (Fig. 3).
The RR decreased significantly for both the HFNC responders
and the standard-treatment responders after admission. The RR
in the HFNC non-responder group remained high, but in the
standard-treatment non-responders it decreased after admis-
sion. In the responders in the HFNC group, RR dropped from
54 breaths/min (95% CI 51–57) to 51 breaths/min (95% CI
48–54), with that of the non-responders increasing from 54
breaths/min (95% CI 48–60) to 58 breaths/min (95% CI 48–69)
(P = 0.07) at 60 min. However, the differences in RR became
significant at 180 min (P < 0.05).
Of the 61 patients in the HFNC group, 8 (13%) were admitted
to the PICU (HFNC non-responders) compared with 53 (87%)
who remained on the paediatric ward (HFNC responders). In
the standard-treatment group, 10 patients (31%) required PICU
admission (standard-treatment non-responders), and 23 (69%)
remained on the paediatric ward (standard-treatment respond-
ers) (OR 4.086, 95% CI 1.0–8.2; P = 0.043). Between the
responders and non-responders in both groups (HFNC and
standard treatment) there were no physiological and demo-
graphic differences on admission (Table 2). Of those patients
admitted to the PICU, one patient in the HFNC group and three
in the standard-treatment group required a period of NIV. The
remaining patients referred to the PICU received HFNC treat-
ment only at 2 L/kg/min. No patients were intubated.
Hospital LOS was similar between the two groups (P = 0.56),
with the median time being 92 h for both the HFNC and
standard-treatment groups (95% CI 52–140). LOT was similar
for patients admitted to the PICU and those who remained on
the paediatric ward in the standard-treatment group as well as
the HFNC group (P = 0.07 and P = 0.32, respectively).
Discussion
The data from our study show that HFNC treatment can safely
be used in a regular paediatric ward with a 1:4 nursing ratio, as
no serious adverse event was observed. We determined that the
safety of HFNC treatment can be monitored using clinical indi-
cators such as HR and RR, providing a safe boundary for HFNC
use in the ward. Responders and non-responders to HFNC treat-
ment can be identified and described using HR and RR within
60 min of application. It is reasonable to anticipate that a future
larger RCT may make similar findings of reduced PICU admis-
sion rates (4 times less likely) by following our protocol.
This pilot study was tested in a ‘real-world’ environment where
standard care was not changed, only the oxygen delivery device.
This approach allowed separation of oxygen delivery-specific
aspects of the treatment and identification of responders and non-
responders, whichwas important to demonstrate as a safety aspect
ofHFNC treatment. Infants responding toHFNC treatment showed
decreased HR within the first hour of initiation. The RR also
dropped in the responders, but with a slight delay at 180 min. The
non-responders to HFNC showed no change in HR and RR within
the first 60 min of observation. Non-responders to HFNC may
warrant medical review for potential PICU admission. A similar
pattern was also observed in the standard-treatment group, in
which responders and non-responders to standard treatment
could be identified within 60 min. Interestingly, in the standard-
treatment group the RR in the non-responders droppedwithin the
first 60 min compared with the responders, but the differences
were not statistically significant. This drop in RR may have been
due to a mild degree of hypoxaemia or may be explainable by the
low number of patients in the study. This concept of certain
parameters differentiating responders from non-responders has
been identified inother studies.12One limitationof the studydesign
is that the repeated measurement of HR and RR were robust
descriptors but not necessarily predictors of response or non-
response for both the intervention and comparison groups. Real
predictors such as prematurity, heart disease and pre-existing
Fig. 2 Changes in heart rate (HR) in intervention and comparison groups
after inclusion in the study. For both the standard-treatment responders
and the high-flow nasal cannula (HFNC) responders, the HR decreased sig-
nificantly (***P < 0.001, ANOVA). HR remained high and did not change
significantly for the patients requiring paediatric intensive care unit admis-
sion (the HFNC and standard-treatment non-responders). Values are shown
as mean and 95%CI.
Fig. 3 Changes in respiratory rate (RR) in intervention and comparison
groups after inclusion in the study. For both the high-flow nasal cannula
(HFNC) responders and standard-treatment responders, the RR decreased,
but the decrease was significant only for the standard-treatment respond-
ers (*P < 0.05, ANOVA). RR remained high in HFNC non-responders and
decreased in the standard-treatment non-responders. Values are shown as
mean and 95%CI.
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chronic disease or condition on presentation need to be explored in
a larger randomised trial.
No patients subsequently admitted to the PICU needed intuba-
tion, and all continued either on HFNC or NIV. This low intubation
rate is consistent with our and others’ previously reported use of
HFNC in bronchiolitis.9,11 The early use of HFNC in a paediatric
ward reduced the number of PICU admissions without any serious
adverse events having been observed. We speculate that the early
application of HFNC treatment is the key element, preventing
further progressionof airwayobstructionand reversing someof the
atelectasis. A recent uncontrolled study comparing HFNC with
nasal CPAP showed that HFNC may be associated with a similar
efficacy and even a trend towards a reduction in need for seda-
tion.13This experience is alignedwith the trend towardsuseof early
NIV ingeneral.2However,HFNC treatmentdidnot shortenhospital
LOS overall, and its associated physiological effect does not modu-
late the course of the underlying viral illness.
While hospital LOS was not shortened during the study, there
are fiscal implications for reducing PICU admissions. The
current cost for a 92-h combined PICU and ward admission in
our hospital is estimated at A$15 517 per patient. The costs for
the same patient on the paediatric ward are estimated at
A$4992 per patient. It is predicted that the annual cost saving
for our 19-bed PICU with 1400 admissions annually would be
approximately A$1.2 million.
For a future RCT, the definition of high flow needs to be dis-
cussed. The original idea of delivering higher flow rates at >2 L/min
originated from a need for better humidification of the delivered
oxygen. In the past, this was achieved using higher flow rates.
These higher flow rates created inadvertent CPAP. Previously pub-
lished papers have explained some of the physiological effect of
high flow with inadvertent CPAP.3,5,14,15 A study by Milesi et al.3
showed that flow rates of approximately 1.5–2 L/kg/min created a
positive pharyngeal pressure during the entire respiratory cycle.
Interestingly, a recent study byMundel et al.16 in healthy adults has
shown that during the inspiratory phase little or no positive pres-
sure is delivered, and only during the expiratory phase is positive
pressure observed. Further detailed physiological studies measur-
ing changes on high flow, particularly of the intrathoracic pres-
sures, are needed.
Generally, flow rates > 2 L/min subnasally in infants are
regarded as ‘high flows’ with a maximal limit of 8–10 L/min.
This maximum of 10 L/min using our HFNC device was not
based on any clinical or physiological rationale but solely on the
decision of the device manufacturer. For this study, flow was
titrated at 2 L/kg/min with a maximal flow of 10 L/min. In
infants with a high RR, relatively high-flow rates are needed to
match the maximal inspiratory flow of the patient. The choice of
2 L/kg/min is based on the fact that in the past with the older
generation of continuous-bias-flow ventilators, the bias flow
was set at 2 L/kg/min to match the high inspiratory flows.17
Another finding was that we were able to wean the HFNC to
room air (21% O2) before the HFNC was switched off, and no
weaning of the flow rate was allowed. The oxygen in the control
group was weaned from 2 L/min to off according to SpO2. This
approach followed a shift in paradigm that considers that an
early oxygen requirement can be treated with CPAP by recruit-
ing previously collapsed lung regions. The weaning approach
did not prolong the time of respiratory support or hospital LOS.
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Limitations
This study may be criticised because of its non-randomised
design. Our ethics review board denied us permission to
perform a RCT and requested a pilot study investigating the
safety of HFNC treatment first. After completion of the study, we
were allowed to retrospectively analyse a case control group
(standard oxygen therapy) of all infants with bronchiolitis who
were admitted within the same time frame and fulfilled the
inclusion criteria but were not enrolled in the study (due to
the study investigator not being contacted). This group matched
the study group in their demographic and physiological data on
admission and were treated in the same paediatric ward using
the same 1:4 nursing ratio and hospital bronchiolitis manage-
ment protocol. The small number of patients in the study does
not allow for a strong conclusion, and only a RCT will address
the question of the effects of HFNC treatment in the ward
environment.
Conclusion
This pilot study produced interesting results on the safety of
HFNC treatment in a ward environment. It gives guidelines as to
how a larger RCT may be conducted. Physiological parameters
such as HR and RR correlate well with the response to treatment
and hence potential PICU admission. With viral bronchiolitis
being the most common reason for non-elective admissions to
PICUs in Australia, using HFNC treatment in paediatric wards
may result in substantial cost savings without impact on safety
of patient care. It would be worthwhile to undertake a RCT and
investigate the fiscal implications of reducing PICU admissions
by utilising this treatment in the ward environment.
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Chapter 7: Discussion 
7.1 Introduction 
The preceding chapters have presented the current literature and evidence for the 
management of bronchiolitis, including with HFNC, and the methodology and results of the 
pilot study. This chapter will discuss the findings from the case series, systematic review 
and pilot study, and expand on the strengths and limitations of the thesis. 
7.2 Case series 
The purpose of the case series was to describe three typical cases of patients admitted to 
the PICU, and the use of HFNC therapy. The pathophysiologies chosen were 
representative of causing moderate to severe respiratory distress, either in the upper 
airways (asthma), lower airways (bronchiolitis) or due to cardiac disease 
(cardiomyopathy). Before this, the use of HFNC as a treatment in paediatric patients for 
respiratory compromise from varied pathophysiologies had not been reported. In each 
presented case, HFNC therapy was used successfully and there were no adverse events, 
such as air leak syndrome, nasal trauma or abdominal overdistention. However, these 
results cannot be externally generalised due to inherent limitations with case series 
methodology. 
7.2.1 Limitations of case series 
Case studies can be a valuable research and educational resource and when reported 
around a particular aspect of care – they can provide new insights and stimulate research 
in response to knowledge gaps. In areas of rapid clinical change, case series can present 
and discuss new therapies in a timely manner. However, they have limited external 
validity, and are low on the hierarchy of level of evidence.163,186  
7.2.1.1 Potential bias 
The cases were selected because they were typical presentations of PICU patients with 
the intention to find and describe the common progress of patients being managed with 
HFNC therapy in PICU. However it is conceivable that each case was unwittingly chosen 
because there was a positive clinical course using HFNC therapy.  
Data entry was another source of potential bias. The data was extracted from the PICU 
clinical information system, however it was manually entered into Microsoft® Excel 2010 
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worksheets. Human factors may influence the accuracy of the data entry. However, in an 
attempt to mitigate this and provide data integrity, validation strategies were implemented 
within the worksheets, and data was manually and visually inspected by an independent 
person. 
7.2.2 Summary of case series 
The case series suggests that HFNC therapy may be an effective treatment for patients 
with respiratory distress due to underlying pathophysiologies of asthma, bronchiolitis and 
cardiomyopathy. Using HFNC therapy may prevent invasive ventilation in these three 
clinical scenarios, improve recovery times, and shorten length of PICU stay. However, 
there is limited generalisability to populations as a whole due to the inherent weakness of 
case series.  
While these patients were admitted to the PICU, it is possible that the infant with 
bronchiolitis could have been managed on a ward, if there was a hospital protocol and 
policy in place to support this. In order to address the possibility of administering HFNC 
therapy on a paediatric ward, a systematic review of the evidence and pilot study were 
undertaken. 
7.3 Systematic review 
The purpose of the systematic review was to identify and synthesise paediatric studies on 
the use of HFNC. By pooling data from homogenous studies into a meta-analysis, 
statistical significance may be found supporting either a positive or negative impact of 
HFNC. This can further inform clinical practice. 
As The Cochrane Collaboration is the gold standard for conducting systematic reviews, the 
reviews were undertaken with this organisation. Due to the age of infants (from birth up to 
44 weeks post-term), two reviews were required with two different Cochrane groups.  
7.3.1 Limitations of systematic review 
The Cochrane Neonatal Review Group (CNRG) administers all reviews on pre-term 
infants, including those post term up to 44 weeks while the CARG excludes this cohort 
from their reviews. Infants aged term to 44 weeks post gestational age (or 28 days old) are 
one of the most frequently admitted sub-groups to Australian PICUs, comprising 9% of 
total admissions (and a quarter of those <12 months old).166 This pattern is likely mirrored 
internationally. Therefore, to fully address the use of HFNC within paediatric populations, it 
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was essential that the full age spectrum of children was explored; hence, two protocols 
were conducted with different groups.  
While this allowed the exploration of discrete data around neonates versus children, it 
constrained the ability to present all data from one source, that is, the CARG review. It is 
perhaps important to have less rigidity around the grouping in this age group – most 
reviews with the CNRG centre on pre-term infants (those <37 weeks gestation and cared 
for in a NICU). For those infants >37 weeks gestation and up to 44 weeks, who are 
included in paediatric studies because they are admitted to a paediatric facility, there 
should be the provision to include them in the one systematic review. Of note, the Acute 
Respiratory Review Group do not place any limitations on the overlap of age with the 
CNRG, as evidenced by the review into HFNC and bronchiolitis with a stated age of less 
than 24 months.144  
7.3.2 Summary of systematic review 
While the systematic review completed with CARG was an important exercise, the lack of 
identified studies that met the inclusion criteria meant there was nothing to report. 
However, some identified upcoming clinical trials may meet the inclusion criteria and be 
able to be included into the two-yearly reviews. 
7.4 Pilot study 
The purpose of the pilot study was to investigate the use of HFNC therapy to manage 
infants with bronchiolitis in the paediatric ward. Bronchiolitis was isolated as a 
pathophysiology, over asthma and cardiomyopathy detailed in the case series, due to the 
prevalence of this condition and the potential impact on practice change. Choosing infants 
with bronchiolitis allowed maximum homogeneity within the sample. 
7.4.1 Key results 
The aim of the pilot study was to assess the safe and efficient use of HFNC therapy 
outside of the PICU.  The primary outcome to support the aim was admission to PICU.  
The pilot study showed that HFNC therapy for infants with bronchiolitis, commenced early 
in the PED, reduced admission to the PICU. Moreover, the study demonstrated that 
effective response to the therapy could be determined at 60 minutes post-application by 
assessing physiological variables such as heart rate and respiratory rate, and considering 
a composite score of all variable (as determined within early warning tools).  Previous 
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studies have identified a reduction in heart rate as a measure of clinical improvement in 
paediatric populations following HFNC therapy.15,147This concurs with other studies 
describing a similar response-to-treatment time observations.15,145–147,149 The significance 
of this is that infants who may 'fail' treatment can be identified early in their course, with an 
appropriate response of PICU review and/or admission, thereby adding a level of safety 
and quality to the management of these infants outside of high acuity areas. 
No major adverse events (cardiac arrest, air leak syndrome, bradycardia) occurred in the 
pilot study, and few to none are reported in recent paediatric publications.15,143,146–149,151,152 
However, it remains an important and valid concern. While air leak syndrome has been 
reported in a case series by Hedge and Prodhan,154 no substantive link conclusively 
determined if HFNC therapy was the cause of the air leak events. Indeed chance, 
selection and reporting biases inherent in case series methodology could account for 
these adverse events. Yet it remains a reasonable concern, and being aware may 
increase clinician vigilance surrounding these potential and specific adverse events in 
implementing HFNC therapy for any patient.  
Further, of the pilot study infants receiving HFNC therapy who were admitted to the PICU 
(8%), none required intubation. This result again is reflected in the small number of 
paediatric studies that have investigated HFNC use in the ward environment.143,149  
 
7.4.1.1 Key post-hoc results 
Although not a primary or secondary outcome identified in the design of the pilot study, 
there has been burgeoning interest in how infants receive their nutritional support while on 
HFNC. A number of paediatric studies have reported that oral feeding has been tolerated 
in this group.143,145,146,149,150 Oral feeding is a clinically important variable and one that 
justified post-hoc analysis. In the pilot study, 35% of infants on HFNC were orally (either 
bottle or breast) fed, with a further 31% receiving a combination of oral and nasogastric 
feeding during the study period. None of those orally fed were admitted to PICU. In the 
ward in which this study was conducted, nurses are the front-line staff that monitor, 
assess, identify and implement changes to feeding protocol. Therefore, this result 
suggests that those infants responding to HFNC therapy, as identified at 60 minutes, are 
likely to be able to orally feed, and that nurses at the bedside are able to distinguish 
between those who can manage oral feeding and those who cannot. 
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7.4.2 Limitations to the pilot study 
Pilot studies have numerous purposes and are an important way to explore feasibility,182 
with lessons learned preventing major problems in the planning and running of a larger 
study. With this pilot study into the use of HFNC in the paediatric ward, some limitations 
require further elaboration and exploration. 
7.4.2.1 Institutional constraints with study design 
Within the realm of evidenced based health care, the hierarchy for assessing the degree to 
which information from research can be trusted are termed 'levels of evidence'.163 
Traditionally, levels of evidence are presented in a pyramid format (described in Chapter 
4), with meta-analysis and systematic reviews at the pinnacle, closely followed by well-
constructed RCTs. When designing the HFNC study, the initial plan was conduct it as an 
RCT, the gold standard for assessing a specific therapeutic intervention. However, in June 
2010, conversations with the Executive Director of the Mater Children's Hospital and the 
Hospital Board made it clear that a request to conduct an RCT in the ward environment 
would be refused. While it is not possible to reconstruct the processes and rationale which 
led to this decision, it is likely that the absence at that time of any precedent studies 
centred in a paediatric ward, and concerns over the safety of using this therapy outside of 
the ICU held considerable influence. Consequently, by way of compromise, a pilot study 
design was proposed and subsequently received institutional approval. One concession of 
the revised study design is the claim to external validity for the findings – the extent to 
which they can be generalised to other situations may be limited. 
The study initially envisaged that children aged 1 day to24 months with a diagnosis of 
bronchiolitis, and admitted to two specific paediatric wards (one public and one private) at 
the Mater Children's Hospital, would be considered for inclusion in the study. However, 
access to one of the wards was denied by the then Acting Director of Nursing (A/DON), on 
the basis that it would too difficult for the private ward to be involved in a study. This 
gatekeeping limited the study to one public ward which only admitted infants aged 1day to 
12 months and resulted in systemic restrictions to the inclusion criteria. Not only was the 
age restricted to 1 day to 12 months, but before consent, parents needed to be screened 
as to their private health fund status. Parents who chose to be admitted to the private ward 
were not approached for participation in the study. However, some parents chose not to 
use the option of having their child admitted as a private patient, consented to the study 
and were admitted to the public ward. No other changes occurred in the way the patients 
were managed except for using HFNC therapy. 
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7.4.2.2 Methodological issues – bias, blinding and protocol violations 
Potential bias was introduced into the study by the selection of participants. While criteria 
for inclusion and exclusion existed, and all staff had been extensively educated on the 
study protocol, it became apparent that many potential study participants were being 
missed. This was determined from the meticulous screening log that was kept during the 
recruitment period and that was retrospectively updated during the week from the PED 
database (EDIS™), which is managed 24/7 by the PED ward clerks. Every patient who is 
triaged is entered into the database with their demographic details and initial diagnosis, 
ensuring the database is a reliable source of data of patients seen in the PED.  
The use of PED medical staff to consent patients to the study proved to be an institutional 
constraint, as recruitment and consent of patients was perceived by the PED Director as 
additional work for PED doctors. Changes were therefore made, and the author carried out 
recruitment, with availability 24/7 for the duration of the study recruitment period. Initially 
nursing staff were hesitant to call late at night and in the early morning, but as the study 
progressed, staff became more engaged and called at all hours when a patient was 
identified.  This may have introduced some potential for systematic bias in recruitment in 
the early stages of the study.  However, analysis of the demographic, physiological, clinical 
and treatment characteristics of the intervention and comparison groups demonstrated that 
there was no difference between the groups.   
Calculation of the sample size was a limitation, and Chapter 5 acknowledged the difficulty 
of sample size calculation for pilot studies. Briefly, these include cost, realistic timeframes, 
and intention and outcomes desired for the planning of the larger RCT. The result was that 
the method for calculating a true sample size of effect was not ideal. However, as this was 
a pilot, and there was an assumption of a decrease in PICU admissions, the sample size 
was sufficient to enable power calculations for the RCT. 
Another potential limitation was that the nursing staff could not be blinded to the study 
group. It is reasonable to suggest that this could lead to observation bias of staff in their 
documentation, even with a protocol in place. This raised the possibility of nursing staff 
unconsciously influencing the outcome, especially in relation to the timing of referral or 
non-referral to the PICU. This could affect internal validity of the study results. A plan to 
mitigate this was implemented in the form of conscientiously following up the patients, to 
determine nursing staff understanding, adherence, and satisfaction with the protocol. Staff 
education during the study period was continued by the Nurse Educator contracted to the 
study. 
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Even with conscientious follow up of the study patients, a number of protocol violations 
occurred, involving paediatric consultant medical staff. These were spread evenly over the 
study period, with four recorded in the first 30 patients and 4 in the second 31 patients. 
The violations consisted of consultants increasing the FiO2 in response to increased work 
of breathing, despite the patient saturating at >98% via peripheral plethysmography. This 
resulted in patients not being weaned from oxygen as per the protocol, a violation that 
could potentially lead to an increased length of therapy time. To remedy this, a PICU 
intensivist reiterated the study protocol to the consultants. On the whole, the majority of 
consultants did have 'buy-in' to the study, and realised that there were safety procedures 
in place to identify the deteriorating patient, and that admission to PICU would not be 
compromised. 
Nurses were also responsible for protocol violations in not weaning the FiO2 when 
saturations (SaO2 via peripheral plethysmography) was >98%. In one case, the patient 
was left on a FiO2 of 0.3 with SaO2 recorded at 99% for 20 hours. While this did not cause 
any harm to the patient, it is reasonable to conclude this may have extended the patient's 
stay in hospital. This incident highlighted the inherent weakness in any clinical study 
relying on clinicians to consistently adhere to study protocols.  
7.4.2.3 Early warning tools 
While the use of an early warning tool was justified in Chapter 5, there remain limitations 
behind the particular use of the CEWT and its modification into the HiFOD collection form. 
Early warning tools are designed to assist clinical staff in recognising the deteriorating 
patient, reducing response delay and thereby preventing avoidable mortality and 
morbidity.187 Within paediatrics exist a number of either validated, peer reviewed, and/or 
published early warning tools, such as the Brighton Paediatric Early Warning Score,181 
Bedside Paediatric Early Warning System Score (PEWSS),188 the Bristol Paediatric Early 
Warning Tool (PEWT) 180  and a number of others that have been modified to suit specific 
cases.189 CEWT closely resembles the Bedside PEWSS and was initially tested on infants 
with bronchiolitis. However, it has not been prospectively validated, peer reviewed nor 
published.  
Using any of the tools named above would have been appropriate to capture physiological 
data during the study, and to provide an extra level of 'safety' as they have been 
prospectively validated and are considered reliable (Table 7.1). The sensitivity (that is, 
measures of the proportion of actual positives) and specificity (that is, actual negatives that 
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are correctly identified as such)184 of each tool are important in determining their ability to 
correctly identify those patients who are deteriorating. ROC curves of greater than 0.80 are 
considered to be significant and support assumptions of tool validity and the ability to 
predict actual deterioration. The Brighton PEWS and the Bedside PEWSS satisfy this in 
the prospectively validated studies.  
However, as the Mater Children's Hospital was to imminently roll out the CEWT (Appendix 
3), which had been approved and incorporated into Queensland Health hospitals, 
institutional constraints demanded the use of the CEWT tool over any other. For this study, 
one modification to CEWT was required to capture the flow rate and FiO2 of the 
equipment, hence the name change to HiFOD. It was not until the final 4 months of the 
pilot study that the CEWT was rolled out in the study ward for all patients.  
A consequence of using an unpublished and unvalidated tool (CEWT in the form of 
HiFOD) for the pilot study was that the composite scores were not reported in the 
published paper. The manuscript peer reviewers and the journal editors recommended 
that in the absence of published evidence of the CEWT validity and reliability, data 
composite scores be excluded from the manuscript. Yet, a recent review of paediatric early 
warning systems incorporated into hospitals in the United Kingdom found that the majority 
of systems implemented in hospital institutions were unpublished and unvalidated.190 
After 2010, the development and use of early warning tools has greatly expanded in 
Australia. New South Wales, Victoria and Australian Capital Territory all have paediatric 
early warning system tools in place,191 which have many similarities with CEWT, but minor 
differences in weighting of scores and what triggers a medical emergency team call. 
7.4.2.3.1 Sensitivity and specificity 
For the purpose of attempting to validate the HiFOD score for patients requiring HFNC, 
area under the curve ROC analysis was undertaken. The inclusive HiFOD score had a 
ROC curve of 0.80 from 61 participants. However, with the comparison group comprising 
only 33 patients, the numbers were too small to provide a clear indication of the true 
sensitivity and specificity of the HiFOD tool to accurately predict the deteriorating patient. 
At best, the ROC curve may describe a positive predictive value of the HiFOD score. This 
idea was elaborated on in a response article to the Bristol PEWT, which questioned this 
tool's true ability to claim sensitivity and specificity.192 Further analysis on the performance 
of the HiFOD and CEWT tools is essential, as is that true and valid sensitivity and 
specificity is determined at specific values, such as has been done with the Bedside 
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PEWSS. However, it is beyond the scope of this thesis to provide further analysis and 
validation of the CEWT/HiFOD tool, or of other "track and trigger" systems in use in 
Australia. 
Table 7.1 – Comparison of paediatric early warning tools validation 
 Brighton PEWS181,187 
Bedside 
PEWSS188,193 
Bristol 
Paediatric 
Early Warning 
Tool 
(PEWT)180 
HiFOD 
Components 3 items, score range 0–9  
7 items, 
referenced to 
age, score 
range 0–26  
5 items (A to 
E) with sub 
items (2–4)  
9 items 
referenced to 
age, score 
range 0–12 
Initial study – 
participants 
unknown number 
over 3 months 
87 cases, 128 
control, single 
centre 
360 patients 
over 6 months 
61 patients 
over 10 
months 
Initial study –
sensitivity and 
specificity (%) 
respectively 
Not reported  0.78 and 0.95 at score 5 
0.66 and 0.99 
to trigger the 
tool 
0.80 and 0.40 
at score 5 
Initial study – 
ROC Not reported 
0.90 in initial 
study, 0.87 in 
prospective 
study 
Not reported 0.80 
Prospectively 
validated study 
2979 patients, 
newborn to 
22 years, over 12 
months, single 
centre 
2074 patients, 
international, 
multicentre 
case control (4 
hospitals) 
Not 
prospectively 
validated 
N/A 
Sensitivity and 
specificity (%) 
respectively 
0.33 and 0.99 at 
score 7; 0.13 and 
0.99 at score 8 
0.64 and 0.91 
at score 7; 0.57 
and 0.94 at 
score 8 
Unknown N/A 
ROC 0.89 0.87 Unknown N/A 
ROC = Receiver operator characteristic 
 
7.4.3 Outcomes of pilot study 
A secondary aim of the pilot study was to inform the sample size for a larger, multi-centre 
RCT.  Currently (as of mid-2014), a larger study with a target of 800 participants has 
commenced in regional centres in South East Queensland.  Another outcome of the pilot 
study has been the implementation of HFNC therapy into the routine management of 
infants with bronchiolitis on the study ward. When the results of this pilot study were 
presented to the Executive Board of the Mater Children's Hospital, this treatment protocol 
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and therapy received their endorsement. The pilot study has informed the development of 
clinical guidelines (Appendix 7) that now govern clinical practice in using HFNC in the 
study ward.  
7.4.4 Summary of pilot study 
The pilot study has demonstrated that HFNC can be used within a paediatric ward setting. 
Patients who may not respond to HFNC therapy can be identified within 60 minutes. The 
likelihood of adverse events associated with HFNC therapy is low. While HFNC therapy 
may not alter hospital length of stay, it may reduce admission to PICU. Infants can be 
orally fed while on HFNC therapy, but this requires expert clinical judgement. This remains 
a small sample of patients and the ability to generalise to a wider population is still 
restricted.  To conduct a larger, multi-centre RCT, approximately 800 participants would be 
required to achieve the null hypothesis. 
7.5 Conclusion 
While the institutional constraints originating from the Mater Children's Hospital have been 
addressed and overcome, for other institutions it opposition to HFNC therapy may still 
remain. Objections revolve around the themes such as:  
• Safety –  
o Does HFNC therapy mask symptoms of the deteriorating child? 
o Are these infants and children at risk of delayed specialist care due to being 
managed in a ward? 
• Quality –  
o What is the true financial benefit of reduced PICU admissions?  
o Is there a measurable psychosocial impact on parents, families and 
communities? 
• Perception –  
o What are the underpinning feelings and thoughts of clinicians when 
considering the implementation of a new therapy?  
For these to be overcome and addressed at an institutional level, rigorous discussion is 
needed involving all key stakeholders, in an environment that is open and safe. This 
discussion needs to not only consider expert opinion, but understand the value research 
adds to the decision-making process. Ultimately what is needed in paediatrics is a large-
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scale RCT that can answer many of the safety issues that have been speculated in 
retrospective and observational studies with HFNC therapy. 
This chapter has discussed the key results of this thesis, exploring the limitations of the 
case series, systematic review and the pilot study. The final chapter will detail 
recommendations for further consideration and conclude the overall evidence for HFNC 
therapy. 
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Chapter 8: Recommendations and conclusion 
8.1 Introduction 
The previous chapter discussed the results and limitations of the case series, systematic 
review and pilot study undertaken for this thesis. This chapter will present 
recommendations for further study, and conclude the results in the context of current 
evidence and theory. 
8.2 Summary 
This thesis aimed to acquire and disseminate knowledge through research that would 
guide clinicians using HFNC therapy for managing infants with respiratory distress. 
Evidence for the use of HFNC has been developed at the level of case series and pilot 
study, with ongoing two-yearly evaluation of two systematic reviews. These reflect the use 
of HFNC within both high acuity areas, such as PICUs and low acuity areas, such as 
paediatric wards. Both the case series and pilot study have added to the growth of 
literature in the paediatric forum for HFNC use.  
Dissemination of knowledge to guide clinicians has been achieved through publications, 
which describe the use of HFNC in a case series, present systematic review using The 
Cochrane Collaboration framework, and the completed pilot study. These publications, 
generated from this thesis, appear in relevant, peer-reviewed journals, ensuring the wide 
distribution of the findings. The impact factors of the journals are: 1.193 – Journal of 
Paediatric and Child Health; 1.265 – Australian Critical Care; and 5.939 – Cochrane 
Collaboration of Systematic Reviews. The pilot study has been presented at local, national 
and international conferences, further ensuring dissemination across a wide range of 
paediatric clinicians and researchers.  
8.3 Recommendations  
This thesis has shown that HFNC therapy in the ward may reduce admissions to PICU. 
Those not responding to therapy, 'non-responders', may be identified within 60 minutes. 
There need not be any changes to existing nurse to patient ratios, and nutritional delivery 
options are described. Yet other potential outcomes and benefits exist that are beyond the 
scope of the thesis. Further work could be done in the areas of staff experience, 
patient/parent satisfaction, financial benefit, mode of feeding, and clinical use. 
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8.3.1 Staff experience 
Clinician acceptance of a clinical therapy or practice is key to the successful uptake of 
change.194 While the pilot study did not formally examine the experience of staff in using 
HFNC in the ward setting, there was anecdotal support for the therapy from the ward 
Nurse Unit Manager, Nurse Educator and clinical staff using HFNC. Other studies have 
briefly mentioned preferences for HFNC, such as mentioned by Hilliard et al143. A factor to 
Hilliard's study concluding early was the bias staff had towards using HFNC therapy 
instead of traditional head box for infants with bronchiolitis. The HFNC equipment was 
easy to use and allowed for easier nursing care.143 This theme was also present as a 
component of a thesis by Peeler.195 However studies examining in detail staff experience 
in using HFNC are absent, and this may be worthy of further investigation. 
8.3.2 Patient/parent experience 
Understanding the perceptions of patients and parents when introducing a change in 
therapy or practice can be powerful in developing cohesion between health professionals 
and patients/carers. While the pilot study did not include a formal interview or 
questionnaire, the opinion of parents was sought during the daily ward rounding. 
Anecdotally, parents often stated that they could see the positive effect that HFNC was 
having on the breathing of their infant. They found HFNC allowed them to hold their infant 
and on occasion breast feed, which allowed the mother a sense of connectedness. This 
has been explored in detail in the thesis by Peeler,195 however within paediatric literature 
there are no publications surrounding the patient or parent experience with HFNC use. 
While comfort levels are reported within adult studies128,130,132 and the COMFORT score 
has been reported as a surrogate measure for tolerance of HFNC itself,80 no published 
studies illuminate this important aspect of HFNC therapy. Examining this would be of 
benefit, but beyond the scope of this thesis. 
8.3.3 Cost–benefit  
An impediment to the successful uptake of clinical practice change can be  perceptions of 
practical benefits gained versus financial cost.196 While Martinez150 stated that there was a 
significant cost saving in managing infants within the ward using HFNC therapy as 
opposed to the PICU, there was no robust detail that quantified the financial gain, which 
limited the ability to independently assess the claim. It would be appropriate to assess and 
quantify the health economics of implementing HFNC use in paediatric wards. While cost 
saving should never replace safety concerns, nor be a factor in managing children in lower 
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acuity areas, it remains a relevant and important area for further investigations. These 
questions are, however, beyond the scope of this thesis. 
8.3.4 Mode of feeding 
The optimal method of feeding while receiving HFNC therapy is an unknown quantity. 
Within the pilot study, the mode of feeding was discerned from post-hoc analysis, and was 
not an intended outcome. While there is growing consideration of this aspect of treatment 
in recent neonatal and paediatric literature,145,146,150,158 to date no published controlled trial 
or observational study has focused on describing or managing infant and child nutrition 
while on HFNC therapy. To address this gap in knowledge, a study is being undertaken on 
the pilot study ward at Mater Children's Hospital, following the implementation of clinical 
practice guidelines. 
8.3.5 Clinical use 
Practice use of HFNC therapy in neonatal nurseries has been explored in both Australia, 
New Zealand, and the United Kingdom.158,197 The surveys have found that use of HFNC is 
widespread and clinical practice is diverse. Anecdotal evidence obtained from 
conversations with many clinicians at international and national conferences has revealed 
increasing uptake of HFNC use in paediatric wards. This practice creep is unknown in 
terms of when, how, and who guides and implements this treatment option. A detailed 
survey of paediatric hospitals (and wards within adult hospitals) within Australia and New 
Zealand on their use of HFNC may be worthy of further investigation.  
8.4 Conclusion  
Overall this thesis has demonstrated that HFNC therapy is a useful adjunct in managing 
infants and children with respiratory distress. The case series underpinned the use of 
HFNC therapy across a wide spectrum of pathophysiologies, and the positive course that 
may follow. It further adds to the body of evidence for HFNC therapy use in the PICU, and 
expands its use from just infants with bronchiolitis. The pilot study further showed that 
implementing HFNC therapy in the paediatric ward environment may reduce admissions to 
the PICU. The pilot study also established that physiological parameters can alert a 
clinician to the early response of a patient to the therapy. If there is no meaningful 
decrease in heart rate, respiratory rate or composite score within 60 minutes of therapy 
initiation, there is a high probability that the patient will require specialist care and 
observation in an ICU.  
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There is no doubt that practice creep in using HFNC therapy is growing throughout the 
world, and in all hospital settings. Yet no large RCT has produced evidence that 
completely underpins and validates HFNC therapy. This is true for paediatrics, neonates 
and adults. However, the pilot study from this thesis has been instrumental in advising a 
large, multicentre RCT currently under way in South East Queensland, Australia. 
Ultimately, this thesis has achieved its aim and contributed significantly to understanding 
the use of HFNC therapy for children and infants with respiratory distress. The Cochrane 
Collaboration review, case series, and pilot study have all contributed to the total body of 
knowledge surrounding HFNC therapy in the paediatric population. This will improve 
outcomes by assisting clinicians in their decision-making process for implementing and 
assessing appropriate treatment options, and aid in guiding researches in further 
exploration of this subject.  
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A B S T R A C T
This is the protocol for a review and there is no abstract. The objectives are as follows:
We aim to determine if the use of HFNC is better than other forms of non-invasive therapy in paediatric patients who require respiratory
support.
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B A C K G R O U N D
Description of the condition
Respiratory support is central to the care of critically ill children.
Support may be needed due to underlying disease processes such
as respiratory infections or pneumonia, neuromuscular disorders,
cardiac conditions or failure, and other mechanisms such as up-
per airway obstruction, trauma and injury, or post-surgical inter-
ventions. Respiratory support can be delivered non-invasively in
the form of oxygen therapy or continuous positive airway pressure
(CPAP) or invasively via mechanical ventilation. Children with
significant respiratory distress and hypoxaemia often require the
latter. This may result in various forms of trauma to the lungs
and airways, collectively known as ventilator induced lung injury
(VILI) (Dahlem 2003; The ARDS Network 2000).
While VILI is the major concern with intubation and mechanical
ventilation, there are other effects on the body that need to be con-
sidered. The increased use of sedative drugs may lead to neuropa-
thy or myopathy, which can increase recovery time. In turn there
may be the need for cardiovascular support in the form of drug
infusions to maintain blood pressure. All of these factors increase
the costs of the care provided to the child. Non-invasive methods
of ventilation are an ideal method of providing respiratory sup-
port without the need for intubation and may avoid some of the
additional harm associated with positive pressure ventilation.
Non-invasive ventilation can be as simple as oxygen therapy deliv-
ered via a face mask, nasal cannula or head box through to devices
deliveringCPAP via the face andmask interface or nasopharyngeal
tubes, with pressure generated by a dedicated driver or water col-
umn (that is bubble CPAP) (Frey 2001; Frey 2003; Klein 1986).
Those devices delivering CPAP can reduce the work of breathing
and improve functional residual capacity, potentially avoiding in-
tubation, reducing VILI, and preventing other possible causes of
harm (Reid 1984; Thorsteinsson 2002).
A disadvantage of this method of delivery is that it is cumber-
some and the masks and tubes used are poorly tolerated by young
children and infants (Yong 2005). This can make the delivery of
CPAP variable thereby resulting in ineffective ventilation. Having
a system that can deliver CPAP and be comfortable and well toler-
ated by children is an important consideration in providing non-
invasive respiratory support.
Description of the intervention
High flow nasal cannula (HFNC) therapy has recently been in-
troduced to a range of patients from preterm infants to adults,
addressing the need for a simple, effective method of providing
respiratory support (Campbell 2006;McGinley 2009;McKiernan
2009; Shoemaker 2007). It has an advantage over simple oxygen
therapy in that the gas mixture can be heated and humidified,
thereby reducing damage to upper airwaymucosa, and the concen-
tration of inspired oxygen can also be titrated as required. This can
prevent inflammatory reactions and the naso-pulmonary bron-
choconstrictor reflex triggered by cold, dry air (Spentzas 2009).
It has been shown that the delivery of nasal air at high flow rates
may cause incidental delivery of CPAP (Dysart 2009; Spence
2007; Wilkinson 2008). The effects of this are yet to be fully un-
derstood. It may be that the high flow flushes the dead space of the
nasopharyngeal cavity resulting in alveolar ventilation as a greater
fraction of minute ventilation. It may also assist in the washout
of carbon dioxide, which may then reduce apnoeas secondary to
hypercapnia and improve ventilation (Dysart 2009). High flow
rates may also provide an amount of positive pressure and thereby
overcome upper airway obstruction, again improving ventilation
(McGinley 2009).
The amount of CPAP generated depends on the flow delivered
relative to the size of the patient, the size of the nasal cannula
used, and the potential leak around the nasal cannula (Kubicka
2008; Lampland 2009; Sreenan 2001). Three retrospective studies
assessing HFNC therapy have demonstrated that overall ventilator
days were significantly decreased after the introduction of this
therapy when compared to retrospective historical control groups
(McKiernan 2009; Schibler 2011; Shoemaker 2007).
HFNC therapy has also been reported to be better tolerated by
the patient than other forms of non-invasive ventilation (Roca
2010). This can reduce the need for sedation that is required to
help tolerate more invasive or uncomfortable forms of respiratory
support.
Why it is important to do this review
HFNC therapy is an emerging treatment option for the respiratory
support of children, especially in the intensive care unit. To date,
most of the findings have been from neonatal and adult studies,
with little clinical experience reported in the paediatric population
(McKiernan 2009). The Cochrane review on high flow nasal can-
nula from the Cochrane Neonatal Group concluded that there is
insufficient evidence to determine HFNC effectiveness and that
more research is needed (Wilkinson 2011). At present there is a
protocol for the systematic review assessing HFNC effectiveness
in the adult population, which is in progress with the Cochrane
Anaesthesia Group (Corley in process). There is also a protocol
with the Cochrane Acute Respiratory Infections Group assessing
HFNC therapy for infants with bronchiolitis (Beggs 2012). This
review differs in that it covers a wider age range and more diverse
pathophysiologies.
It is necessary to assess the use of this therapy amongst the paedi-
atric population as there are potential risks associated with its use.
Neonatal studies have described scalp emphysema and pneumo-
cephalus as potential risks, along with nasal mucosal trauma and
bleeding (Jasin 2008; Kopelman 2003). There is also concern that
this therapy in the neonatal population provides unpredictable,
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high pressures that could damage the preterm lung (Lampland
2009). These risks need to be assessed in the paediatric popula-
tion.
HFNC has the potential to improve outcomes in critically ill chil-
dren. It is readily applied and is not resource or cost intensive.
Staff can easily be trained in the application of HFNC and in the
care of children using this therapy. It may reduce the incidence of
intubation in paediatrics and may reduce the length of intubation
as HFNC holds potential as an adjunct between extubation and
low flow nasal prong oxygen delivery. The potential also exists that
children requiring this therapy may be cared for outside of the
paediatric intensive care unit (PICU).
O B J E C T I V E S
We aim to determine if the use of HFNC is better than other
forms of non-invasive therapy in paediatric patients who require
respiratory support.
M E T H O D S
Criteria for considering studies for this review
Types of studies
We will include prospective, randomized controlled trials (RCTs)
and quasi-randomized studies.
Types of participants
We will include paediatric participants aged from four weeks cor-
rected age to 16 years requiring respiratory support.
Types of interventions
For the purposes of this review, we will define high flow nasal
oxygen as the delivery of heated, humidified oxygen or blended
oxygen with air via a nasal cannula at flow rates of greater than
2 L/minute. HFNC will be compared with other means of non-
invasive respiratory support, such as cot, hood or tent oxygen; low
flow nasal cannula (flow rates equal to or less than 2 L/min); and
continuous positive airway pressure (CPAP).
Types of outcome measures
Primary outcomes
1. Hospital mortality
2. Intubation rate
3. Treatment failure (defined by the use of additional respiratory
support)
Secondary outcomes
1. Duration of any form of respiratory support in hours (mechan-
ical ventilation, non-invasive ventilation, high flow nasal cannula)
2. Length of stay in days in hospital
3. Clinical severity score
4. Length of PICU stay in days
5. Complications:
• air leaks (pneumothorax, pneumomediastinum,
pneumopericardium or pulmonary interstitial emphysema
(PIE)) reported either individually or as a composite outcome
• nasal trauma (defined as erythema or erosion of the nasal
mucosa, nares or septum assessed by a blinded observer)
• nosocomial sepsis (defined as positive blood or
cerebrospinal fluid (CSF) cultures)
• barotrauma
• gastrointestinal distention
Additional outcomes measured in trials will be added as secondary
outcomes following the literature search.
Search methods for identification of studies
Electronic searches
We will obtain all relevant studies irrespective of language or pub-
lication status (published, unpublished, in press, and in progress)
using the following methods. We will apply no limits in terms of
language or year of publication.
We will search the current issue of the Cochrane Central Register
of Controlled Trials (CENTRAL) (The Cochrane Library); MED-
LINE via Ovid SP (January 1966 to date); EMBASE via Ovid
SP (January 1980 to date); CINAHL via EBSCO Host (1982 to
date); LILACS via the BIREME interface (1982 to date).
We will search electronic databases of higher degree theses for rele-
vant unpublished trials: Index to Theses (1950 to date), Australian
Digital Theses Program (1997 to date) and Proquest Digital Dis-
sertations (1980 to date).
We will combine our MEDLINE search strategy with the
Cochrane highly sensitive search strategy for identifying random-
ized controlled trials (RCTs) as suggested in the Cochrane hand-
book for Systematic Reviews of Interventions (Higgins 2011). We
will adopt the MEDLINE search strategy (see Appendix 1) for
searching in all other databases.
For ongoing trials, we will search the Meta Register of Controlled
Trials (http://www.controlledtrials.com/) and the National Re-
search Register (http://clinicaltrials.gov/).
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Searching other resources
We will handsearch citations from included studies.
We will not exclude studies on the basis of language.
We will contact authors known in the field to determine if unpub-
lished work is available.
Data collection and analysis
Selection of studies
Six authors ( SM, JJC, FB, JH, AS, KG) will undertake the review.
We will use the search strategy described to obtain titles and ab-
stracts of studies that may be relevant to the review. Two authors
(SM and JJC) will independently perform this screening. We will
discard studies that are not applicable, and the reason for each
trial that is excluded will be documented. We will resolve disagree-
ments by consulting with a third author (FB), who will decide on
inclusion or not.
We will compile a list of eligible trials, with a unique identifier,
on a form for eligible trials contained within the data extraction
form (see Appendix 2).
Data extraction and management
We will adapt the standardized Cochrane Anasthesia Review
Group (CARG) data extraction form (Appendix 2) to capture rel-
evant data specific to this review. We (SM and JJC) will use this
form independently to extract and collect data from the relevant
studies. We (SM and JJC) will resolve any discrepancies in the data
extracted by discussion.
Assessment of risk of bias in included studies
Two authors (SM and JJC) will independently assess the method-
ological quality of the eligible trials. Any disagreements will be
resolved by a third author (FB). We will include a risk of bias table
as recommended in the Cochrane Handbook for Systematic Reviews
of Interventions (Higgins 2011). The judgements ’low risk’, ’high
risk’ and ’unclear risk’ will be used in the table to determine bias.
SMwill enter the data into the Reviewmanager Software (RevMan
5.1) with verification of data entry conducted independently. The
following domains will be assessed.
1.Random sequence generation.
2. Allocation concealment.
3. Blinding of participants and personnel, and outcome assessors.
4. Intention-to-treat analysis.
We will use pre-defined criteria for treatment failure (switching to
an alternative respiratory support modality) and intubation.
Measures of treatment effect
We will summarize trials that meet the inclusion criteria in tables
to allow for comparison of characteristics and quality. Excluded
studieswill be tabulatedwith the reason for exclusiondocumented.
For dichotomous outcome data, such as mortality, we will use risk
ratio (RR) to determine effect. It will be displayed on a table as
’number with event’ and ’number without event’. For continuous
data we will collect the mean and standard deviation and display
it on a table. If different scales are used to measure continuous
data across trials wewill calculate the standardizedmean difference
(SMD) to determine treatment effect.
We will analyse outcomes from comparable trials with 95% con-
fidence intervals (CI) to estimate each trial’s treatment effect. We
will compare the results graphically using forest plots, with risk
ratio (RR) as the point estimate for dichotomous outcomes and
mean difference (MD) as the point estimate for continuous out-
comes.
Dealing with missing data
We will contact the corresponding author of the study to source
missing data. If the corresponding author does not respond, or if
it is not possible to find them, then we will include the trial in
question in the review butwewill analyse the effects of its inclusion
or exclusion on the overall results as part of the sensitivity analysis.
Assessment of heterogeneity
We will analyse heterogeneity using the Chi2 test on N-1 degrees
of freedom, with an alpha of 0.1 used for statistical significance,
and with the I2 statistic (Higgins 2011). I2 values of 25%, 50%
and 75% correspond to low, medium and high levels of hetero-
geneity, respectively. We will set an I2 threshold of greater than
50% to indicate a substantial variation across trials due to hetero-
geneity. We will use a fixed-effect model if we find insignificant
heterogeneity between trials. We will use a random-effects model
if significant heterogeneity exists between trials (Higgins 2011).
Wewill test for homogeneity between trials for each outcomeusing
the Cochran’s Q statistic, with P less than or equal to 0.10.
We will assess the clinical diversity (clinical heterogeneity) and
methodological diversity (risk of bias assessment) of the included
studies. We will undertake subgroup analysis to examine possible
clinical variability when the I2 statistic is less than 50% but het-
erogeneity remains statistically significant.
We will analyse outcome data from trial populations rather than
individuals in order to explain possible sources of variability (
Higgins 2011).
Assessment of reporting biases
We will assess publication bias or small study effects by preparing
a funnel plot. We will test for funnel plot asymmetry if there are
greater than 10 studies included in the meta-analysis.
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Data synthesis
We will review the summary tables of included trials to identify
clinical heterogeneity amongst trials. If there are two or more ran-
domized trials with comparable populations undergoing similar
interventions, we will do a meta-analysis with a random-effects
model using RevMan 5.1.
Subgroup analysis and investigation of heterogeneity
We will perform subgroup analysis to explore possible sources of
heterogeneity (for example participants, interventions). Hetero-
geneity among participants could be related to age, corrected ges-
tational age and underlying pathophysiological condition. Het-
erogeneity in treatment could be related to the amount of flow
delivered in relation to body weight.We will explore the impact of
differing flow rates with a subgroup analysis. We will tabulate and
assess adverse effects with descriptive techniques as they are likely
to be different for the various subgroups. Where possible, we will
calculate the RR with 95% CI for each adverse effect. We will use
a narrative summary of findings when there is clear evidence of
heterogeneity amongst trials (Sutton 2008).
Wewill examine differences in populations based on the following.
1. Age (corrected).
2. Pathophysiology, as follows:
• type 1 respiratory failure;
• type 2 respiratory failure;
• parenchymal lung disease;
• neuromuscular disorders;
• respiratory drive;
• airway obstruction;
• preterm birth.
Sensitivity analysis
We will perform a sensitivity analysis, exploring the causes of het-
erogeneity and the robustness of results if there is an adequate
number of studies. We will perform sensitivity analysis of trials
with low-risk of bias versus high-risk of bias. We will compare
random-effects model and fixed-effect model estimates for each
outcome variable.
Summary of findings
Wewill use the principles of the GRADE system (Guyatt 2008) to
assess the quality of the body of evidence associated with specific
outcomes: mortality, intubation, failure of treatment or escalation
to non-invasive ventilation, length of PICU stay, length of time
on any form of respiratory support, oxygenation and respiratory
assessment tools in our review and construct a summary of findings
(SoF) table using the GRADE software. The GRADE approach
appraises the quality of a body of evidence based on the extent to
which one can be confident that an estimate of effect or association
reflects the item being assessed. The quality of a body of evidence
considers, within a study, the risk of bias (methodologic quality),
the directness of the evidence, heterogeneity of the data, precision
of effect estimates and risk of publication bias (Guyatt 2008).
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A P P E N D I C E S
Appendix 1. Search strategy for MEDLINE (Ovid SP)
1. (exp Oxygen Inhalation Therapy/ and intubation rates*.af.) or (high flow adj3 (nasal or prong or cannula)).mp. or (nasal adj3
oxygen).mp.
2. ((randomized controlled trial or controlled clinical trial).pt. or randomized.ab. or placebo.ab. or drug therapy.fs. or randomly.ab. or
trial.ab. or groups.ab.) not (animals not (humans and animals)).sh.
3. 1 and 2
Appendix 2. Data extraction form
Review title or ID
Study ID (surname of first author and year first full report of study was published e.g. Smith 2001)
Report IDs of other reports of this study (e.g. duplicate publications, follow-up studies)
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Notes:
1. General Information
Date form completed (dd/mm/yyyy)
Name/ID of person extracting data
Report title
(title of paper/ abstract/ report that data are extracted from)
Report ID
(ID for this paper/ abstract/ report)
Reference details
Report author contact details
Publication type
(e.g. full report, abstract, letter)
Study funding sources
(including role of funders)
Possible conflicts of interest
(for study authors)
Notes:
2. Study Eligibility
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Study Charac-
teristics
Eligibility criteria
(Insert eligibility criteria for each
characteristic as defined in the Pro-
tocol)
Yes No Unclear Location in text
(pg & ¶/fig/table)
Type of study Randomized Controlled Trial
Controlled Clinical Trial
(quasi-randomized trial)
Participants Paediatric patients aged from 4
weeks corrected age to 16 years
Types of inter-
vention High flow nasal Oxygen(heated/
humidified, flow >2lt/kg/min)
Comparator: non invasive respi-
ratory support such as cot/tent/
hood, low flow oxygen or CPAP
Types of out-
come measures
Hospital mortality; intubation
rate; treatment failure.
Secondary: duration of any form
of respiratory support; length
of hospital stay; clinical severity
score; length of PICU stay; com-
plications- air leak, nasal trauma,
nosocomial sepsis, barotrauma,
gastrointestinal distention
INCLUDE EXCLUDE
Reason for ex-
clusion
Notes:
DO NOT PROCEED IF STUDY EXCLUDED FROM REVIEW
3. Methods
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Descriptions as stated in report/pa-
per
Location in text
(pg & ¶/fig/table)
Aim of study
Design (e.g. parallel, crossover,
cluster)
Unit of allocation
(by individuals, cluster/ groups or
body parts)
Start date
End date
Total study duration
Ethical approval needed/ ob-
tained for study Yes No Unclear
Notes:
4. Risk of Bias assessment
See Chapter 8 of the Cochrane Handbook (Higgins 2011)
Domain Risk of bias Support for judgement Location in text
(pg & ¶/fig/table)
Low risk High risk Unclear
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(Continued)
Random sequence
generation
(selection bias)
Allocation
concealment
(selection bias)
Blinding of partic-
ipants and person-
nel
(performance bias)
Outcome group: All/
(if required) Outcome group:
Blinding of out-
come assessment
(detection bias)
Outcome group: All/
(if required) Outcome group:
Incomplete
outcome data
(attrition bias)
Selective outcome
reporting?
(reporting bias)
Other bias
Notes:
5. Participants
Provide overall data and, if available, comparative data for each intervention or comparison group.
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Description as stated in report/paper Location in text
(pg & ¶/fig/table)
Total no. randomized
(or total pop. at start of study for NRCTs)
Clusters
(if applicable, no., type, no. people per cluster)
Withdrawals and exclusions
(if not provided below by outcome)
Age
Sex
Severity of illness
Co-morbidities
Other treatment received (additional to
study intervention)
Subgroups measured
Subgroups reported
Notes:
6. Intervention groups
Copy and paste table for each intervention and comparison group
Intervention Group 1
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Description as stated in report/paper Location in text
(pg & ¶/fig/table)
Group name HFNC
No. randomized to group
(specify whether no. people or clusters)
Description (include sufficient detail for
replication, e.g. content, dose, components)
Duration of treatment period
Timing (e.g. frequency, duration of each
episode)
Delivery (e.g. mechanism, medium, inten-
sity, fidelity)
Co-interventions
Notes:
Comparison Group 1
Description as stated in report/paper Location in text
(pg & ¶/fig/table)
Group name Invasive Ventilation
No. randomized to group
(specify whether no. people or clusters)
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(Continued)
Description (include sufficient detail for
replication, e.g. content, dose, components)
Duration of treatment period
Timing (e.g. frequency, duration of each
episode)
Delivery (e.g. mechanism, medium, inten-
sity, fidelity)
Co-interventions
Notes:
Comparison Group 2
Description as stated in report/paper Location in text
(pg & ¶/fig/table)
Group name Non-Invasive Ventilation
No. randomized to group
(specify whether no. people or clusters)
Description (include sufficient detail for
replication, e.g. content, dose, components)
Duration of treatment period
Timing (e.g. frequency, duration of each
episode)
14High flow nasal cannula therapy for respiratory support in children (Protocol)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
(Continued)
Delivery (e.g. mechanism, medium, inten-
sity, fidelity)
Co-interventions
Notes:
7. Outcomes
Copy and paste table for each outcome.
Outcome 1
Description as stated in report/pa-
per
Location in text
(pg & ¶/fig/table)
Outcome name Hospital Mortality
Time points measured
Time points reported
Outcome definition (with di-
agnostic criteria if relevant)
Person measuring/reporting
Unit of measurement
(if relevant)
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(Continued)
Scales: upper and lower lim-
its (indicate whether high or low
score is good)
Is outcome/tool validated?
Yes No Unclear
Imputation of missing data
(e.g. assumptions made for ITT
analysis)
Assumed risk estimate
(e.g. baseline or population risk
noted in Background)
Power
Notes:
Outcome 2
Description as stated in report/pa-
per
Location in text
(pg & ¶/fig/table)
Outcome name Intubation Rate
Time points measured
Time points reported
Outcome definition (with di-
agnostic criteria if relevant)
Person measuring/reporting
Unit of measurement
(if relevant)
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(Continued)
Scales: upper and lower lim-
its (indicate whether high or low
score is good)
Is outcome/tool validated?
Yes No Unclear
Imputation of missing data
(e.g. assumptions made for ITT
analysis)
Assumed risk estimate
(e.g. baseline or population risk
noted in Background)
Power
Notes:
Outcome 3
Description as stated in report/pa-
per
Location in text
(pg & ¶/fig/table)
Outcome name Treatment Faiulre- escalation to
other form of respiratory support
Time points measured
Time points reported
Outcome definition (with di-
agnostic criteria if relevant)
Person measuring/reporting
Unit of measurement
(if relevant)
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(Continued)
Scales: upper and lower lim-
its (indicate whether high or low
score is good)
Is outcome/tool validated?
Yes No Unclear
Imputation of missing data
(e.g. assumptions made for ITT
analysis)
Assumed risk estimate
(e.g. baseline or population risk
noted in Background)
Power
Notes:
Outcome 4
Description as stated in report/pa-
per
Location in text
(pg & ¶/fig/table)
Outcome name Duration of respiratory support
Time points measured
Time points reported
Outcome definition (with di-
agnostic criteria if relevant)
Person measuring/reporting
Unit of measurement
(if relevant)
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(Continued)
Scales: upper and lower lim-
its (indicate whether high or low
score is good)
Is outcome/tool validated?
Yes No Unclear
Imputation of missing data
(e.g. assumptions made for ITT
analysis)
Assumed risk estimate
(e.g. baseline or population risk
noted in Background)
Power
Notes:
Outcome 5
Description as stated in report/pa-
per
Location in text
(pg & ¶/fig/table)
Outcome name Complications- air leak, nasal
trauma, nosocomial sepsis, baro-
trauma, gastrointestinal distention
Time points measured
Time points reported
Outcome definition (with di-
agnostic criteria if relevant)
Person measuring/reporting
Unit of measurement
(if relevant)
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(Continued)
Scales: upper and lower lim-
its (indicate whether high or low
score is good)
Is outcome/tool validated?
Yes No Unclear
Imputation of missing data
(e.g. assumptions made for ITT
analysis)
Assumed risk estimate
(e.g. baseline or population risk
noted in Background)
Power
Notes:
Outcome 6
Description as stated in report/pa-
per
Location in text
(pg & ¶/fig/table)
Outcome name Length of Hospital stay
Time points measured
Time points reported
Outcome definition (with di-
agnostic criteria if relevant)
Person measuring/reporting
Unit of measurement
(if relevant)
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(Continued)
Scales: upper and lower lim-
its (indicate whether high or low
score is good)
Is outcome/tool validated?
Yes No Unclear
Imputation of missing data
(e.g. assumptions made for ITT
analysis)
Assumed risk estimate
(e.g. baseline or population risk
noted in Background)
Power
Notes:
Outcome 7
Description as stated in report/pa-
per
Location in text
(pg & ¶/fig/table)
Outcome name Clinical severity score
Time points measured
Time points reported
Outcome definition (with di-
agnostic criteria if relevant)
Person measuring/reporting
Unit of measurement
(if relevant)
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(Continued)
Scales: upper and lower lim-
its (indicate whether high or low
score is good)
Is outcome/tool validated?
Yes No Unclear
Imputation of missing data
(e.g. assumptions made for ITT
analysis)
Assumed risk estimate
(e.g. baseline or population risk
noted in Background)
Power
Notes:
Outcome 8- secondary outcome
Description as stated in report/pa-
per
Location in text
(pg & ¶/fig/table)
Outcome name Length of PICU stay
Time points measured
Time points reported
Outcome definition (with di-
agnostic criteria if relevant)
Person measuring/reporting
Unit of measurement
(if relevant)
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(Continued)
Scales: upper and lower lim-
its (indicate whether high or low
score is good)
Is outcome/tool validated?
Yes No Unclear
Imputation of missing data
(e.g. assumptions made for ITT
analysis)
Assumed risk estimate
(e.g. baseline or population risk
noted in Background)
Power
Notes:
8. Results
Copy and paste the appropriate table for each outcome, including additional tables for each time point and subgroup as required.
Dichotomous outcome
Outcome HFNC Invasive Ventilation Non Invasive Ventilation Details
No. with
event
No. without
event
No. with
event
No. without
event
No. with
event
No. without
event
Intubation
Failure of
Treatment
Hospital Mor-
tality
Complica-
tions
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Continuous outcome
Out-
come
Unit of
Mea-
sure-
ment
HFNC Group Invasive Ventilation
Group
Non Invasive
Group
Details
n M SD n M SD n M SD
Length
of PICU
stay
Clinical
Severity
Score
Dura-
tion of
Respira-
tory sup-
port
LOS-
Hospital
9. Applicability
Have important populations been ex-
cluded from the study? (consider disadvan-
taged populations, and possible differences in
the intervention effect)
Yes No Unclear
Is the intervention likely to be aimed at
disadvantaged groups? (e.g. .lower socioe-
conomic groups)
Yes No Unclear
Does the study directly address the re-
view question?
(any issues of partial or indirect applicability)
Yes No Unclear
Notes:
24High flow nasal cannula therapy for respiratory support in children (Protocol)
Copyright © 2012 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.
10.Other information
Description as stated in report/paper Location in text
(pg & ¶/fig/table)
Key conclusions of study authors
References to other relevant studies
Correspondence required for further
study information (from whom, what and
when)
Notes:
H I S T O R Y
Protocol first published: Issue 5, 2012
C O N T R I B U T I O N S O F A U T H O R S
Conceiving the review: Sara Mayfield (SM)
Co-ordinating the review: SM
Undertaking manual searches: SM
Screening search results: SM and Jacqui Jauncey-Cooke (JJC)
Organizing retrieval of papers: SM
Screening retrieved papers against inclusion criteria: SM and JJC
Appraising quality of papers: SM, JJC and Judith Hough (JH)
Abstracting data from papers: SM and JJC
Writing to authors of papers for additional information: SM
Providing additional data about papers: SM
Obtaining and screening data on unpublished studies: SM
Data management for the review: SM, JJC and Fiona Bogossian (FB)
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Entering data into Review Manager (RevMan 5.1): Sara Mayfield
RevMan statistical data: SM and Kristen Gibbons (KG)
Other statistical analysis not using RevMan: KG
Interpretation of data: SM, JJC, FB, JH and Andreas Schibler (AS)
Statistical inferences: SM, JJC, FB and KG
Writing the review: SM
Securing funding for the review: n/a
Performing previous work that was the foundation of the present study:
Guarantor for the review (one author): FB
Person responsible for reading and checking review before submission: JJC, FB, AS and JH
D E C L A R A T I O N S O F I N T E R E S T
Sara Mayfield and Andreas Schibler are working on studies with HFNC in the paediatric intensive care unit where they work. To date
the trials are observational in nature and not in line with RCTs, however this may change in the future. However, any trial that may be
included from these authors will be acknowledged and assessed by an independent person (JH, FB or JJC).
Andreas Schibler: Fisher and Paykel have supported my research by funding one project and supplying equipment in another. Neither
projects are published as yet, but may be eligible for inclusion in this review. If any of the studies in the review are deemed to hold a
conflict of interest with me, then they will be assessed by an independent person (JH, FB, SM or JJC).
Jacqueline Jauncey-Cooke: none known.
Judith L Hough: none known:
Kristen Gibbons: none known.
Fiona Bogossian: none known.
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Appendix 2: Consent for pilot 
Parent Information Sheet 
 
Project Title: High Flow Nasal Prong Oxygen Delivery.  A pilot study to 
investigate safety, quality and practicality for a future 
randomised controlled trial 
 
Investigators: A/Prof A. Schibler PICU consultant, Mater Children’s Hospital 
 Dr. M. Harris    Respiratory and Sleep Medicine, Mater Children’s 
Hospital 
 Dr. C. Dakin     Respiratory and Sleep Medicine, Mater Children’s 
Hospital 
 Dr. G. Stone    Emergency Department, Mater Children’s Hospital 
 Dr. K. McCaffery   PICU, Mater Children’s Hospital 
 Dr. D. Levitt      Paediatrics, Mater Children’s Hospital 
 Ms. S. McKee    Director of Nursing,   Mater Children’s Hospital 
 
 
 
We would like to invite your infant to participate in this study.  Your infant has a viral 
respiratory illness (bronchiolitis).  Infants with bronchiolitis may need supplemental oxygen. 
This can be given using a face mask, subnasal prongs or using more invasive means like face 
mask ventilation or invasive ventilation through a breathing tube inserted into the child's 
windpipe. Over the last 5 years we have used in the Paediatric Intensive Care Unit (PICU)  a 
new oxygen delivery system, called, High Flow Nasal Prongs (HFNP) to support work of 
breathing.  We are introducing this method of treatment to the paediatric wards in this hospital.  
This study aims to assess the quality, safety and practicality of this method in the ward 
environment. 
 
Why is the study being done? 
 
Respiratory viral illnesses are the leading cause of infants and children requiring hospitalisation.  
Approximately 8000 admissions occur annually in Australia.  The Mater Children’s PICU has been using 
HFNP since 2005 in infants with viral respiratory illnesses and has shown that it reduces the need to use 
more invasive means to support the breathing of these patients, such as inserting a breathing tube.  It is 
believed that this mode of treatment can be safely used in the regular paediatric ward environment. This 
study serves as a pilot study to assess criteria for a larger study, in which the long term benefits of HFNP 
treatment in bronchiolitic infants will be investigated. 
 
How is the study being done? 
 
There has already been extensive training of staff in the Emergency Department and the paediatric wards 
to use the HFNP system.  As well as training on a HFNP data collection form.  This form will assist the ED 
clinician and nursing staff to safely assess your infants breathing requirements.  Once your infant is placed 
on HFNP (as per protocol), observations of their breathing rate, heart rate and other parameters according 
to the HFNP form  will be taken as per ward policy for the care of an infant with bronchiloitis.  A change in 
score >6 will lead the nurse to seek medical review.  From here the treating doctor will decide on treatment 
as clinically indicated, which may include admission to PICU.   
 
 
 
 
Are there any risks or discomforts? 
 
HFNP is an established form of breathing support for infants with respiratory illnesses in the PICU area. 
The nasal prongs used for the HFNP treatment are the same as we would use for standard oxygen 
delivery. Your child will therefore not have any other risks or discomfort.  Any change in clinical status on 
the ward will be reviewed by the treating doctor and arrangements made to transfer to the PICU if needed. 
 
What are the potential benefits? 
 
Although this study will have no direct benefits to your infant, it will help us gain more of an understanding 
on the effect of HFNP on the respiratory state of this group of infants. 
 
Who will have access to the research records? 
 
Nursing and medical staff in ED, on the wards and in PICU who are involved with this study will have 
access to the information collected.  Your infant’s privacy will be maintained at all times.  Your infants name 
will not be used in any presentations or publications of the study results. 
 
Will there be any costs for taking part in the study? 
 
There will be no additional costs for participants in this study. 
 
Do I have to take part in this study? 
 
Your infant’s participation in the study is entirely voluntary.  If you decide now, or at a later stage, that you 
do not wish to participate in this research project, that is entirely your right and will not in any way affect any 
present or future treatment. 
 
Who do I speak to if any problems arise? 
 
If you are concerned for your infant then you must tell the nurse or doctor caring for them.  If you have any 
concerns about the way in which the research has been carried you, please do not hesitate to contact Sara 
Mayfield on 31635698. 
This study has been approved by the Mater Health Services Human Research Ethics Committee and you 
may contact the Mater Research Secretariat on 3163 1585, should you have any complaints about the 
conduct of the research, or wish to raise any concerns.  The Research Secretariat may contact the Patient 
Representative or Hospital Ethicist as its discretion. 
 
Thankyou for your time and consideration of participation in this study. 
 
 
 
 
 
 
Consent Form for Parents or Guardians 
 
Project Title: High Flow Nasal Prong Oxygen Delivery.  A pilot study to investigate safety, quality and     
practicality for a future randomised controlled trial. 
 
Investigators:    A/Prof A. Schibler PICU consultant, Mater Children’s Hospital 
                           Dr. M. Harris    Respiratory and Sleep Medicine, Mater Children’s Hospital 
                           Dr. C. Dakin     Respiratory and Sleep Medicine, Mater Children’s Hospital 
                           Dr. G. Stone    Emergency Department, Mater Children’s Hospital 
                           Dr. K. McCaffery   PICU, Mater Children’s Hospital 
                           Dr. D. Levitt      Paediatrics, Mater Children’s Hospital 
                           Ms. S. McKee    Director of Nursing,   Mater Children’s Hospital 
 
 
· We understand that we have been asked to allow our infant to participate in a study to look at the use of 
HFNP in the paediatric ward 
· We have read and understood the information sheet. 
· The details of the study have been explained to us and our questions have been answered satisfactorily. 
· The possible risks and benefits of our infant participating have been explained to us. 
· We understand that the project is for the purpose of research and not for treatment, so may not directly 
benefit us or our child. 
· We have been informed that the confidentiality of the information will be maintained and safeguarded and 
give permission for access to our infants medical records for the purpose of research. 
· We give permission for medical practitioners, other health professionals, and hospitals outside this hospital, 
to release information concerning our infant’s disease and treatment which is needed for this trial and 
understand that such information will remain confidential. 
· We understand that we may withdraw our infant form the study at any time without affecting the care he/she 
receives. 
 
CONSENT 
I/We ___________________________________________________________, being the parent(s)/guardians of 
___________________________________________give permission for our baby to take part in this study.  
I/We would like to be informed of the study results     NO?         YES?        If yes please provide contact telephone 
number    ………………………………. 
SIGNED  
(Parent(s)/Guardian(s))     DATE 
____________________________________________   _______________________ 
SIGNED (Witness)     DATE 
____________________________________________ _______________________ 
SIGNED (Investigator)     DATE 
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Appendix 3: CEWT tool 
!"
#
$
"
%
#
&
'
(
%
)
#
(
$
#
%
*
(
+
#
,
(
$
!
(
$
-
#
.
/
'
-
(
$
0
1
2
3
3
#
#
4
#
#
1
5
6
7
1
3
1
!"#$%&'
( !"#$%&(
) !"#$%&)
* !"#$%&*
!" #$%&#$" #'(&#)*'+&%',-#$.-&/0*'+$%-#1$0&-#+%'$#'(&#
)2/)3&#.*%45#)3*6&#*%#&1&/7&%68#6*33#+11&4+*'&38
! +,-"%&%.%$/%0"1&"-,,
"!#$%&'()*
!" #*%#$.-&/0*'+$%#1$0&-#+%'$#$%&#$" #'(&#-(*4&4#*/&*-5#
*44#2)#'(&#)*'+&%',-#"233#9:;<#-6$/&#*%4#'*=&#*6'+$%#
*-#4&-6/+.&4#+%#'(&#>6'+$%-#.$?#.&3$@
+',-(./% A$/#/2/*3#*%4#/&1$'&#"*6+3+'+&-
"!#$%
&'()*
+',-(.
012 , B.'*+%#*#"233#9:;<#-6$/&, 9*//8#$2'#*%4#4$621&%'#*))/$)/+*'&#
+%'&/0&%'+$%-#*-#)/&-6/+.&4, !%6/&*-&#"/&C2&%68#$" #$.-&/0*'+$%-, D*%*7&#*%?+&'8#E#)*+%#E#"&0&/, F&0+&@#$?87&%#/&C2+/&1&%', 9$%-+4&/#+%"$/1+%7#'&*1#3&*4&/
314 , ;*/4#4$6'$/#'$#/&0+&@#@+'(+%#GH#1+%2'&-, I$'+"8#'&*1#3&*4&/, B.'*+%#*#"233#9:;<#-6$/&#*"'&/#+%'&/0&%'+$%-, !" #%$#/&0+&@#@+'(+%#GH#1+%2'&-5#&-6*3*'&#'$#
/&7+-'/*/#/&0+&@
516 , F&7+-'/*/#'$#/&0+&@#)*'+&%'#J#/&-)$%-&#@+'(+%#
KL#1+%2'&-, !" #%$#/&0+&@#@+'(+%#KL#1+%2'&-5#$/#+" #63+%+6*338#
6$%6&/%&45#)3*6&#&1&/7&%68#6*33, B.'*+%#*#"233#9:;<#-6$/&#*"'&/#+%'&/0&%'+$%-, F&7+-'/*/#'$#&%-2/&#6$%-23'*%'#+-#%$'+"+&4, ;*/4#4$6'$/#'$#*''&%4
78  9:;'*%*<*)=*.'>%';::, F&7+-'/*/#'$#*''&%4, :%-2/&#6$%-23'*%'#+-#%$'+"+&4
9:;'*%*<*)=*.'>%';::%-?%;.>%(?%,@*%?(::(A-.=B,$)*&$&," !,+'$
&"&
8'$9
#
 
 "  #.# # #:# # #(
$
C
D
+
E
,	 !$, *!%$(&!  &"'$"$,M$2#*/&#@$//+&4#*.$2'#'(&#)*'+&%'
C+#2##.&-3$
F9#4-5-,&6$#0/5
GH#7-"%&.-58
FC#4#0&2%9:$%-;<%$
I;,*
$-<*
C*/J-);,()>%);,*$&% 
*==
)
==
='
(
='
>= >=
>' >'
*= *=
*' *'
)= )=
)'
)
)'
(=
*
(=
('
!
('
C*/J-);,()>%K-/,)*//
!%?%$% * !"#"$"
@#A%$-;% ) %&'"$()"
@3,A ( %*+'
43, ,*+
L
M
%   !$ '$% $ !  * B&= ) B&=(C= ( (C=
D&( D&(
@#A%&#E&A%,3?%$1
L
M%
&;,N);,-(.
F*
(
F*
GF
)
GF
G=
*
G=
+$#:%&"<-0/%
$*<J*);,N)*

)
>'H= >'H=
>' >'
*FH= *FH=
*F
(
*F
*GH= *GH=
*G *G
*IH= *IH=
*I *I
*JH= *JH=
*J *J
*=H=
)
*=H=
O*;),%);,*&% 
*(F'
)
(F'
(G' (G'
(I'
(
(I'
(J' (J'
(=' (='
(>' (>'
(*' (*'
()' ()'
((' (('
(''
(
(''
F'
)
F'
G'
*
G'
I' I'
J'
!
J'
P:((K%J)*//N)*
####
&'()*%/>/,(:-'%P9
)()'
((= ((=
((' (('
('= ('=
('' (''
F= F=
F' F'
G= G=
G' G'
I=
(
I=
I' I'
J=
)
J=
J' J'
==
*
==
='
!
='
>= >=
				
 B&)&5%" ( -./0"1D&)&5%" 2./0"1
E*Q*:%(?%'(./'-(N/.*//
!" #+%4+6*'&4#*%4#)*'+&%'#+-#*-3&&)5#
&%-2/&#'(&8,/&#*@*=&#.&"$/&#-6$/+%7
K,%$; 3+"$)
L%$:-, ( 4"$5(+
+-30 * 6(*7
M0$%56H ! 87$"09:
$(,;:%"!#$%&'()*
D.,*)Q*.,-(./ %/H&NKO
"
#
$
$
%
&
'
(
)
%
*
%
+
#
(
,
%
-
.
/
0%*%
1!23
!
"
#$
"
%
#&
'
(%
)
#($
#%
*
(+
#,
($
!
($
-
#.
/
'
-
($
;
)
&
%
##
M$2#12-'#6*3623*'&#*#?N::%"!#$%/'()*B
N# (.%;K<-//-(.
N# +" #)*'+&%'#+-#K*,*)-();,-.= $% %!$!$*!'$! $ !'&&"& &
>-+4&#"/$1#'(&#*.$0&5#4$#*))/$)/+*'&#$.-&/0*'+$%-#*'#*%#*))/$)/+*'&#"/&C2&%68#"$/#)*'+&%',-#63+%+6*3#-'*'&
A$/#;R.()<;:#$.-&/0*'+$%-5#8$2#12-'#6$%'+%2&#'$#6(&6=#2%'+3#%$/1*3
>%8#$.-&/0*'+$%-#(N,/-K*#'(&#/*%7&#$" #'(&#7/*)(5#8$2#12-'#A)-,*#*-#*#%21.&/

P#";#$O5&0-.% P%53/0-;3#0
P-;% Q3.%
P#";#$O5&53/0-;R$%
S%-$;&$-;% ;#
2%563$-;#$1&$-;% ;#
;#T,##A&6$%55R$%
;#U
)&
5-;R$-;3#0
!" #*.%$/1*3#$.-&/0*'+$%-#*/&#&?)&6'&4#"$/#)*'+&%',-#63+%+6*3#6$%4+'+$%5#)3&*-&#%$'&#.&3$@#*66&)'&4#)*/*1&'&/-#
"$/#"2'2/&#6*33-
&"&
8'$9
#
 

 "  #.# # #:# # #(
&"&
8'$9
#
 
 "  #.# # #:# # #(
"@-:K)*.S/%!;):>%
#;).-.=%$((:%T"!#$U
#
9;-.%+//*//<*.,%"@;),%D./,)N',-(./
% !

% 

% #$!
"
% 	 
 D?%(.%-.?N/-(./V%N/*%J;-.%-.?N/-(.%'@;),
D.,*)Q*.,-(./
K
T
V
P
W
7
X
S
Y
Z
[
\
@
4
!" #*%#
+%'&/0&%'+$%#+-#
*41+%+-'&/&45#
/&6$/4#@*)*#
*%4#%$'&#3&''&/#
+%#!"#$%&$"#'(")#
/$@#$0&/#)*7&#
+%#*))/$)/+*'&#
'+1&#6$321%
9;-.%+//*//<*.,%$((:/% &)&&""$!"$&" %%%% &&!!
% % GE+""
!R//%5;%A&-/%]&&
)&.#0;<5&;#&I&1%-$5
:*6(#6*'&7$/8#+-#-6$/&4#
H#OP5#/&-23'+%7#+%#*#'$'*3#
-6$/&#$" #HOKH
V-;%/#$3%5 !"#$%&' !"#$%&( !"#$%&)
A*6& I$#)*/'+623*/#
&?)/&--+$%#$/#-1+3&
B66*-+$%*3#7/+1*6&#$/#"/$@%5#
@+'(4/*@%5#4+-+%'&/&-'&4
A/&C2&%'#'$#6$%-'*%'#"/$@%5# )#'($  % I$/1*3#)$-+'+$%5#$/#
/&3*?&4
Q%&*-85#/&-'3&--5#'&%-& R+6=+%75#$/#3&7-#4/*@%#2)
>6'+0+'8 * #'&* !$
)$-+'+$%5#1$0&-#&*-+38
#'$ %&  !$&
'&%-&
$$!$$ 
9/8 !$*)!$%" D$*%-#$/#@(+1)&/-5#$66*-+$%*3#6$1)3*+%' 9/8+%7#-'&*4+385#-6/&*1-#$/#-$.-5#"/&C2&%'#6$1)3*+%'-
9$%-$3*.+3+'8 9$%'&%'5#/&3*?&4 F&*--2/&4#.8#$66*-+$%*3#'$26(+%75#
(277+%75#$/#.&+%7#'*3=&4#'$5#4+-'/*6'*.3&
S+""+623'#'$#6$%-$3&#$/#
6$1"$/'
% % %#(.=%W%P;X*)%G;'*/
!R//%5;%A&-/%]&*^&1%-$5
T$+%'#'$#&*6(#"*6&#*%4#2-&#
@$/4-#'$#4&-6/+.&#)*+%
>-=#6(+34#'$#6($$-&#"*6&#
.&-'#4&-6/+.+%7#'(&+/#)*+%
#
% % FN<*)-';:
!R//%5;%A&-/%]&I^&1%-$5
>-=#6(+34#'$#+4&%'+"8#3&0&3#$" #
)*+%#"/$1#-6*3&
' I G F ('( ) * > J=
F(%9;-. H(K*);,*%9;-. #()/,%9;-.
9;-.%+//*//<*.,%"@;),
Q3.%
K";3#0
KH ,Q/7&%'#/&7+-'/*/#/&0+&@U#
9$%-+4&/#$)+$+4-U,
! &&'& $(
+" #)*+%#/&1*+%-#-&0&/&#*"'&/#
)&/1+''&4#+%'&/0&%'+$%-U
+-30&
!"#$%
V
W
X ,>41+%+-'&/#)/&-6/+.&4#
*%*37&-+*,F&7+-'/*/#/&0+&@#+" #%$#
+1)/$0&1&%',9$%-+4&/#/&"&//*3#'$#'& $( 
+%'&/0&%'+$%-#+%&""&6'+0&
Y
L
Z
G ,>41+%+-'&/#)/&-6/+.&4#
*%*37&-+*,;*/4#4$6'$/#/&0+&@#'$#
)/&-6/+.&#+" #/&C2+/&4
P
K
H
T#,R5
!%4+6*'&#@(&%#![#$/#&)+42/*3#
.$32-#7+0&%
W0;%$-,
T#\#T*/*6&'*1$3 "!
2%E%$%0"%]&&_#0/&PH\H`&S#"8%0:%$$1&@HZH`&_3,5#0&PH`&_308%,5;%30&@H\H`&[,30%&4HWH]&_#0/O5&W55%0;3-,5&#E&+%A3-;$3"&4R$530/`&%AH&I`&!;H&\#R35`&)''*`&6H&('=)&9&('=*H&V#61$3/<;%A&:1&@#5:1` &Y0"H&2%6$30;%A&:1&6%$.3553#0H
@%$8%,`&!H`&L#%6%,9\%a35`&QH`&!<-1%?3;b`&ZH`&c&@-,?31-`&!H&d(FFIeH&Q<%&7\KVV]&K&:%<-?3#R$-,&5"-,%&E#$&5"#$30/&6#5;#6%$-;3?%&6-30&30&1#R0/&"<3,A$%0H&+%A3-;$3"&4R$530/&)*d*e`&)F*9)FIH&f&)'')`&Q<%&2%/%0;5&#E&;<%&M03?%$53;1&#E&
@3"<3/-0H&K,,&$3/<;5&$%5%$?%AH
Q3.%&
K";3#05]& +-30&!"#$%,Q/7&%'#/&7+-'/*/#/&0+&@U#
9$%-+4&/#$)+$+4-U,
! &&'& $(
+" #)*+%#/&1*+%-#-&0&/&#*"'&/#
)&/1+''&4#+%'&/0&%'+$%-U
KH
V
W
,>41+%+-'&/#)/&-6/+.&4#
*%*37&-+*,F&7+-'/*/#/&0+&@#+" #%$#
+1)/$0&1&%',9$%-+4&/#/&"&//*3#'$#>62'&# $(  &$( &! %
+%&""&6'+0&
X
Y
L
Z
,>41+%+-'&/#)/&-6/+.&4#
*%*37&-+*,;*/4#4$6'$/#/&0+&@#'$#
)/&-6/+.&#+" #/&C2+/&4
G
P
K
,I$#*6'+$% H
,
!%4+6*'&#@(&%#![#$/#
&)+42/*3#.$32-#7+0&%
;%$-,
T#\#T*/*6&'*1$3 "!
0%*%
1!23"!44%5627%*%1!23
G()%)N);:%;.K%)*<(,*%?;'-:-,-*/
E
!
&
&
%$
O
+
F
%0
%Y
!
+
C
%
'
8
'
/
<
#/
$
!
#'
)
.
"
%
)
187 
 
Appendix 4: MCH HREC approval 


190 
 
Appendix 5: UQ ethics approval 

192 
 
Appendix 6: MCH HREC amendment 

194 
 
Appendix 7: Ward HFNC guidelines 
In the Mercy tradition, the Mater will be renowned as a leader in the delivery of exceptional 
health care through a sincere commitment to the Mater values of:
Mercy, Dignity, Care, Commitment and Quality
Guideline name: High flow therapy for patients with
bronchiolitis
Date developed: October 2013
PRINCIPLE: To ensure safe delivery and effective management 
of high flow therapy for infants under 12 months of age with 
bronchiolitis at Mater Children’s Hospital (excluding Paediatric 
Intensive Care Unit.
High flow nasal prong (HFNP) is a system designed to deliver heated 
humidified oxygen (02) at high flows using a specially designed Fisher and 
Paykel® (F&P) Airvo2 delivery system and circuit with optiflow prongs 
(OPT 314,316 and 318)
HFNP is a treatment for infants with respiratory distress from bronchiolitis1.
The effects of HFNP therapy are five fold:
1 It flushes the dead space of the nasopharyngeal cavity allowing for 
better ventilation as well as oxygenation2
2 It provides a flow adequate to support inspiration thereby reducing 
the inspiratory work of breathing1, 2
3 The heated humidified gas improves lung and airway compliance2
4 It provides the ability to deliver accurate gas mixtures at body 
temperature with 100% humidity, thus facilitating mucociliary 
transport and minimising the viscosity of secretions2-4
5 It can deliver end distending pressure (CPAP)2-5
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GUIDELINES:
Initiating therapy in Paediatric Emergency Department (PED)
or 8 South:
1. Inclusion criteria:  Infants with bronchiolitis and an oxygen 
requirement under the age of 12 months to their birth date.
a. Oxygen requirement is determined by oxygen saturations.
b. Work of breathing, while not a direct indicator of oxygen 
requirement, is nonetheless a marker of respiratory distress, and 
may contribute to the individual clinicians’ decision making
2. Exclusion criteria:
a. Infants with choanal atresia
b. Infants with tracheostomy
c. Infants with suspected foreign body aspirate
d. Infants with nasopharyngeal tube
3. Nursing or medical staff may initiate high flow therapy following medical 
review for the patients that meet the inclusion criteria.
4. All patient’s with high flow therapy will have a nasogastric tube inserted 
intended for aspiration of air that may accumulate in the stomach.
5. All patient’s with high flow therapy will have access to adequate 
emergency equipment available at the bedspace.
6. The patient will have the appropriate nasal prongs applied to face and 
secured with wiggle pads provided.
7. The flow rate will be calculated at 2L/kg/min to a maximum of 25L.  If 
the patient weight exceeds 12.5 kg, commence treatment flow rate at 
25L, do not increase beyond 25L in PED or the ward setting.
8. On initial application commence with flow of 6L and gradually increase 
the flow until 2L/kg flow is achieved. This increase in flow should be 
done over 30 seconds – 1 minute. This is because high flows (above
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8L) may initially be uncomfortable for the patient until they adjust to the 
sensation.
ALERT
In the ward setting
The flow rate will not exceed 25L and the FiO2 will not 
exceed 60% 
9. The FiO2 will be commenced at 60% and weaned by 5% increments 
until oxygen saturations are stable and remain above 93%. Do not 
increase the FiO2 beyond 60% in the PED or the ward setting.
10. If there is no improvement in oxygen saturations and/or FiO2
requirement remains greater than 50% within 60 minutes of 
commencing high flow therapy, a PICU review will be requested. If
there is further deterioration, escalate review process as per CEWT
actions.
11. It is recognised that weaning to this level make take 1-2 hours, but high 
flow “responders” can be identified by their initial response to the 
treatment within the first hour.  Consider PICU review if not responding.
12.Once the therapy has been initiated, do NOT turn off the flow to assess 
the patient.
Transfer from PED to 8 South
13.The FiO2 will be less than or equal to 50% prior to transfer to 8 South, 
this may take up to 1-2 hours to establish.
14.The PED or ward paediatric registrar will review the patient prior to 
transfer to assess suitability for care in 8 South.
15.The hospital nurse manager/patient flow manager will notify 8 South 
team leader 30 minutes prior to patient transfer.
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16.The nurse allocated to care for the patient in 8 South, will ensure the 
bedspace is prepared, contact ward services for assistance with 
transfer, receive handover using the SHARED tool and transfer the 
patient from PED to 8 South.
17.During the transfer the Airvo2 will not operate without power, leave
nasal prongs in situ, apply face mask oxygen 4L and recommence the 
therapy as soon as able once in 8 South.
Ongoing Management of high flow therapy
18.The patient will be continuously monitored with a pulse oximetry while
the high flow therapy is in place.
19.Reassess the patient at least every hour. Continue to decrease FiO2 if
oxygen saturations remain above 98%.  Decrease FiO2 by 5% 
increments, ensuring oxygen saturations remain between 93% - 98%.
20. If the patient deteriorates or oxygen saturations fall below 93%
increase the FiO2 by 5% increments, ensuring the oxygen saturations 
remain between 93-98% and escalate review process as per CEWT
actions.
21. If FiO2 requirements increase to greater than 50%.  Contact the 
medical registrar to review the patient within 30 minutes. If the FiO2 is
further increased the PICU registrar must be contacted for patient 
review within 15 minutes of increased FiO2. Do not increase the FiO2
beyond 60% in the ward setting.
22.Minimum of hourly observations will be recorded on the Children’s
Early Warning Tool < 1 year and Paediatric Respiratory Observation 
Chart.
The nursing staff will aim to maintain oxygen 
saturations between 93-98% by titrating the 
FiO2 in 5% increments.
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23.Feeding Requirements
Feeding regime as per medical plan
a. The infant may feed orally or enterally as indicated by condition, 
refer to guideline: Acute Bronchiolitis Management in PED -
MHC-WCH-C-142.
b. Shorter/smaller volume more frequent oral feeds should be 
trialled first, if not tolerated, trial bolus feed via nasogastric tube.
If there is respiratory deterioration with bolus feeds, consider 
continuous nasogastric feeds until improvement in patient 
condition.
c. Aspirate the nasogastric tube prior to each feed or 4th hourly if 
continuous nasogastric feeds are being administered.
i. To check the tube placement
ii. To reduce air that may cause abdominal distension
24.Observations
a. The infant will have continuous heart rate and oxygen saturation 
monitoring via pulse oximeter and oxygen saturation monitor.
b. Document minimum of hourly respiratory rate, respiratory 
distress, oxygen saturations, heart rate on the Child Early 
Warning Tool <1 year old (CEWT).
c. Document other observations on the CEWT as patient condition 
dictates.
d. Document hourly respiratory assessment on the Paediatric
Respiratory Observation Chart
e. Document hourly high flow therapy system checks on the 
Paediatric Respiratory Observation Chart, including FiO2, flow 
rate, water check.
f. Visual check of nasal prong position and observe skin integrity 
around nasal prongs.
g. Patients requiring radiological investigations should remain in 
PED/8 South if possible, to avoid ceasing and recommencing 
therapy.
25.Patient handling and other cares
a. Provide a restful environment for the infant, consider grouping 
cares and minimal handling as appropriate.
b. Provide oral hygiene minimum of every 4-6 hours if patient is nil 
by mouth.
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c. Provide pressure area cares as directed by the risk assessment 
conducted each shift.
d. Reposition oxygen saturation probe 2-4 hourly or more 
frequently if required.
26.Suctioning & 0.9% Sodium Chloride 
a) Maintain airway patency with nasal suctioning to clear excessive
nasal secretions. Consider that suctioning may cause oedema
and further irritate the airway. 
b) Sodium chloride drops or atomised sodium chloride are not 
required due to humidification provided by the circuit.
27.Rapid clinical deterioration
a. Follow the actions on the CEWT
b. Call for help, initiate Medical Emergency Team (MET) call.
c. Bag and mask breaths can be delivered while the nasal prongs 
remain insitu.
28.Weaning high flow therapy
a. Wean FiO2 to 21% 
b. Once weaned to 21%, continue to observe patient for 4 hours 
while at this treatment flow
c. If patient is stable turn off the flow – do not wean the flow rate
d. Clinical signs the patient is stable include:
i. Decreased work of breathing
ii. Normal or improved heart rate
iii. Normal or improved respiratory rate
iv. Saturations above 93%
e. If patient has pre-existing oxygen requirement, an individualised 
weaning plan must be documented by the medical officer in the 
medical notes.
i. Recommendation is to wean to 25% FiO2 at treatment 
flow, observe the patient for 4 hours, if stable, convert to 
low flow at pre-existing oxygen requirement flow.
29.Deterioration post high flow therapy wean
a. If after high flow therapy has been weaned the patient has an
increased work of breathing or oxygen saturations fall below
93%, consider re-initiation of high flow or low flow oxygen 
therapy.
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b. If recommencing on high flow oxygen commence at initial
treatment flow rate and FiO2 – 21%, increase FiO2 by 5% 
increments to keep oxygen saturations above 93%
c. Request medical review
Appendix 1
Each cot space will be equipped with a 15L flow meter and will be attached to
the Airvo2.
1. Components of System:
1. 900PT531 circuit 
2. Nasal Prong
3. F&P MR850 Humidifier base (only this base is compatible) 
4. Water Bag
5. Oxygen tubing
A. Prong selection:
i. The following parameters should be utilised when 
selecting nasal cannula. 
1. OPT 314 for neonates, with flow limited at 8L/min
2. OPT 316 for infants to 20L/min
3. OPT 318 for infants/paeds to 25L/min
2. Set Up:
A. Select appropriate size nasal prong, and connect to adaptor on circuit,
connect the circuit to the Airvo machine.
B. Place the chamber in the Airvo machine and attach water bag. The
water bag must run freely and be placed as high as possible above the 
humidifier to achieve flow of water into the humidifier chamber.
C. Turn the Airvo2 machine on and adjust the flow rate to the prescribed 
rate
D. Ensure Airvo2 is attached to oxygen outlet, adjust the oxygen flow rate 
to achieve desired oxygen concentration.
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E. Wiggle pads used to secure the prongs to the patients face and can be 
replaced as needed, particularly for the patient with moderate to large 
secretions.
F. System is ready for use. 
LINKS:
MHS-WCH-C-079 Oxygen Therapy
http://MatDCS/DocCube/default.asp?Id=5306
MHS-WCH-C-086 Humidification Guidelines
http://MatDCS/DocCube/default.asp?Id=3892
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